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Successful determination of small molecules in complex biological systems requires 
implementation of robust analytical methodologies able to provide reliable information in a cost-
effective and efficient manner. Solid phase microextraction (SPME) is a versatile, non-exhaustive 
sample preparation tool that has been demonstrated to be well-suited for facile analysis of 
biological matrices such as plasma, blood, and tissue. In SPME, a small amount of extraction phase 
immobilized on a solid support is utilized for the extraction of analytes of interest, either from the 
sample headspace or by direct immersion of the fiber in the matrix of choice. For the analysis of 
non-volatile compounds in complex biological matrices, SPME coatings made of sorbents 
embedded in a biocompatible binder (e.g. polyacrylonitrile (PAN)) are directly immersed into the 
sample under study for a defined period of time so as to allow for sufficient and reproducible 
extraction of analytes. The main advantages of such coating materials rely on their ability to 
provide high selectivity for extraction of small molecules; their aptness for immobilization in 
different support geometries; their inertness and robustness, which even enables their reusability 
in complex biological matrices; and their suitability towards in vivo extractions. In view of these 
advantages, the body of this doctoral thesis presents novel applications and developments of SPME 
for both targeted and untargeted analysis of different biological matrices such as biofluids and 
brain tissue.  
The first part of the research conducted for this thesis encompasses the application of SPME in 
thin-film format for high throughput determination of multiple prohibited substances in plasma. A 
biocompatible SPME extraction phase made of hydrophilic-lipophilic balance (HLB) particles 
immobilized with PAN was employed for extractions, demonstrating satisfactory extraction 
capabilities for 25 compounds of a wide range of polarities (logP from -2 to 6.8). By taking full 
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advantage of the 96 thin-film handling capability of the automated system, a preparation time of 
approximately 1.5 min per sample can be achieved. Rewarding results in terms of absolute matrix 
effects were found for the majority of the studied analytes, given that 24 out of 25 compounds 
exhibited values in the range 100 - 120%. The method was validated in terms of linearity (R2> 
0.99), inter and intra-day accuracy (85 – 130%) and precision (< 20%), and limits of quantitation 
(0.25 – 10 ng mL-1 for most compounds).  
Based on the positive results obtained after employing the developed method for the analysis of 
doping compounds in plasma samples, and considering the need for cost-effective and single use 
devices, the possibility of employing alternative materials to manufacture SPME devices was 
explored. To that end, new thin-film SPME devices prepared on plastic as potential single-use 
samplers for bioanalysis were developed and tested. Polybutylene terephthalate (PBT) was 
selected as a support based on its chemical resistance, low cost, and suitability as a material for 
different medical grade components. The proposed devices were assessed in terms of robustness, 
chemical stability, and possible interferences upon exposure to different solvents and matrices. 
Satisfactory results were obtained upon utilization of the manufactured samplers for the 
quantitation of multiple drugs in biofluids such as urine, plasma, and whole blood. Interestingly, 
our results showed that more than 20 extractions in complex biofluids can be performed without 
incurring significant changes in coating performance. These findings evidenced the robustness of 
PAN-based coatings applied on polymeric substrates, and opened up opportunities for the 
introduction of new support materials for manufacture of SPME biocompatible devices aimed at a 
wide range of applications. 
Taking into account that SPME is a non-exhaustive extraction technique where analytes are 
extracted via free concentration, assessing the effect of variable matrix composition on final SPME 
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recoveries is invaluable in avoiding biased results. With this in mind, part of this thesis also 
involved the investigation of the effect of hematocrit (Hct) levels on SPME extractions from whole 
blood. The obtained results demonstrated that the Hct effect in SPME is dependent on the analytes 
of interest, and that different outcomes can be attained by varying experimental conditions such as 
coating type, convection, and extraction time. Interestingly, the relative affinities of target 
compounds for matrix components and coating materials were demonstrated to be one of the main 
determining factors on the final effect that erythrocyte levels impart on SPME recoveries. 
Although Hct content was shown to affect the extraction of each analyte differently, and be 
dependent on experimental parameters, correction of matrix variability is enabled through the use 
of appropriate internal standards. 
In view of the rewarding results obtained in the analysis of a broad range of target analytes, SPME 
in its fibre configuration was evaluated based on its performance for untargeted analysis of brain 
tissue. For that purpose, the metabolite coverage provided by C18, mixed mode (MM), and HLB 
7 mm fibres following extraction from brain homogenate at static conditions was assessed. Our 
results demonstrated that for compounds of medium to high polarity, both HLB and MM coatings 
were able to offer similar coverage at the same desorption conditions. For extraction of lipids, C18 
and HLB exhibited the best recoveries with the use of 1:1 methanol:isopropyl alcohol as desorption 
solvent. Interestingly, the use of different desorption solvents was found to greatly influence the 
final composition of the brain extract obtained via SPME. Other parameters such as extraction 
time, coating washing step, and inter-fibre reproducibility were also considered and discussed. 
Lastly, the balanced metabolite coverage provided by SPME was successfully utilized for in vivo 
monitoring of metabolic changes occurring in the hippocampus of rat brain after electrical 
stimulation (DBS) of the ventromedial prefrontal cortex (vmPFC), which has been previously 
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shown to induce anti-depressant like effects in rodents.  The use of in vivo SPME enabled the 
monitoring of significant variations, not only among small polar metabolites such as amino acids, 
but also in lipids belonging to different classes. Compounds such as citrulline, glutamate, taurine, 
uric acid, sphingomyelins, and phosphatidylethanolamines, among others, exhibited statistically 
significant changes after acute exposure of animals to electrical stimulation for 3 hours. Although 
additional studies are needed to establish the contribution of the biochemical changes observed in 
this study to the effect of DBS in the treatment of depression, our work provided new directions 
towards a better understanding of the mechanisms taking place in the brain upon application of 
















First and foremost, I am highly grateful to God for granting me this wonderful opportunity of 
pursuing my graduate studies abroad.  
I would like to express my deepest gratitude to my supervisor and mentor, Professor Janusz 
Pawliszyn, for giving me the opportunity to be part of his research group - first as a Masters 
student, and now as a PhD candidate. I am sincerely grateful for being given the opportunity to be 
involved in so many exciting projects, for having been allowed to attend important conferences 
and scientific meetings where I could present my results and learn from other researchers, and for 
the valuable learning opportunities provided by Prof. Pawliszyn’s research group. 
I would like to thank my committee members, Professor Wojciech Gabryelski, Professor Michael 
Chong, and Dr. David Bell, for the time and efforts they have spent reading my thesis, and for their 
guidance and advice. I would also like to thank my external examiner, Professor Oliver Fienh, and 
my internal examiner, Professor Paul Craig, for accepting the invitation to be part of the evaluation 
committee of my work, and for the time and patience they spent in examining my thesis. Thanks 
to the examining committee for nominating my thesis to the Pearson Medal award. 
I would like to extend my gratitude to those colleagues that helped me in different ways during my 
doctoral studies. I would like to specially thank Dr. Barbara Bojko for her guidance and help at 
the beginning of my PhD.  
I want to say a big thank you to my lovely friends Ezel Boyaci and Emanuela Gionfriddo for their 
constant support, great company, and genuine friendship throughout these years - I was very lucky 
to have you both around to discuss science, to chat about life, and to laugh at everything. I want to 
also thank my dearest friends Erica Silva, Erasmus Cudjoe, and Jiang Ruifen for being so 
xi 
 
supportive at the beginning of this journey - I will always treasure the great times we spent 
together. My sincere gratitude also goes to Nikita Looby for her friendship and for always being 
so keen to correct my English.  
I am privileged to thank my colleague and husband, German A. Gómez Ríos, for his endless love, 
support, help, hope, and advice. Thanks for always being by my side, thanks for what we are 
together, and thanks for bringing so much happiness to my life. 
Lastly, I owe my deepest gratitude to my parents Emilce and Henry, to my siblings Henry Mauricio 
and Estefanía, and to the Gómez-Ríos family, their encouragement and unconditional love means 

















This thesis is dedicated to God, who gave me the resilience I needed during my journey towards 
the completion of this program; to my wonderful husband - without his unconditional love and 
encouragement, none of this would be possible; and lastly, to my parents, Emilce and Henry, and 



















Table of Contents 
 
 
Examining Committee Membership ................................................................................................ii 
Author’s Declaration ....................................................................................................................... iii 
Statement of Contributions ............................................................................................................. iv 
Abstract ........................................................................................................................................... vi 
Acknowledgements .......................................................................................................................... x 
Dedication ...................................................................................................................................... xii 
Table of Contents .......................................................................................................................... xiii 
List of Tables ................................................................................................................................ xix 
List of Figures .............................................................................................................................. xxii 
List of Abbreviations ................................................................................................................... xxx 
Chapter 1: Introduction ................................................................................................................... 1 
1.1. Preamble ........................................................................................................................... 1 
1.2. Sample preparation in bioanalysis .................................................................................... 1 
1.2.1. Traditional sample preparation methods for LC-MS-based bioanalytical studies .... 3 
1.2.2. In vivo sample preparation for tissue analysis .......................................................... 7 
1.3. Sample preparation in MS-based metabolomics ............................................................ 10 
1.4. Solid phase microextraction (SPME) ............................................................................. 19 
xiv 
 
1.4.1. The principle of SPME ........................................................................................... 19 
1.4.2. Thin-film microextraction: another geometry of SPME ......................................... 25 
1.4.3. Analysis of biofluids using SPME and LC-MS ...................................................... 26 
1.4.4. DI-SPME and LC-MS for in vivo animal studies ................................................... 29 
1.4.5. SPME and LC-MS in clinical metabolomics .......................................................... 31 
1.5. Research objective .......................................................................................................... 34 
Chapter 2: High throughput targeted analysis in plasma using thin-film solid phase 
microextraction ............................................................................................................................. 37 
2.1. Preamble and introduction ................................................................................................. 37 
2.1.1. Preamble ...................................................................................................................... 37 
2.1.2. Introduction ............................................................................................................. 37 
2.2. Experimental .................................................................................................................. 39 
2.2.1. Materials and supplies............................................................................................. 39 
2.2.2. Working solutions ................................................................................................... 40 
2.2.3. Plasma samples ....................................................................................................... 40 
2.2.4. Thin-film SPME devices......................................................................................... 41 
2.2.5. Sample preparation: automated Concept 96-blade SPME system .......................... 41 
2.2.6. LC-MS/MS conditions ............................................................................................ 42 
2.3. Results and discussion .................................................................................................... 45 
xv 
 
2.3.1. Coating selection and desorption conditions .......................................................... 46 
2.3.2. Extraction conditions: pH, temperature, time and selection of internal standards . 51 
2.3.4. Method validation ................................................................................................... 60 
2.4. Conclusions .................................................................................................................... 62 
Chapter 3: Solid phase microextraction devices prepared on plastic support as potential single-
use samplers for bioanalytical applications .................................................................................. 65 
3.1. Preamble and introduction .......................................................................................... 65 
3.1.1. Preamble ................................................................................................................. 65 
3.1.2. Introduction ............................................................................................................. 65 
3.2. Experimental section ...................................................................................................... 69 
3.2.1. Materials and supplies............................................................................................. 69 
3.2.2. Preparing thin-film SPME devices on PBT support ............................................... 70 
3.2.3. Sample preparation for LC-MS/MS analysis .......................................................... 71 
3.2.4. LC-MS/MS conditions ............................................................................................ 73 
3.3. Results and discussion .................................................................................................... 74 
3.3.1. Characterization of PAN-HLB coating prepared on plastic and evaluation of PBT 
as a support for SPME ........................................................................................................... 74 
3.3.2. Using SPME devices on polymeric support for the analysis of doping substances in 
urine, plasma, and blood ........................................................................................................ 79 
xvi 
 
3.3.3. Assessment of HLB-PAN coating wettability ........................................................ 90 
3.3.4. Evaluation of the robustness and reusability of SPME thin-film devices prepared 
on plastic substrate using high-throughput configuration. .................................................... 91 
3.4. Conclusions .................................................................................................................... 94 
Chapter 4: The effect of hematocrit on solid phase microextraction ............................................ 96 
4.1. Preamble and introduction ............................................................................................. 96 
4.1.1. Preamble ................................................................................................................. 96 
4.1.2. Introduction ............................................................................................................. 96 
4.2. Experimental section ...................................................................................................... 99 
4.2.1. Materials and supplies............................................................................................. 99 
4.2.2. Working solutions ................................................................................................. 100 
4.2.3. SPME procedure ................................................................................................... 101 
4.2.4. LC-MS/MS conditions and data processing ......................................................... 102 
4.2.5. Data analysis ......................................................................................................... 103 
4.3. Results and discussion .................................................................................................. 103 
4.4. Conclusions .................................................................................................................. 116 
Chapter 5: Evaluation of solid phase microextraction as a sample preparation tool for untargeted 
analysis of brain tissue ................................................................................................................ 118 
5.1. Preamble and introduction ........................................................................................... 118 
xvii 
 
5.1.1. Preamble ............................................................................................................... 118 
5.1.2. Introduction ........................................................................................................... 118 
5.2. Experimental ................................................................................................................ 123 
5.2.1. Materials and supplies........................................................................................... 123 
5.2.2. Investigation of SPME coating coverage and desorption conditions ................... 123 
5.2.3. Evaluation of the washing step in SPME lipid analysis ....................................... 124 
5.2.4. Extraction time investigation ................................................................................ 125 
5.2.5. LC-MS analysis .................................................................................................... 125 
5.2.6. Data analysis ......................................................................................................... 127 
5.3. Results and discussion .................................................................................................. 128 
5.3.1. Assessment of SPME coverage for the analysis of brain tissue metabolome ....... 129 
5.3.2. Assessment of SPME coverage for the analysis of lipids in brain tissue ............. 146 
5.3.3. Extraction time profiles ......................................................................................... 158 
5.4. Conclusions .................................................................................................................. 169 
Chapter 6: Application of solid phase microextraction (SPME) for in vivo monitoring of 
metabolic changes after deep brain stimulation (DBS) .............................................................. 171 
6.1. Preamble and introduction ........................................................................................... 171 
6.1.1. Preamble ............................................................................................................... 171 
6.1.2. Introduction ........................................................................................................... 171 
xviii 
 
6.2. Experimental procedure ............................................................................................... 176 
6.2.1. Materials ............................................................................................................... 176 
6.2.2. SPME sampling procedure and analysis ............................................................... 177 
6.2.3. LC- mass spectrometry (MS) analysis .................................................................. 178 
6.2.4. Data analysis ......................................................................................................... 179 
6.3. Results and discussion .................................................................................................. 179 
6.4. Conclusions .................................................................................................................. 197 
Chapter 7: Summary and future directions ................................................................................. 199 
7.1. Summary ...................................................................................................................... 199 
7.2. Future directions ........................................................................................................... 203 
Letter of copyright permission .................................................................................................... 206 












List of Tables 
 
 
Table 2.1. Optimum MS/MS parameters and chromatographic conditions for the selected target 
compounds (positive mode). Underlined compounds were tuned in positive and negative 
mode. ..................................................................................................................................... 43 
Table 2.2. Optimum MS/MS parameters and chromatographic conditions for the selected target 
compounds (negative mode). ................................................................................................. 45 
Table 2.3. Carryover found for different solvent compositions (all desorption solvents tested 
were acidified with 0.1% formic acid). Results obtained from the second desorption after 
extracting from a PBS solutions spiked at 100 ng mL-1. Desorption volume and time were 
1200 μL and 60 min in all the cases. ..................................................................................... 49 
Table 2.4. Evaluation of the effect of temperature on the amount extracted from PBS and plasma 
spiked at 100 ng mL-1 and mixed with 1 M buffer (9:1 plasma:buffer). Extraction time was 
fixed at 75 min (n=4 pins). .................................................................................................... 53 
Table 2.5. Internal standards used in the proposed SPME method. ............................................. 56 
Table 2.6. Absolute and relative matrix effects found for the proposed method. ......................... 58 
Table 2.7. Method validation for plasma analysis at optimized SPME conditions. ..................... 61 
Table 3.1. List of support materials commonly used to manufacture SPME devices.82 ............... 67 
Table 3.2. Summary of experimental conditions selected for SPME. .......................................... 73 
Table 3.3. Evaluation of absolute matrix effects in blank solution coming from desorption of new 
plastic HLB devices, and in extracts of blank urine and plasma obtained with such plastic 
devices (n=6, extracts spiked at 50 ng mL-1 and analyzed in positive ionization mode). ..... 78 
xx 
 
Table 3.4. Figures of merit for urine and plasma analysis using rounded SPME-HLB-PBT 
devices. .................................................................................................................................. 80 
Table 3.5. Enrichment factors calculated in the different matrices evaluated. ............................. 81 
Table 3.6. Figures of merit for whole blood analysis using rounded SPME-HLB-PBT devices. 86 
Table 3.7. Absolute matrix effects assessed in whole blood ........................................................ 89 
Table 3.8.  Transition ratios calculated from standards and from the tested matrices. Values were 
calculated by dividing the qualifier transition signal by the quantifier transition.  
Concentrations of up to 3 times LOQ values were considered for this calculation. ............. 89 
Table 3.9.  Average absolute recoveries obtained when using HLB thin-films prepared on PBT 
support to extract from PBS spiked at 70 ng mL-1 (n=6 thin-films)...................................... 93 
Table 4.1. Model compounds with their corresponding physicochemical properties and MS/MS 
detection parameters. Analytes are listed in order of hydrophobicity. ................................ 103 
Table 4.2. Slopes of the calibration curves constructed using blood with different Hct levels in 
the range between 5 and 100 ng mL-1 (no internal standard). ............................................. 107 
Table 4.3. Corrected calibration curve slopes for those cases where F>Fcrit. ........................... 116 
Table 5.1. Chromatographic conditions employed for this study. .............................................. 126 
Table 5.2. MS conditions for untargeted analysis of brain extracts. ........................................... 127 
Table 5.3. Comparison of feature intensities as a function of their desorption solvent (methanol 
vs. 1:1 (v/v) ACN:water). Only features with pooled QC/blank (solvent and fiber blanks) 
ratios above 5, RSD values below 30 %, and intensities above 3000 were taken into 
consideration for this comparison. ....................................................................................... 134 
Table 5.5. Comparison of detected lipid-related features by coating type. Only features with 
pooled QC/blank (solvent and fiber blanks) ratios above 5, RSD values below 30 %, and 
xxi 
 
intensities above 3000 were taken into consideration. All ratios were calculated using peak 
areas. .................................................................................................................................... 152 
Table 5.6. Summary of RSD values estimated for lipid-related features detected in positive and 
negative mode (n=4).  Only features with pooled QC/blank (solvent and fiber blanks) ratios 
above 5, pooled QC RSDs below 30 %, and intensities above 3000 were considered for the 
calculations. ......................................................................................................................... 153 
Table 5.7. Second assessment of RSD values estimated for lipid-related features detected in 
positive and negative mode via C18 fibers (n=4).  Only features with pooled QC/blank 
(solvent and fiber blanks) ratios above 5, pooled QC RSDs below 30 %, and intensities 
above 3000 were considered for the calculations. ............................................................... 156 
Table 5.8. Assessment of RSD values estimated for lipid-related features detected in positive and 
negative mode at different extraction times using C18 fibers (n=4). .................................. 168 
Table 6.1. Dysregulated metabolites characterized by MS/MS and employment of authentic 













List of Figures 
 
 
Figure 1.1. Microdialysis system. The perfusate inlet is connected to a slow flow pump. The 
dialysate is collected for further analysis. ............................................................................... 8 
Figure 1.2. General MS-based metabolomics workflow. ............................................................. 13 
Figure 1.3. General schematic of the SPME process. ................................................................... 20 
Figure 1.4. Schematic of SPME workflow for analysis of tissue samples. .................................. 30 
Figure 2.1. Comparison of C18, HLB and PS-DVB coatings performance in the extraction of 
various drugs from plasma spiked at 100 ng mL-1 (logP values in brackets). Extraction time 
was set at 75 min and the sample volume was 1200 μL (9:1 plasma:buffer). ....................... 48 
Figure 2.2. Comparison of desorption efficiency at 10, 20 and 45 min (n = 4 pins and 1200 µL of 
desorption solution (4:1 methanol:acetonitrile with 0.1% formic acid)). Extractions were 
performed from PBS spiked at 100 ng mL-1.......................................................................... 50 
Figure 2.3. Concept 96 blade system with uniform temperature control on the extraction station.
 ............................................................................................................................................... 52 
Figure 2.4. Extraction time profiles in PBS and plasma for metoprolol (logP 1.6) and stanozolol 
(logP 3.81) (n=4). .................................................................................................................. 56 
Figure 2.5. Summary of optimized SPME conditions for the analysis of prohibited substances in 
plasma. ................................................................................................................................... 57 
Figure 3.1. Rounded thin-film SPME devices prepared as described (A), microscope pictures of 
the HLB coating applied on the rounded plastic pieces (B), SEM image of the morphology 
of the coating on PBT support using 30x magnification (C) and SPME-HLB-PBT devices 
(on flat PBT support) in an arrangement compatible with the Concept 96 system (D). ....... 75 
xxiii 
 
Figure 3.2. Inter-device relative standard deviation values (RSDs, %) obtained from coated 
rounded PBT pins (n=20) for various drugs. Extractions were performed from PBS spiked at 
50 ng mL-1. The extraction time was 45 min. ....................................................................... 76 
Figure 3.3. Blanks run in positive full scan mode (100 – 1000 m/z) using TSQ vantage. A 
cleaning step was performed by exposing the rounded coated PBT devices to a mixture of 
organic solvents (2:1:1 v/v methanol:acetonitrile:isopropanol) for 60 min under vortex 
agitation conditions. .............................................................................................................. 78 
Figure 3.4. Representative SRM chromatograms corresponding to extracts obtained from urine, 
plasma and whole blood spiked at LOQ levels. Salbutamol (A), methamphethamine (B), 
stanozolol (C), clenbuterol (D), GW501516 (E), and toremifene (F). .................................. 82 
Figure 3.5. Comparison of absolute recoveries found using HLB thin-films with and without 
PAN over-coating applied by dipping. Extractions were performed from PBS spiked at 70 
ng mL-1. The extraction time was 60 min. ............................................................................. 84 
Figure 3.6. Evaluation of the effect of four different washing step approaches (10 s static, 10 s 
with vortex, two 5 s steps with vortex and three 5 s steps with vortex) on the final amount 
desorbed from rounded SPME-HLB-PBT devices (n = 4). Extractions were performed from 
PBS spiked at 50 ng mL-1 and mixed with 1 M buffer (9:1 ratio). The extraction time was set 
to 45 min. ............................................................................................................................... 85 
Figure 3.7. Microscope picture and SEM images (30x magnification) taken from SPME-HLB-
PBT devices after being exposed for 90 min to whole blood. ............................................... 87 
Figure 3.8. Water contact angles for HLB-PAN, C18-PAN and only-PAN coatings. Images were 
acquired every 2 s over a 10 min period. ............................................................................... 90 
xxiv 
 
Figure 3.9. Microscope pictures of PAN-HLB thin-films obtained by cutting pieces of 2.3 mm 
width from a coated flat PBT rectangular piece (8 x 10 cm). ............................................... 92 
Figure 3.10. Evaluation of the stability and robustness of the HLB-PAN coating applied on PBT 
support. Consecutive extractions were performed from plasma (A) and whole blood (B) 
spiked at 70 ng mL-1 and mixed with 1 M phosphate buffer in a 9:1 ratio (sample:buffer) 
(n=6). Extractions from whole blood were carried out using HLB thin-films with PAN-over 
coating. .................................................................................................................................. 93 
Figure 4.1. Extraction time profiles for salbutamol (a and b), propranolol (c and d), exemestane 
(e and f), THCCOOH (g and h). Plots on the left side summarize results for MM-F at 400 
rpm, and plots on the right side summarize results for HLB-D at 1500 rpm. ..................... 108 
Figure 4.2. Relative recoveries obtained after extracting from 70% Hct blood (hemolyzed vs. 
non-hemolyzed). These experiments were conducted using HLB-D at 1500 rpm and an 
extraction time of 90 min..................................................................................................... 113 
Figure 5.1. Features detected per coating type at different desorption conditions (positive mode). 
Features were classified according to their average relative intensities (n=4 fibers per 
coating). ............................................................................................................................... 131 
Figure 5.2. Features detected per coating type at different desorption conditions (negative mode). 
Features were classified according to their average relative intensities (n=4 fibers per 
coating). ............................................................................................................................... 132 
Figure 5.3. Ion maps corresponding to features detected in positive mode after extraction from 
brain homogenate with C18, MM, and HLB 7 mm fibers/ Desorptions carried out in 
methanol and 1:1 (v/v) ACN:water. Only features having pooled QC/blanks (solvent and 
xxv 
 
fiber blanks) ratios above 5, RSD values below 30 % in the pooled QC, and intensities 
above 3000 were plotted. ..................................................................................................... 135 
Figure 5.4. Ion maps corresponding to features detected in negative mode after extraction from 
brain homogenate with C18, MM, and HLB 7 mm fibers. Desorptions carried out in 
methanol (left) and 1:1 (v/v) ACN:water (right). Only features having pooled QC/blanks 
(solvent and fiber blanks) ratios above 5, RSD values below 30 % in the pooled QC, and 
intensities above 3000 were plotted..................................................................................... 136 
Figure 5.5. Principal component analysis (PCA) plots corresponding to C18, MM and HLB 
desorption extracts obtained in methanol and ACN:water in positive mode (left) and 
negative mode (right). Only features exhibiting pooled QC/blank (solvent blanks and fiber 
blanks) ratios above 5 and having pooled QC RSD values below 30 % were considered for 
these plots. ........................................................................................................................... 138 
Figure 5.6. OPLS-DA plots (left) and S-plots (right) corresponding to the comparison of 1:1(v/v) 
ACN:water (1) and methanol (2) extracts from all the coating types in positive (above) and 
negative (below) modes. Features highlighted have |p1| > 0.05 and |p(corr)1| > 0.8. .......... 139 
Figure 5.7. Summary of the main features discriminating 1:1 (v/v)ACN:water and methanol 
extracts (from the S-plots). The markers represent the features with the highest intensities at 
each of the specified conditions........................................................................................... 140 
Figure 5.8. Representative metabolites identified in brain extracts obtained with the three 
different coating types using 1:1 (v/v)ACN:water as desorption solvent (n=4 fibers). ...... 142 
Figure 5.9. Representative metabolites identified in brain extracts obtained with the three 
different coating types using methanol as desorption solvent (n=4 fibers). ........................ 143 
xxvi 
 
Figure 5.10. OPLS-DA plots and S-plots corresponding to a comparison of HLB(1) and MM (2) 
extracts in positive (above) and negative (below) modes. Features highlighted have |p1| > 
0.05 and |p(corr)1| > 0.8. ..................................................................................................... 145 
Figure 5.12. Lipid-related features detected in negative mode for each coating type after 
extraction from brain tissue. Features were classified according to their average relative 
intensities (n=4 fibers per coating type). ............................................................................. 148 
Figure 5.13. Ion maps corresponding to lipid-related features detected in positive mode after 
extraction from brain homogenate for 30 min with C18, MM, and HLB 7 mm fibers, 
followed by desorption in 1:1 (v/v) methanol:isopropanol. Only features having pooled 
QC/blank (solvent and fiber blanks) ratios above 5, RSD values below 30 % in the pooled 
QC, and intensities above 3000 were considered. ............................................................... 150 
Figure 5.14. Ion maps corresponding to lipid-related features detected in negative mode after 
extraction from brain homogenate for 30 min with C18, MM, and HLB 7 mm fibers, 
followed by desorption in 1:1 (v/v) methanol:isopropanol. Only features having pooled 
QC/blank (solvent and fiber blanks) ratios above 5, RSD values below 30 % in the pooled 
QC, and intensities above 3000 were considered. ............................................................... 151 
Figure 5.15. Evaluation of different washing solutions after 30 min extractions from plasma 
(above) and brain homogenate (below). RSD values were calculated based on peak areas 
detected in five SPME fibers (n=5). .................................................................................... 155 
Figure 5.16. Cloud plots corresponding to a pairwise comparison of HLB extracts obtained in 
positive mode. Features showing significant differences (p-value<0.05 and fold changes > 
1.5) in a comparison between two pairwise groupings, 5 versus 40 min extractions (above) 
xxvii 
 
and 30 versus 40 min extractions (below), are represented in green (higher intensities in 40 
min extracts) and red circles (higher intensities in 5 and 30 min extracts). ........................ 160 
Figure 5.17. Cloud plots corresponding to a pairwise comparison of MM extracts obtained in 
positive mode. Features showing significant differences (p-value<0.05 and fold changes > 
1.5) in a comparison between 2 pairwise groupings, 5 versus 40 min extractions (above) and 
30 versus 40 min extractions (below), are represented in green (higher intensities in 40 min 
extracts) and red circles (higher intensities in 5 and 30 min extracts). ............................... 161 
Figure 5.18. Extraction time profiles constructed with HLB and MM coatings corresponding to 
representative metabolites occurring in brain tissue (n=4). ................................................. 163 
Figure 5.19. Cloud plots corresponding to the pairwise comparison of 5 versus 40 min 
extractions conducted with C18 fibers and run using the LC-MS method for lipids analysis. 
Features showing significant differences (p-value<0.05 and fold changes > 1.5) in positive 
(above) and negative (below) modes are represented in green (higher intensities in 40 min 
extracts) and in red circles (higher intensities in 5 min extracts). ....................................... 165 
Figure 5.20. Cloud plots corresponding to a pairwise comparison of 30 versus 40 min extractions 
conducted with C18 fibers, and run using the LC-MS method for lipids analysis. Features 
showing significant differences (p-value<0.05 and fold changes > 1.5) in positive (above) 
and negative (below) modes are represented in green (higher intensities in 40 min extracts) 
and red circles (higher intensities in 30 min extracts). ........................................................ 166 
Figure 5.21. Extraction time profiles corresponding to representative fatty acids and lipids 
occurring in brain tissue (n=4). Extractions were conducted using C18 fibers, and the post-
extraction rinsing step was carried out in 10 % acetone (v/v). Lysophosphatidyletha-
xxviii 
 
nolamine (LysoPE), galactosyl or glucosyl ceramide (Gal/GlcCer), sphingomyelin (SM), 
phosphatidylethanolamine (PE), phosphatidylserine (PS), and phosphatidylcholine (PC). 167 
Figure 6.1. Sampling holder designed for in vivo brain sampling of rats. .................................. 176 
Figure 6.2. General schematic of the sampling procedure. ......................................................... 177 
Figure 6.3. Box plots, MS/MS spectra obtained at 20 NCE, and overlaid extracted ion 
chromatograms corresponding to citrulline (A, B and C) and glutamate (D, E and F). *** p-
value<0.0001, ** p-value<0.001, * p-value<0.01. .............................................................. 185 
Figure 6.4. Box plots, MS/MS spectra obtained at 20 NCE, and overlaid extracted ion 
chromatograms corresponding to taurine (A, B and C) and uric acid (D, E and F). *** p-
value<0.0001, ** p-value<0.001, * p-value<0.01. .............................................................. 187 
Figure 6.5. Box plots (A), overlaid extracted ion chromatograms (B), and MS/MS spectrum 
obtained at 20 NCE (C) for the feature m/z 333.2075. Comparison of experimental MS/MS 
spectrum with PGA2 (D), and 8-iso PGA2 (E) MS/MS spectra. *** p-value<0.0001, ** p-
value<0.001, * p-value<0.01. .............................................................................................. 191 
Figure 6.6. Metabolomic cloud plots representing upregulated (green) and downregulated (red) 
features (p-value<0.01, fold change>1.5) detected in positive mode using C18 fibres. 
Comparisons of baseline versus post-DBS extracts, and controls versus treated animals are 
shown above and below, respectively. ................................................................................ 193 
Figure 6.7. Metabolomic cloud plots representing upregulated (green) and downregulated (red) 
features (p-value<0.01, fold change>1.5) detected in negative mode using C18 fibres. 
Comparisons of baseline versus post-DBS extracts, and controls versus treated animals are 
shown above and below, respectively. ................................................................................ 194 
xxix 
 
Figure 6.8. Boxplots and overlaid extracted ion chromatograms of representative lipids showing 
statistically significant differences when comparing before (BL) versus after DBS and 
control versus after DBS extracts *** p-value<0.0001, ** p-value<0.001, * p-value<0.01.
 ............................................................................................................................................. 195 
Figure 7.1. Summary of the advantages of SPME as a sample preparation technique in the 



















List of Abbreviations 
 
 
20-HETE 20-hydroxyeicosatetraenoic acid 
6-OHDA 6-hydroxydopamine  
ACN  acetonitrile 
ADSA axisymmetric drop shape analysis  
AGC automatic gain control  
AMPA α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid  
ANOVA analysis of variance 
BG basal ganglia  
BL baseline 
 
BSA bovine serum albumin  
CAMH Center for Addiction and Mental Health  
CE capillary electrophoresis  
cGMP cyclic guanosine monophosphate 
CNS central nervous system  
CSF cerebrospinal fluid  
CUMS chronic unpredictable mild stress model  
CV coefficient of variation  
CW/TPR carbowax/templated resin  
DBS deep brain stimulation  
DBSS dried blood spots 
DI direct immersion  
xxxi 
 
DMF N,N-dimethyl formamide  
DS dilute-and-shoot  
DVB divinylbenzene 
EDTA ethylenediaminetetraacetic acid  
GABA gamma-aminobutyric acid  
GalCer galactosylceramide 
GC gas chromatography  
GluCer glucosylceramide 
GPi globus pallidus internus  
Hct hematocrit 
H-ESI heated electrospray ionization 
HILIC hydrophilic interaction chromatography 
HLB hydrophilic lipophilic balanced  
HLB-D hydrophilic lipophilic balanced coated devices 
HPLC high performance LC 
HRMS high resolution MS  
HS headspace 
IsoPs isoprostane 
LC liquid chromatography  
LHb lateral habenula  
LLE liquid-liquid extraction  
log P logarithmic octanol-water partition coefficients  
LOQ limit of quantitation 
xxxii 
 
LysoPE lysophosphatidylethanolamine  
MALDI matrix-assisted laser desorption ionization  
MD microdialysis 
MEPS microextraction by packed sorbent 
MIP molecularly imprinted polymers  
MM mixed mode, C18 or C8 with benzenesulfonic acid group 
MM-F mixed mode fibres 
MRPL minimum required performance levels 
MS mass spectrometry  
MS/MS tandem MS  
MTBE methyl tert-butyl ether 
NCE normalized collision energy  
NMDA N-methyl-D-aspartate  
NMR nuclear magnetic resonance  
NO nitric oxide  
NOS nitric oxide synthase  
OPLS orthogonal partial least squares  
PA polyacrylate  
PAN polyacrylonitrile 
PBA phenyl boronic acid  
PBS phosphate-buffered saline solution  




PCA principal component analysis  
PD Parkinson’s disease  
PDMS polydimethylsiloxane 
PE phosphatidylethanolamine 
PET positron emission tomography  
PFP  pentafluorophenyl  
PLS partial least squares  
PP protein precipitation  
ppb parts per billion  
ppm part per million 
PPY polypyrrole-based polymers 
PRM parallel reaction monitoring  
PS-DVB polystyrene-divinylbenzene  
QC quality control 
RAM restricted access materials  
RP reversed phase 
rpm revolutions per minute 
RSDs relative standard deviations  
SEM scanning electron microscopy  
SM sphingomyelin 
SNpr substantia nigra pars reticulate  
SPE solid phase extraction 
SPME solid phase microextraction  
xxxiv 
 
SRM selected reaction monitoring  
STN subthalmic nucleus  
TA tranexamic acid  
THC tetrahydrocannabinol 
THCCOOH (±)11-nor-9-carboxy-Δ9- tetrahydrocannabinol 
TOF time-of-flight  
UV ultraviolet detection 
VAMS volumetric absorptive microsampling  
vmPFC ventromedial prefrontal cortex  
WADA World Antidoping Agency 
XOR xanthine oxidoreductase  
β-NAD β-nicotinamide adenine dinucleotide 














Chapter 1: Introduction 
 
1.1. Preamble 
Nathaly Reyes-Garcés was the sole writer of this chapter. An excerpt of this introduction (500 
words) was already published in the paper “E.A. Souza-Silva, N. Reyes-Garcés, G.A. Gómez-
Ríos, E. Boyaci, B. Bojko and J. Pawliszyn. A critical review of the state of the art of solid phase 
microextraction of complex matrices III. Bioanalytical and clinical applications. Trends Anal. 
Chem. 2015, 71, 249-264”, and is being reprinted in this thesis with permission of Elsevier, and in 
compliance with Elsevier and University of Waterloo policies. 
I, Erica Souza-Silva, authorize Nathaly Reyes-Garcés to use the material for her thesis. 
I, German A. Gómez-Ríos, authorize Nathaly Reyes-Garcés to use the material for her thesis. 
I, Ezel Boyaci, authorize Nathaly Reyes-Garcés to use the material for her thesis. 
I, Barbara Bojko, authorize Nathaly Reyes-Garcés to use the material for her thesis. 
 
1.2. Sample preparation in bioanalysis 
Bioanalysis can be defined as the field that covers the measurement of analytes of interest in a 
given biological system. In this sub-discipline of analytical chemistry, exogenous and endogenous 
compounds in complex biological matrices, such as biofluids and tissue, for instance, are analysed 
by employment of multiple methodologies tailored according to the analyte(s) of interest. The 
general bioanalytical workflow involves a series of steps, namely sampling, sample storage, 
sample preparation, instrumental analysis, and data processing, all of which are critical in 
guaranteeing reliable measurements. Considering the complexity of certain biological matrices 
and, in some cases, the demand for the processing of large numbers of samples in short periods of 
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time, bioanalytical chemists are constantly seeking new strategies that allow for cheap, fast, and 
accurate results. Currently, procedures encompassing mass spectrometry (MS) coupled with 
separation techniques such as gas chromatography (GC) or liquid chromatography (LC) have been 
adopted as instrumental methodologies in various analytical laboratories. For that reason, new 
developments in sample preparation strategies are almost always oriented to be compatible with 
such type of instrumentation. Taking into account the high selectivity offered by MS, and more 
specifically tandem MS (MS/MS) and high resolution MS (HRMS), the time spent optimizing 
sample preparation in targeted analysis today has certainly been minimized as compared to that 
needed for previously used procedures such as the earlier technique of choice, high performance 
LC (HPLC) coupled with ultraviolet detection (UV).1 In regards to untargeted analysis, while 
simple and non-selective sample preparation methodologies are highly preferred, special 
precautions in terms of sample manipulation must be taken into consideration so as to ensure 
analyte integrity. Irrespective of the type of analysis being carried out, non-selective sample 
preparation of highly complex biological matrices can lead to the co-extraction of interferences 
capable of inducing ion suppression/enhancement in electrospray ionization (ESI) and/or 
compromising the performance of the analytical instrumentation. In this context, the evaluation 
and introduction of alternative sample preparation methodologies able to fulfill the needs of the 
application of interest are invaluable in the progress towards more efficient analytical strategies. 
With this in mind, in the following sub-section, a summary centered on the advantages and 
disadvantages of typical sample preparation approaches used to handle biological matrices, such 
as dilute-and-shoot (DS), protein precipitation (PP), liquid-liquid extraction (LLE) and solid phase 
extraction (SPE), is presented. As the molecular composition of such complex matrices is quite 
diverse, for the purpose of the currently presented work, only analysis of small compounds and 
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metabolites with molecular weights below 1200 Da has been considered for discussion. Next, 
important aspects pertaining to sample preparation for in vivo and untargeted metabolomics studies 
are discussed. Lastly, solid phase microextraction (SPME) is introduced as an attractive alternative 
tool in sample preparation of biological matrices for both targeted and untargeted studies.  
 
1.2.1. Traditional sample preparation methods for LC-MS-based bioanalytical studies 
The most common sample preparation approaches for the analysis of biofluids are DS, PP, LLE, 
and SPE. Depending on the type of matrix being analyzed, as well as the compounds of interest, 
one or a combination of these approaches is typically employed. DS, for instance, has been broadly 
reported as an adequate technique for processing of urine samples prior to LC-MS. In DS, an 
aliquot of sample matrix is further diluted with water by a factor ranging from 1:1 to 1:10.2 As 
urine is a nearly protein-free matrix, this approach seems quite convenient for multiresidue studies. 
However, the salt content and highly variable composition of urine render this methodology very 
prone to ion suppression effects, particularly for the analysis of early eluting compounds.3  
For analysis of biofluids characterized by a high protein content, PP is perhaps the most widely 
used sample preparation method. In this approach, an aliquot of sample matrix is mixed with a 
miscible organic solvent such as methanol or acetonitrile in proportions that vary from 1 to 4 
“parts” of solvent per each “part” of biofluid. Use of other precipitating agents, such as salts, strong 
acids, and even heat, has also been reported.4 In addition, several authors have studied the 
efficiency of different precipitants in terms of the percentage of protein being removed from the 
matrix. For example, in terms of protein removal efficiency, acetonitrile, 10% trichloroacetic acid 
(w/v), and zinc sulfate have been observed to be more effective than other precipitants.5 However, 
in terms of LC-MS compatibility and absolute matrix effects, acetonitrile and 10% trichloroacetic 
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acid (w/v) are indicated as the best options for protein removal.4,5 Although PP is a very simple 
strategy that provides good coverage for both polar and non-polar compounds, the final extract 
may contain high concentrations of matrix interferences that can hinder mass spectrometry 
analysis of certain compounds.  
LLE, in turn, involves the use of a non-water miscible organic solvent to extract analytes of 
interest. Organic solvents such as hexane, cyclohexane, ether, ethylacetate, and methyl tert-butyl 
ether (MTBE) have all been used in different applications.4 LLE offers satisfactory performance 
in terms of salt and protein removal. As extraction of a given analyte is affected by its charge (pKa) 
in this approach, the pH of the solution as well as the physicochemical characteristics of the analyte 
of interest play an important role in determining the extraction efficacy of LLE applications. 
Similarly to PP, LLE is a simple technique that has been used for decades. Nonetheless, the 
significant disadvantages this method imparts in terms of poor recovery of polar analytes, the 
possibility of emulsion formation, and lack of selectivity when conducting targeted analysis should 
not be neglected. It is worth emphasizing that both LLE and PP have been semi and fully automated 
in a 96-well plate format for the high-throughput analysis of biological fluids.6,7 As a means to 
account for ionization effects and for the poor selectivity of both PP and LLE, careful evaluation 
of these methodologies in different sample batches with the use of appropriate internal standards 
is highly recommended as part of the method validation.  
SPE, as one of the most widely employed sample preparation methods, has also been extensively 
reported in the analysis of different biological matrices.8 In SPE, the sample matrix is passed 
through a cartridge packed with a sorbent material that displays high affinity for the target analytes. 
Prior to elution of compounds of interest from the sorbent bed, different rinsing solutions can be 
used to remove interferences from the cartridge so as to allow for improved selectivity. The 
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availability of various types of sorbent chemistries that enable the isolation of a wide range of 
compounds is undoubtedly an important advantage of SPE. Indeed, the development of new 
sorptive materials has been closely related to the expansion and broad acceptance of this technique 
as a sample preparation strategy in different fields. In many cases, SPE overcomes the 
disadvantages of LLE and PP in regards to sample dilution, lack of selectivity, and ionization 
suppression effects.4 However, SPE requires longer optimization and sample preparation times, 
the extraction cartridges are usually expensive and single-use, and, depending on the complexity 
of the sample under study, clogging of cartridges may occur. When aiming for concomitant 
exhaustive extraction of multiple compounds with SPE, careful attention should be paid so as to 
not exceed the breakthrough volume of the compounds with lesser affinity for the sorbent material. 
To date, SPE has been successfully automated for multiple sample analysis, and is available in a 
96-well plate format, providing sufficient throughput in bioanalytical applications.9,10 For analysis 
of small sample volumes (around 10 µL), a miniaturized version of SPE, or MEPS 
(microextraction by packed sorbent), has gained wide acceptability in the bioanalytical field. 
Unlike typical SPE applications, in MEPS, each cartridge can be used several times, and on-line 
coupling with GC and LC is enabled. Applications of MEPS in bioanalysis have been thoroughly 
reviewed.11  
In a discussion of sample preparation workflows employed to analyse biofluids, the dried blood 
spots (DBSS) technique is also worth of mention. DBSS is an alternative to traditional blood 
sampling that has gained wide acceptance in clinical analysis due to its low sampling 
invasiveness.12,13 In DBSS, a small volume of blood (less than 20 µL) from a finger prick is 
collected onto filter paper cards and allowed to dry; subsequent desorption of the spot is then 
performed into an LC compatible solvent. As samples are deposited onto a paper and stored at 
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room temperature, no special storage or handling conditions are required for this technique. The 
main limitations of DBSS are associated with the need for highly sensitive instrumentation due to 
the low sample volume loaded on the paper (particularly in cases where the analyte is present at 
very low concentration), the potential degradation of unstable analytes due to storage conditions, 
and considerable variability in blood spreading owing to the type of paper used (chromatographic 
effect) and hematocrit levels (blood viscosity depends on hematocrit).14 A more in-depth 
discussion pertaining to DBSS considerations is provided in Chapter 4. Due to the increasing 
applicability of DBSS in bioanalysis, significant progress has been made on automated on-line 
desorption of DBSS coupled with LC-MS/MS.12,15–17 Based on the simplicity and low invasiveness 
of DBSS, further implementation in tests of clinical interest is foreseen for this technique. 
The analysis of tissue, as a complex yet indispensable matrix in bioanalytical studies, also plays a 
vital role in targeted and untargeted analysis. It is well-known that workflows for isolation of 
analytes of interest from such complex media are labour intensive and time consuming. When 
preparing such types of samples, a homogenization step prior to the extraction process is almost 
always required. Depending on the type of tissue matrix (e.g. soft tissue such as brain or liver, 
tough tissue such as muscle or heart, or hard tissue such as skeletal bone) as well as on the analytes 
of interest (stable compounds or fragile metabolites), different homogenization strategies, such as 
grinding, cryogenic pulverizing, bead beating, sonication, and enzymatic homogenization, among 
others, can be used prior to extraction.18,19 Further, the addition of solvent during the 
homogenization step has been observed to greatly facilitate the homogenization process as well as 
the extraction of analytes.20  After tissue homogenates are obtained, PP and/or LLE, followed in 
some cases by SPE to improve extraction selectivity, can be carried out to isolate the analytes of 
interest.    
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1.2.2. In vivo sample preparation for tissue analysis 
The study of biological systems typically involves a sampling step, where an aliquot representative 
of the status of the system is taken for further analysis. However, continuous monitoring of the 
system under investigation at close to real-time conditions can elucidate important information 
regarding the system that is not always accessible via traditional sample preparation workflows. 
For tissue analysis, the attainment of representative samples with aims of monitoring an organism 
at different time points is unlikely to be achieved without significantly compromising the status of 
the studied system. In this context, strategies for in vivo sample preparation have been proposed 
and implemented in several study cases. Of the currently available techniques today, microdialysis 
(MD) is perhaps the most widely used and accepted, with its applicability for in vivo and 
continuous measurement of several metabolites in various types of human and animal tissue 
demonstrated in various studies. In MD, a small probe with a semi-permeable membrane (typical 
molecular cut-off 10-50 kDa) is employed to determine the extra-cellular concentration of the 
analyte of interest. As illustrated in Figure 1.1, a perfusate solution,  generally a buffer selected to 
resembles the composition of the extra cellular fluid, is pumped through a catheter (0.5 – 10 
µL/min) that has been previously placed in the sampling site. As the perfusate flows, diffusion of 
analytes from the sampling media into the membrane takes place due to a concentration gradient. 
Simultaneously to the permeation of analytes into the acceptor phase, molecules of perfusate can 
also diffuse towards the sampling media. The dialysate (perfusate containing analytes) is collected 
for a defined period of time for further instrumental analysis.21 MD has been successfully used in 
conjunction with LC-MS for in vivo determinations of several hydrophilic and small metabolites 




Figure 1.1. Microdialysis system. The perfusate inlet is connected to a slow flow pump. The 
dialysate is collected for further analysis. 
 
drugs and drug metabolites.22 Nonetheless, MD exhibits some limitations in the analysis of 
compounds prone to non-specific adsorption.22,23 As a strategy to overcome this shortcoming, the 
incorporation of additives such as cyclodextrin and bovine serum albumin (BSA) in the perfusate 
solution has been proposed.22,24 Although this approach has proven to be useful in the 
determination of several neuropeptides and endocannabinoids, decreases in the mass transfer 
process have been observed to occur in certain applications; further, the addition of BSA has been 
shown to restrict the attainment of a protein-free dialysate, thus requiring the addition of another 
step to the sample preparation workflow. Another disadvantage of MD relates to the not-so-
compatible composition of the dialysate for MS analysis.22 The high content of salts found in the 
perfusate solution, as well as the typical low concentrations that are attained in MD, both hinder 










clogging of the MS inlet. To overcome this hindrance, a number of strategies aimed at avoiding 
the introduction of salts into the MS analyzer, including the use of divert valves, employment of 
an additional sample preparation step such as LLE or SPE (on-line or off-line), and column 
switching, have been reported by various authors in the literature.25–27 Yet, despite the rewarding 
results obtained in the determination of several metabolites and exogenous compounds through 
the use of such approaches, the employment of MD in bioanalytical applications is limited due to 
its unsuitability for analysis of large hydrophobic compounds such as lipids, which are known 
biomarkers of significant biochemical interest. In this regard, SPME has been demonstrated to 
provide complementary information to MD. A more in-depth discussion regarding the application 
of SPME towards in vivo determinations of different compounds and metabolites can be found in 
Section 1.3. 
Push-pull perfusion is yet another in vivo sampling approach that allows for the collection of tissue 
interstitial fluid. In this technique, artificial fluid is infused into tissue through one tube, while the 
collection of the infused fluid is performed with a second tube placed close to the infused area. 
Although push-pull perfusion is a relatively simple approach to access tissue information, this 
technique can induce significant tissue damage, as fluid is pumped into tissue using flows in the 
range of µL/min. With aims of overcoming this drawback and so as to improve spatial resolution, 
researchers introduced a modified version of this technique, namely low-flow push-pull perfusion, 
that employs significantly smaller flows and uses narrow bore capillaries.28 The suitability of this 
methodology for in vivo tissue monitoring, particularly in neurochemical studies, has been 
demonstrated and also reviewed.28–31 Although further evaluation of this technique is needed to 
assess its performance in the analysis of a broader range of compounds, it is anticipated that 
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similarly to MD, push-pull perfusion is not well-suited for the determination of hydrophobic 
analytes. 
1.3. Sample preparation in MS-based metabolomics  
Metabolomics can be defined as a field aimed at the systematic and comprehensive study of 
metabolite content (metabolome) present in biological systems. As metabolomics is the endpoint 
of the “omics cascade”, the metabolome directly reflects the biochemical status of the system under 
study, and therefore, can be said to provide the closest representation of the individual phenotype 
of said system. However, due to the highly complex composition of the full metabolome, to date, 
no single platform is capable of accurately measuring all of its components.32 In this context, 
several analytical workflows have been developed and evaluated in terms of metabolite coverage, 
limits of detection, and robustness.2,33–36 Although nuclear magnetic resonance (NMR)-based 
platforms have shown rewarding results in multiple applications, their insufficient performance in 
the detection of metabolites occurring at low concentration levels have limited their applicability 
in certain metabolomics studies.32,36 Conversely, MS-based approaches have been gaining 
increasing attention in metabolomics applications, owing to their capabilities for the analysis of 
compounds at pico and nanomolar concentrations.36 Moreover, the suitability of MS for 
hyphenation with separation techniques such as GC, LC, and capillary electrophoresis (CE) has 
greatly facilitated the study of complex metabolite mixtures, while also aiding in the reduction of 
matrix effects.36 While there are several different separation-MS combinations available to date, 
considering that LC-MS is the most widely used combination in bioanalytical applications, and 
also the approach of choice for the currently presented work, further discussion will be focused on 
LC-MS-based metabolomics workflows.   
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Two main strategies can be followed when performing metabolomics studies. The first, referred 
to as targeted metabolomics, applies to cases where a defined set of metabolites is measured owing 
to their involvement in a specific metabolic pathway, or because such metabolites belong to a 
particular class of compounds. The second strategy is called untargeted metabolomics, also known 
as global metabolomics, and relates to the determination of all detectable metabolites present in a 
given sample.36 Whereas in the first strategy, experimental conditions can be tuned to enhance the 
recovery and detection of metabolites of interest, in the second approach, non-selective parameters 
must be selected with aims to gather unbiased information regarding the biological system under 
study. In regards to the advantages imparted by each approach, in the case of targeted 
metabolomics, fully quantitative information can be obtained, allowing for the validation of 
hypotheses regarding pathways being affected by different stimuli. On the other hand, in 
untargeted metabolomics, new information corresponding to unknown biological mechanisms can 
be unveiled, allowing for an enhanced understanding of biological systems.36 Typical 
metabolomics methodologies, either for targeted or untargeted analysis, generally involve 
comparisons of at least two different groups of samples or individuals, where each group represents 
a defined biological status (e.g. control versus treatment group, or healthy versus diseased group). 
Comparisons can also be drawn out between samples taken from a single group of individuals 
before and after application of a given treatment. The employment of statistical tools allows for 
comparisons to be made between the metabolomes representative of each group, imparting 
valuable information regarding dysregulated compounds associated with different biochemical 
pathways affected by the treatment under investigation. Such studies have been successfully 
undertaken in different research areas with the use of cells, microorganisms, plants, animals, and 
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humans models.37–40 As the scope of this thesis involves the analysis of biological matrices from 
animal and human origin, the oncoming discussion will be primarily focused on such matrices.  
The success of any metabolomics experiment strongly relies on the appropriate execution of each 
of the steps of the analytical workflow (Figure 1.2). As can be seen in Figure 1.2, the first stage of 
a metabolomics study involves sample collection and storage, which must be controlled so as to 
avoid metabolome alterations. While different biological matrices can be used for metabolomics, 
with each demanding an optimized protocol for sample collection and analysis, biofluids are 
commonly selected as matrices of choice owing to their easy collection and biological significance. 
Urine, for instance, is a highly abundant matrix that contains representative information regarding 
all biochemical pathways occurring in a given organism. In addition, urine allows for non-invasive 
collection, which facilitates the sampling step.41 To ensure proper preservation of the metabolites 
of interest, any bacterial activity should be avoided by filtering urine through a 0.22 µm filter after 
sample collection.42 In addition, metabolome integrity should be guaranteed by keeping urine 
samples at - 80 °C, and by avoiding freeze-and-thaw cycles.41 Other important biofluids in 
metabolomics studies are blood fractions. Blood fractions are the most widely used matrices in 
metabolomics, and unlike urine sample collection, collection of such matrices requires the 
involvement of professionally trained personnel. Although both serum and plasma have been 
successfully employed in multiple reports, the clotting procedure undertaken in the collection of 
serum samples has been previously shown to induce changes in metabolome composition.43,44 As 
such, the use of plasma as a matrix of choice may enable a more accurate picture of the metabolic 
status of the investigated individual. When working with plasma and serum, certain factors must 
be taken into consideration. For instance, a suitable workflow for sample collection and storage  
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Figure 1.2. General MS-based metabolomics workflow. 
should ensure that all samples are collected with the same type of anticoagulant (in the case of 
plasma),clotting conditions are controlled (in the case of serum), and that the method being 
employed is capable of avoiding hemolysis during the fractionation step. In addition, a storage 
protocol for blood fractions should include storage of samples preferably at - 80 °C, and be 
designed so as to prevent freeze-and-thaw cycles, which can greatly impact metabolome integrity. 
Other biofluids, such as cerebrospinal fluid (CSF), saliva, human breast milk,  and bile, have been 
also utilized in metabolomics.45 However, due their restricted availability, the number of 
publications reporting the analysis of such biofluids is significantly less extensive than that of urine 
and blood fractions. In addition to the use of biofluids, the analysis of tissue in metabolomics 
studies has gained a lot of attention, owing to the site-specific information that this matrix is 
capable of imparting. Nonetheless, collection of tissue is a very invasive procedure that requires 
highly trained medical personnel, while studies involving rodents usually involve their sacrifice 
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recommended prior to storage of tissue specimens so as to avoid alterations of metabolome 
composition stemming from any remaining blood.34,46 Liquid nitrogen is typically used for tissue 
metabolism quenching, with storage of samples also performed at -80 °C. As this matrix is solid 
and also heterogeneous, a homogenization step at very well-controlled conditions is required prior 
to extraction. Further information regarding considerations in tissue metabolomics is provided in 
Chapter 5.    
After ensuring that the integrity of the metabolites of interest is maintained through application of 
proper controls to sample collection and storage, isolation of the metabolome from other matrix 
constituents can be undertaken. Given the complexity of any biological sample, the sample 
preparation method employed should be able to preserve the metabolome composition, while 
allowing for fast turnover times, reproducible results, and maximum metabolite coverage. Typical 
sample preparation approaches for metabolomics studies involve traditional methods such as DS, 
PP, and LLE, all which have already been described in Section 1.1.1. The advantages of these 
methods rely on their simplicity, affordability, and non-selectivity, which facilitate the processing 
of large volumes of samples. DS, for instance, has been demonstrated to be a suitable approach in 
untargeted urine metabolomics, with satisfactory results in terms of instrumental drifting, retention 
time stability, and repeatability for highly abundant compounds (coefficient of variation (CV) < 
15%) reported when using reversed phase chromatography in combination with MS.47 However, 
in the same study, low intensity signals were found to be characterized by high variability, which 
could be correlated to the absence of a clean-up step and possible matrix effects. For solvent-based 
extraction approaches, PP with the use of organic solvents is recognized as the most broadly used 
strategy in untargeted analysis of biofluids. Several studies directed at the identification of 
optimum PP conditions have shown that the use of methanol, either alone or with other solvents 
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such as ethanol and acetonitrile, offers optimal results in terms of detected metabolite features.48,49 
Moreover, aiming to reduce metabolome alterations, the use of cold solvents has been reported in 
several sample preparation workflows as part of the metabolism quenching step.35,40,50 However, 
it should be highlighted that complete precipitation of proteins is not always easily attained when 
using solvents. For that reason, a careful assessment of  LC column performance should always be 
considered in method development, as protein build up has been shown to decrease typical column 
lifetime.2 As another well-known sample preparation technique, LLE is also widely applied in both 
targeted and untargeted metabolomics. Due to the selectivity of LLE for the extraction of 
hydrophobic compounds, this approach has been particularly useful for the analysis of multiple 
lipid classes. For this purpose, different solvents have been tested with aims to determine which 
solvents enable the best recoveries for various biological matrices. Among recent lipidomics 
studies, the most commonly employed solvent combinations are chloroform/methanol and 
MTBE/methanol.51 Alternatively to using PP and LLE independently, a combination of both 
approaches has been proposed with aims of expanding the coverage of the metabolome extracted 
from a single sample.52 In this interesting methodology, sample preparation of only 20 µL of 
plasma is performed in an HPLC vial by adding small aliquots of water, methanol, and 200 µL of 
MTBE. After mixing and centrifuging the vial contents, separation of the different solvent phases 
occurring in the same vial can be accomplished. Analysis in two different chromatographic 
methods, one for metabolites and one for lipids, is conducted by injecting from the same vial at 
two different needle positions. Besides facilitating the recovery of a broad range of metabolites 
from plasma, this approach has been demonstrated to be highly reproducible in comparison to 
methods that require evaporation and reconstitution. Based on the positive results provided by this 
methodology, an evaluation of its performance in analysis of brain tissue homogenate was also 
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conducted.53 Rewarding results were obtained, with approximately 4000 metabolite features 
detected from 3 mg of tissue. Further assessments of this in-vial dual approach towards the analysis 
of more tissue types should enable better insights regarding its applicability. Another sample 
preparation technique that has been evaluated in metabolomics studies is SPE. Although it may 
seem that the selectivity offered by SPE sorbents is not ideal for global metabolomics applications, 
results worthy of discussion have been obtained. For instance, Michopholus et al. compared PP 
with acetonitrile and methanol versus SPE using C18 cartridges in terms of metabolite features 
extracted from human plasma. Their results demonstrated that SPE allowed for significant 
improvement in method repeatability compared to other methodologies.54 In more recent work, a 
thorough comparison of seven methods, including different conditions for PP, LLE, and SPE, was 
conducted using plasma as a model matrix.55 Results showed that although SPE provided an 
additional 600 features not detected by other methods, the use of multiple extraction approaches 
for analysis of individual samples did not translate into significant improvements in metabolome 
coverage. In addition, the same study confirmed that the best coverages were observed for methods 
using PP with methanol; however, PP approaches were also evidenced to be highly prone to matrix 
effects, which hinder the analysis of low intensity features and can also lead to biased results. As 
can be inferred from the discussion presented until now, there is no sample preparation approach 
available today that is capable of providing a complete, unbiased snapshot of the entire 
metabolome of a given system. In view of the short-comings of the available methodologies, 
various strategies have been implemented to facilitate the gathering of high quality data in 
metabolomics, such as including quality control samples to ensure analytical precision (technical 
replicates) and instrumental stability (instrumental replicates), addition of internal standards to 
account for variations in sample preparation and instrumental drift, randomization of samples 
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injections to avoid any systematic bias, analysis of blank samples to account for background 
artefacts, and the incorporation of sufficient biological replicates, among others. Alternative to 
more conservative methodologies where sample preparation is performed in vitro, the use of in 
vivo sampling/sample preparation for metabolomics presents an interesting opportunity for 
investigations of biological systems from a different perspective. As extractions are carried out 
directly from the living organism, improved recovery of unstable compounds and reduced risks of 
metabolome alterations are facilitated.2,56,57 Moreover, as in vivo applications enable the 
monitoring of the same system or organism at different time points, such applications facilitate the 
detection of small changes that could shed light on different biological processes. MD, for instance, 
has been extensively employed for the concurrent targeted analysis of selected neurotransmitters.29 
Pertaining to applications covering a broader range of metabolites, only few reports analysing MD 
dialysates via LC-MS have been published to date, likely due to the complex composition of the 
perfusion solution. In one of those studies, analysis of dialysates obtained in vivo from a crustacean 
hemolymph was undertaken with the use of CE and matrix-assisted laser desorption ionization 
(MALDI) coupled to ion mobility MS, and also through employment of LC-MS. By employing 
this multifaceted platform, the authors were able to identify 208 metabolites, from which 39 were 
found to be neurotransmitters.58 Similarly, in recent work, MD was employed for the in vivo 
monitoring of wound fluids released from bone and soft tissue healing.59 Results showed that the 
use of proteomics and metabolomics workflows enabled the determination of important biological 
differences between the two wound scenaRíos. Despite the limited number of metabolomics works 
reported in the in vivo sampling/sample preparation field, this approach imparts great promise in 
the metabolomics field, as it can provide complementary information to what is already known 
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from typical in vitro workflows. The role of SPME is this modality will be further discussed in 
Section 1.3.4.    
In regard to the use of LC-MS for instrumental analysis of global metabolomics extracts, a plethora 
of methodologies employing multiple LC columns and various MS analyzers have been described 
and recently reviewed.36,60–62 In terms of separation conditions, distinct chromatographic methods 
using stationary phases such as C18 for reversed phase analysis and hydrophilic interaction 
chromatography (HILIC) are normally applied in the same study. This strategy allows for an 
expansion in metabolome coverage by facilitating the retention of compounds with different 
polarities. Regarding MS analyzers, high resolution instruments such as time-of-flight (TOF) and 
Orbitrap, either with or without quadrupoles, are typically used.36 As the body of this work is 
mostly focused on the sample preparation aspects of metabolomics applications, an in-depth 
discussion of different LC-MS conditions is not presented. 
The last part of the metabolomics workflow involves data processing, statistical analysis, and 
interpretation. As this topic is significantly broad and detailed protocols providing guidance in 
metabolomics data processing and statistical analysis have been published by several authors, only 
a brief overview of the different steps that are normally followed are herein provided.63–67  
In metabolomics data processing and analysis, various software and algorithms can be employed 
to enable extraction of information regarding the detected metabolite features in the entire sample 
set. Each feature is characterized by its m/z, retention time, and intensity. As each metabolite can 
be defined by different adducts, isotopes, and, in some cases, in-source fragments, the annotation 
of features via packages such as CAMERA can aid in the identification of various features related 
to a given analyte.68 Once this information is obtained, statistical analysis can then be carried out. 
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For this purpose, univariate and/or multivariate data analyses are conducted with aims to determine 
which metabolites are being dysregulated due to the condition or treatment under study. Univariate 
analysis is undertaken with aims to estimate statistical changes of individual features or 
compounds across different groups; depending on whether the data is normally distributed and on 
the analytical variance, different parametric (e.g. t-test, Welch’s test and ANOVA) and non-
parametric tests (e.g. Mann Whitney U and Kruskal-Wallis) can be performed. On the other hand, 
in multivariate analysis, all variables (metabolite features) are simultaneously analysed through 
employment of unsupervised (principal component analysis (PCA) and/or supervised methods 
(partial least squares (PLS), and orthogonal partial least squares (OPLS)). Once statistically 
significant discriminating features or metabolites are detected, their identity is confirmed by 
searching their accurate masses in available databases, by interpreting their fragmentation patterns, 
and when available, by running certified standards. Lastly, biochemical interpretation of the data 
can be performed in view of the specific condition and/or treatment being studied. Although this 
step must often be accompanied by in-depth literature revision, several tools to aid in the 
interpretation and correlation of affected metabolic pathways are available and free of charge.  
1.4. Solid phase microextraction (SPME) 
1.4.1. The principle of SPME 
SPME is a non-exhaustive sample preparation approach that integrates sampling and sample 
preparation in a single step. In this microextraction technique, a small amount of extraction phase 
immobilized in the outer part of a solid support is used to isolate analytes of interest from a given 
sample matrix. The microextraction process is undertaken by exposing the SPME probe to the 
sample of interest for a defined period of time at a constant set of experimental conditions. During 
extraction, an amount of analyte proportional to its concentration in the sample is collected 
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onto/into the SPME coating. Depending on the characteristics of the analyte of interest, the SPME 
device can be placed in the headspace (HS) of the sample matrix (only for volatile and semi-
volatile compounds), or can be directly exposed to sampling media via direct immersion (DI). 
Instrumental analysis is carried out either by thermally desorbing the analytes extracted by the 
SPME probe in the injector of a gas chromatograph, or by exposing the SPME coating to a 
desorption solvent, and subsequently injecting the final extract into an LC-MS or any other suitable 
analytical instrument. A schematic illustrating the general SPME workflow is presented in Figure 
1.3.  
 
Figure 1.3. General schematic of the SPME process. 
The successful implementation of SPME for any type of application is strongly dependent on a 
good understanding of the microextraction principles that govern extraction. As SPME is an 
equilibrium extraction technique, maximum analytical sensitivity is attained when the coating is 
exposed to the sample matrix for a time period that is long enough as to allow for equilibration. In 










equilibration has been reached. At such conditions, the amount of analyte extracted is given by 
Equation 1.1, where 𝑛 is the amount of analyte extracted onto the coating, 𝐶𝑓
∞is the concentration 
of analyte in the fibre coating at equilibrium, 𝑉𝑓 is the volume of extraction phase, 𝐶0 is the 
concentration of analyte in the sample matrix, 𝐾𝑓𝑠 is the distribution constant of analyte between 
the extraction phase and the sample matrix, and 𝑉𝑠 is the sample volume.  




                                        1.1 
In cases where the volume of sample is much larger than the volume of the extraction 
phase, 𝐾𝑓𝑠𝑉𝑓 ≪ 𝑉𝑠, Equation 1.1 can be simplified to Equation 1.2. Thus, quantification of 
analytes of interest in systems with volumes considerably larger than that of the extraction phase 
can be accomplished without knowledge of the volume of the sampling media (e.g. on-site 
analysis). 
                                                    𝑛 = 𝐾𝑓𝑠𝑉𝑓𝐶0                                                   1.2 
From Equation 1.2, it is also clear that the amount of analyte extracted at equilibrium is 
proportional to 𝐾𝑓𝑠, namely the distribution constant. This parameter is directly correlated with 
other factors such as the physicochemical properties of a given analyte, coating chemistry, and 
sample matrix characteristics (including temperature, pH, and ionic strength, among others). In 
view of this, satisfactory method sensitivity can be obtained by ensuring favorable 𝐾𝑓𝑠 values, 
which can be accomplished by selecting appropriate coatings, and/or through modifications to the 
sample matrix. It should be noted that Equation 1.1 only applies for coating materials such as 
polydimethylsiloxane (PDMS) or polyacrylate (PA), which extract via absorption. For adsorptive 
extraction phases, the surface active sites where analytes bind should be taken into consideration. 
In such cases, the equilibrium amount of analyte can be estimated as follows: 
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                                     1.3 
where 𝐾 is the analyte’s adsorption equilibrium constant, 𝐶𝑓 𝑚𝑎𝑥 is the maximum concentration of 
active sites in the coating, and 𝐶𝑓
∞ is the equilibrium concentration of analyte in the fibre. 
One of the most important parameters in any microextraction process is extraction time. As 
emphasized previously, maximum sensitivity is achieved at equilibrium conditions; however, as 
large 𝐾𝑓𝑠 provide long equilibration times, the use of SPME at pre-equilibrium, which can achieved 
by accurately controlling extraction time, is certainly preferred in many cases. At such conditions, 
the amount extracted is calculated by using Equation 1.4, where 𝑎 is a time constant and 𝑡 is 
extraction time.69 
                                                         𝑛 = (1 − 𝑒−𝑎𝑡)
𝐶0𝐾𝑓𝑠𝑉𝑠𝑉𝑓
𝐾𝑓𝑠𝑉𝑓+𝑉𝑠
                                               1.4 
Other parameters that affect equilibration time are the convection conditions, the thickness of the 
coating (𝑏 − 𝑎), and the analyte’s diffusion coefficient in the sample (𝐷𝑠). Considering that 
equilibrium is reached when 95% of the equilibrium amount is extracted, equilibrium time can be 
calculated by employing the following Equation: 
                                                           𝑡𝑒 = 𝑡95% = 3
𝛿𝐾𝑓𝑠(𝑏−𝑎)
𝐷𝑠
                                            1.4 
The term δ in Equation 1.4 refers to the thickness of the boundary layer. The boundary layer 
comprises a region in between the bulk of the sample matrix and the extraction phase, where the 
flux of a given analyte is mostly controlled by diffusion. As the thickness of the boundary layer is 
determined by both the agitation conditions and the diffusion coefficient of a given analyte, distinct 
analytes in the same system will have different δ values.  
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At this point, several experimental variables that influence the microextraction process have been 
listed and discussed. As can be inferred from the above discussion, successful application of SPME 
toward any type of study certainly depends on the degree to which experimental parameters that 
affect extraction recoveries are controlled (e.g. convection, temperature, extraction time, etc). 
Another factor that needs to be taken into consideration when employing SPME or any other 
microextraction technique relates to the distribution of the analyte among the different phases 
present in the sampling system. For instance, if SPME is to be applied for the determination of 
hydrophobic compounds in water samples, the stability of the analytes under study should be 
carefully controlled so as to avoid altering their respective concentrations within the sample 
matrix. In such cases, the poor solubility of the analytes in water can lead to losses due to 
adsorption on vessel walls, or owing to their precipitation. As this is not likely to occur in sample 
preparation approaches such as LLE, where the sample container is rinsed with extraction solvent, 
the applicability of SPME can be underestimated by inexperienced users. On this note, it should 
be emphasized that the extraction process in SPME occurs via free concentration.  Accordingly, 
in analyses of complex systems or matrices where multiple phases that could display affinity for 
analytes coexist (e.g. proteins, cells, organic matter, particles, et.), the amount of analyte extracted 
by SPME is not only proportional to its overall concentration in the sampling media, but also 
proportional to the its free concentration at the moment of the extraction. While SPME method 
sensitivity towards the analysis of compounds that exhibit high binding for matrix components can 
be hindered owing to the low availability of such analytes, modifications to the sample matrix may 
be considered to increase their free fractions (e.g. addition of organic solvent). Thus, in spite of 
the limitations it may impose on certain applications that involve the determination of highly 
bound analytes, SPME’s ability to only extract via free concentrations is an attractive bonus in 
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analysis, as it enable determinations of free, total, and therefore bound concentrations of analytes 
in complex systems through the use of appropriate calibration strategies. 
Several SPME calibration approaches have been developed to date, with the choice of calibration 
strategy being dependent on the goals of the research and parameters such as analyte and system 
under investigation.70 Although some calibration methods are not conventional due to the non-
exhaustive nature of SPME, various studies both demonstrating their applicability and reporting 
details regarding their principles and procedures have been published and reviewed in recent 
years.71–73 In the currently presented thesis, matrix-matched calibration was employed as an SPME 
quantification strategy. In matrix matched calibration, total concentrations can be calculated by 
spiking known amounts of analyte in a blank matrix that can truly mimic the intrinsic conditions 
and characteristics of the sample under study. In application of this method, it is critically 
important that satisfactory simulation of the characteristics of the sample matrix be achieved, since 
changes in pH, ionic strength, and protein or organic matter content can significantly affect degree 
to which a given analyte is bound to the matrix; consequently, erroneous concentrations may be 
estimated in cases where such characteristics are not sufficiently accounted for. To compensate for 
possible variations in the extraction conditions and in the sample matrix, the use of an appropriate 
internal standard, ideally deuterated, is highly recommended. If information regarding the free and 
bound concentrations of the analyte is also required, a calibration curve for the analyte should also 
be prepared in a physiological buffer where the analyte is free of binding components (free 
concentration = total concentration).  Other important factors should also be taken into account 
when performing quantification via SPME: first, the organic solvent volume used to spike analytes 
ideally should be kept below 1% so as to avoid alterations in the binding conditions in the sample 
matrix.74 Second, once analytes and internal standards are spiked in the blank matrix for 
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determination of total analyte concentrations, enough incubation time should be allowed so as to 
ensure a complete binding. Third, the sample/solvent volume should be large enough so as to 
ensure that the whole SPME coating is immersed during extraction/desorption. Since sample and 
desorption solvent volumes are typically very similar, sufficient analyte pre-concentration might 
not be achieved through employment of SPME, especially if the analyte under study is present at 
a considerably low concentration level. In such cases, addition of steps such as solvent evaporation 
and reconstitution may be required in the workflow. 
 
1.4.2. Thin-film microextraction: another geometry of SPME 
The most well-known configuration for SPME devices is the fibre geometry, which consists of a 
wire that has a well-defined coated length. However, in accordance with SPME principles, 
extraction devices can adopt multiple geometries and shapes that are tuned based on the application 
of interest. As SPME is a non-exhaustive extraction technique, sensitivity issues can arise in cases 
of considerably low analyte concentrations (𝐶0) or low affinity of compounds of interest for the 
extraction phase (𝐾𝑓𝑠). Therefore, as a strategy to improve method sensitivity, the use of larger 
extraction phase volumes (𝑉𝑓) can be considered as a suitable option (Equation 1.2). While 
increases to extraction phase thickness will lead to longer equilibration times (Equation 1.4), the 
use of larger extraction phase areas, on the other hand,  allows for improved sensitivity without 
sacrificing method throughput.75 Such devices, consisting of a large coated surface area and a thin 
coating thickness (large extraction phase surface area-to-volume ratio), are known as thin-film 
microextraction devices, and have been employed in several applications involving GC- and LC-
amenable compounds.76 In GC applications, PDMS self-supported membranes, as well as 
extraction devices made on a solid supports using PDMS and embedded sorbent particles, have 
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been used for the analysis of samples of environmental origin.75,77,78 Thin-film microextraction 
devices prepared by immobilizing biocompatible extraction phases on stainless steel blades have 
also been employed in various studies involving determination of non-volatile compounds, 
including studies of bioanalytical interest.79,80 Pertaining to the analysis of LC-amenable 
compounds, a fully automated workstation that allows for the high-throughput, simultaneous 
analysis of  up to 96 samples is currently available.81 Indeed, the second chapter of this thesis is 
fully dedicated to the application of this high throughput platform for the analysis of multiple 
doping substances in plasma samples. Considering that the use of thin-film microextraction may 
also allow for close to exhaustive recoveries in certain cases, the term open-bed SPE is also 
applicable to such devices in cases where significant amounts of analyte are extracted, or when 
remarkable depletion of analytes occurs after the extraction. Further details regarding the 
applications, advantages, and disadvantages of thin-film microextraction for the analysis of 
biological matrices are provided in the following sections.  
 
1.4.3. Analysis of biofluids using SPME and LC-MS 
Although SPME was initially introduced for the analysis of volatile compounds of environmental 
interest, the evolution of this sample preparation technique in terms of coating chemistries and 
manufacturing materials has enabled its application in the determination of non-volatile 
compounds in complex biological matrices. The first reports documenting the use of DI-SPME for 
the analysis of different biofluids involved employment of coatings such as PDMS, PA, PDMS/ 
divinylbenzene (DVB) and carbowax/templated resin (CW/TPR).82 Other extraction phases 
employed for the extraction of different compounds from matrices such as blood fractions include 
restricted access materials (RAM), molecularly imprinted polymers (MIP), polypyrrole-based 
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polymers (PPY), sol-gels, as well as immunoaffinity sorbents, where antibodies are immobilized 
for highly selective extractions.82 Although all of the above-mentioned coatings types were able 
to provide satisfactory results in several studies, their low affinity for certain compounds, in 
addition to their short life-times when immersed in complex samples, hindered their further 
implementation in the analysis of biological samples. In this context, the introduction of coatings 
made of a biocompatible binder, such as polyacrylonitrile (PAN), and diverse sorbents, such as 
SPE particles, has greatly facilitated the development and application of SPME as a sample 
preparation tool in bioanalytical applications.83 Among the most important advantages of PAN-
based SPME extraction phases, features such as outstanding robustness in direct exposure 
applications to complex, untreated biological matrices; high selectivity for small molecules; 
satisfactory biocompatibility; and manufacturing cost-effectiveness stand out to showcase the high 
suitability of this coating towards bioanalytical applications. Moreover, given that different types 
of SPE sorbent chemistries can be used in the preparation of PAN-based coatings, such coatings 
enable “tuning” of the most convenient SPME extraction phase according to the analytes of 
interest. Several studies published in the last years have demonstrated the suitability of such 
coatings, in both fibre and thin-film formats, for the determination of various analytes in matrices 
such as urine, plasma, serum, blood, and bile.80,84–88 For instance, in 2012, Boyacı et al. 
demonstrated the suitability of thin-film microextraction devices prepared using C18 and PAN for 
the quantitation of a broad range of controlled substances in urine samples.80 In such work, the 
authors were able to achieve satisfactory results in terms of absolute matrix effects with minimum 
sample pre-treatment, thus supporting the feasibility of employing SPME prior to LC-MS. Bojko 
et al. proved the potential of automated thin-film SPME in clinical analysis by monitoring 
tranexamic acid (TA) in plasma samples of patients undergoing cardiac bypass surgery.89 The 
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high-throughput feature offered by this technology enabled prompt analysis of a large number of 
samples, as well as the determination of TA pharmacokinetic profiles for each patient (n=10). 
Good agreement was found between the proposed methodology and PP. Similarly, Gorynski et al. 
proposed a high-throughput SPME method for the concomitant analysis of both rocuronium 
bromide and TA in plasma.90 Despite the considerable differences between the two target analytes, 
satisfactory results were obtained by employing a weak cation exchanger as an SPME extraction 
phase. In addition to drug analysis, high throughput SPME in thin-film format has been employed 
for the determination of polyunsaturated fatty acids in plasma samples. In that study, the use of a 
C18-PAN as extraction phase enabled the determination of changes in concentrations of fatty acids 
such as α-linolenic acid, arachidonic acid, and docosahexanoic acid in plasma samples of patients 
undergoing cardiac surgery.91 The results obtained from this study certainly demonstrated the 
applicability of SPME towards the quantitative measurement of highly hydrophobic compounds 
that display significant affinity for plasma components. A variety of alternative coating materials, 
including aptamers, magnetic molecularly imprinted polymers, and polythiophene, among others, 
have also been reported as suitable for DI-SPME in biofluids.92–94  In more recent work conducted 
by Gionfriddo et al., a type of fluoropolymer was introduced as a promising binder to immobilize 
hydrophilic lipophilic balanced (HLB) particles for SPME, with extraction followed by 
instrumental analysis with GC and LC platforms.95 The coatings developed in this study 
demonstrated satisfactory performance in evaluations involving whole blood extractions. Given 
their simple manufacturing process, which does not require a thermal curing step, their further 
implementation in a broader range of applications is anticipated. 
Other SPME formats successfully employed in biofluid analyses are in-tube and in-tip SPME. In-
tube SPME, which uses a piece of capillary column as extraction medium, was the first fully 
29 
 
automated SPME approach designed specifically for compatibility with LC analysis. Although this 
technique is limited by the need for very clean samples (so as to avoid clogging of the capillary) 
and its comparative low throughput, in-tube SPME has been reported as the sample preparation 
technique of choice in quite a large number of biomedical analysis studies.96,97 In-tip SPME, in 
turn, is an alternative high-throughput configuration of SPME introduced by Xie, Mullett, Miller-
Stein & Pawliszyn in 2009.98 In this SPME approach, commercial SPME fibers are in-housed in 
poly-propylene pipette tips through employment of polyethylene frits to secure and hold fibres in 
place. The most important advantage of this approach is its compatibility with automated liquid 
handling systems for 96-well plates (e.g., Tomtec Quadra 96) typically used in the pharmaceutical 
industry. In this approach, the SPME sample preparation workflow consists of multiple 
aspiration/dispense cycles. To date, in-tip SPME has been employed for the analysis of drug 
candidates (MK-0533) and (MK-0974) in human plasma, and for the determination of vitamin D3 
in human serum through chemical derivatization.98–100    
 
1.4.4. DI-SPME and LC-MS for in vivo animal studies 
One of the most attractive features of SPME is its suitability for in vivo analysis. Indeed, several 
studies reported to date have demonstrated the applicability of this technology towards monitoring 
of concentrations of different drugs and metabolites in several living biological systems.73,101,102 
As it pertains to the analysis of biofluids, SPME has been successfully used for pharmacokinetic 
monitoring of benzodiazepines, carbamazepine, and carbamazepine-10,11 epoxide 
(carbamazepine metabolite) in animal models, including  models such as beagle dogs and 
rats.103,104 The main advantage of such approach is the elimination of the blood withdrawal step 
from the analytical workflow, which serves to reduce the risk of changes in sample matrix 
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composition and in the free concentration of non-stable analytes. Furthermore, since in vivo SPME 
allows for multiple samplings of the same system over time, the study of ongoing dynamic 
processes, such as drug pharmacokinetics, is facilitated to a considerable extent. A detailed 
protocol regarding the experimental parameters that should be used to determine intravenous 
concentrations of drugs and metabolites by application of SPME is available in the literature.105 
With reference to tissue determinations, SPME has been applied for in vivo analysis of several 
matrices;  a schematic of the general workflow is depicted in Figure 1.4.102 Togunde et al., for 
instance, were able to quantify drugs such as fluoxetine, venlafaxine, sertraline, paroxetine, and 
carbamazepine in rainbow trout and fathead minnow by performing in vivo non-lethal sampling  
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using C18-PAN coatings.106 The rewarding findings of that work indicated that SPME is a well-
suited tool for environmental studies related to fish bioconcentration, as the technique allows for 
continuous monitoring of the same individual specimens over time. Polydopamine sheathed 
nanofibers have also been employed to monitor pharmaceuticals in fish tissue.107 A comparison 
between concentrations of fluoxetine determined in fish tissue through application of LLE and 
SPME demonstrated that both techniques provide statistically equivalent results. In another study, 
SPME and MD were successfully used to measure dopamine, serotonin, gamma amino- butyric 
acid, and glutamic acid changes in rat brain at different time points following fluoxetine 
administration.56 By using 4 mm fibres coated with C18 and benzene sulfonic acid functionality, 
the authors of that work were able to obtain comparable results with both sampling techniques, 
validating the applicability of SPME towards such studies. As evidenced in the literature, the 
biocompatibility of SPME together with its simple deployment has facilitated its evaluation in 
diverse in vivo scenarios. The advantages of this approach for metabolomics studies will be 
presented in the following section.    
 
1.4.5. SPME and LC-MS in clinical metabolomics 
The applicability of SPME for metabolomics studies was initially proposed for profiling of volatile 
metabolites. This particular approach has been satisfactorily implemented in field applications for 
analysis of different matrices, such as serum, urine, bacteria cultures, saliva, and feces, among 
others, via headspace extraction.108–113 Conversely, application of DI-SPME has only been recently 
introduced and evaluated for metabolomics studies using LC-MS analysis. In initial work 
conducted to identify potential SPME coatings suitable for such purpose, Vuckovic et al. reported 
a complete assessment of several SPE-based extraction phase chemistries in terms of metabolite 
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coverage.114 To this end, 42 types of SPE particles, including silica-based, polymer-based, and 
carbon based particles, were immobilized and used in the manufacture of SPME coatings for a 
broad set of metabolites, covering polarities from Log P -7.9 to 7.4. Results showed that mixed 
mode (MM) (C18 or C8 with benzenesulfonic acid group), phenyl boronic acid (PBA), and 
polystyrene-divinylbenzene (PS-DVB) coatings performed best in terms of hydrophilic and 
hydrophobic metabolite extractions. In this context, it is worth highlighting that the applicability 
of SPME for untargeted studies via DI relies on the fact that analytes are extracted via free 
concentration, as was already highlighted in Section 1.3.1. Hence that in biological samples such 
as plasma, where multiple matrix components such as proteins and metabolites occur, it is expected 
that hydrophilic analytes will be present at high free concentrations, as they normally do not 
display significant affinity for any matrix constituents. On the other hand, hydrophobic compounds 
will exhibit low free fractions, as such compounds are usually bound to different matrix 
components such as proteins. Considering that SPME typically provides better extraction 
efficiencies for compounds that display a certain degree of hydrophobicity, balanced metabolite 
coverage can be expected in cases where this technique is used for untargeted studies. Based on 
results obtained in a coating evaluation study, Millipore Sigma (previously Supelco) developed 
SPME devices coated with MM and C18 biocompatible extraction phases for both in vitro and in 
vivo applications.87 In order to assess the performance of SPME versus other sample preparation 
techniques traditionally employed in untargeted metabolomics, a comparison, using human plasma 
as model matrix, was conducted in terms of metabolite features extracted with SPME MM coatings 
versus those detected with ultrafiltration and PP.114 The results obtained in this study demonstrated 
that not only is SPME able to perform comparably in relation to the other two techniques studied 
as it pertains to the number of metabolite features detected, this micro sampling technique was also 
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shown to allow for better recoveries of non-polar metabolites (SPME vs ultrafiltration), as well as 
for a reduction in ionization effects (SPME vs PP). Similar results were observed when SPME and 
MD were used for in vivo sampling from rat brains.56 The findings of this work evidenced that 
SPME was able to facilitate the extraction of hydrophobic metabolites such as lipids, which are 
usually poorly or non-detected in MD extracts, whereas MD allowed for the detection of 
hydrophilic dipeptides and aliphatic amino acids that were not observed with SPME. Thus, the 
obtained findings of this study support the applicability of SPME as a complementary tool to MD 
for in vivo metabolomics studies. As unstable compounds can be lost or degraded into different 
metabolites during traditional sampling and sample preparation steps, in this sense, the feasibility 
of capturing the entire in vivo metabolome of a given system enables the exploration and further 
understanding of biological systems. For instance, in an experiment that sought to compare results 
of  in vivo blood sampling versus those obtained by ex vivo SPME, protein precipitation, and 
ultrafiltration, researchers found that unstable compounds such as β-nicotinamide adenine 
dinucleotide (β-NAD) were only present in extracts corresponding to in vivo SPME.57 Although 
further studies are required in order to confirm the stability of different metabolite types extracted 
in vivo on SPME coatings, the results of the abovementioned study support the notion that SPME 
is capable of capturing an elusive portion of the metabolome by employment of in vivo sampling 
strategies. Other studies involving untargeted analysis via in vivo SPME sampling have been 
undertaken towards the monitoring of metabolic changes in lung and liver grafts during 
transplantation in a pig model.115,116 In this application, researchers were able to observe 
differentiation among extracts obtained from SPME fibres exposed to organ grafts at various stages 
of organ preservation throughout the transplantation process. One of the main advantages of this 
approach includes its feasibility towards monitoring of organ quality with minimum invasiveness, 
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thus minimizing the risk of compromising the organ through its submission to multiple biopsies at 
various sampling points. However, a more in-depth study with a larger number of biological 
replicates is required in order to fully demonstrate the potential of SPME for this application.  
In addition to metabolomics studies applying SPME for in vivo sampling, progress on the 
evaluation and application of SPME thin-film format for high throughput global metabolomics has 
also been observed. In recent work, Mousavi et al. evaluated different coating chemistries for 
extraction of metabolites from Escherichia coli bacteria culture, including PS-DVB, hydrophilic-
lipophilic balance (HLB), PBA, silica-based ionic liquid, and silica-based reversed phase in thin-
film format.117 With aims to expand metabolome coverage, mixtures of different sorbents were 
also investigated. Interestingly, a mixture of HLB and PS-DVB particles in a proportion 1:1 
provided the best results in terms of features detected and covered polarity range. Indeed, this 
approach saw extraction and determination of metabolites with logP values spanning from -7 to 
15, including amino acids, peptides, nucleotides, carbohydrates, polycarboxylic acids, vitamins, 
phosphorylated compounds, and lipids. The developed methodology was then further applied for 
characterization of antibacterial action of cinnamaldehyde and clove oil in E. coli cultures, where 
several metabolic pathways and dysregulated metabolites were successfully identified.118,119  
 
1.5. Research objective 
The main scope of this doctoral dissertation encompasses the application, evaluation, and further 
development of SPME as an alternative technology for the investigation of complex biological 
systems. To this end, the body of this work presents novel progress in SPME coupled to LC-MS 
for both targeted and untargeted analyses of biological fluids and brain tissue.  
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In reference to targeted analysis, Chapter 2 provides a thorough evaluation of SPME in thin-film 
microextraction format for the automated and high throughput analysis of a broad range of doping 
substances (drugs and metabolites) in plasma samples. This work, which was financed by the 
World Antidoping Agency (WADA), demonstrates the capabilities of SPME to provide 
satisfactory sample clean-up prior to LC-MS and to facilitate the concomitant quantitation of 
multiple substances of variable physicochemical properties (logP from -2 to 6.8). With the purpose 
of expanding the range of applications of SPME, Chapter 3 describes the development of new thin-
film SPME samplers consisted of plastic as an alternative support material. The robustness of such 
devices as well as their potential applicability in clinical studies is successfully proven through the 
determination of a broad range of compounds in several biofluids, including plasma, urine, and 
whole blood. In a more fundamental approach, Chapter 4 discloses the effect of variable red blood 
cell content, also known as hematocrit, on the determination of different drugs by application of 
SPME as a sample preparation technique. Parameters such as coating types, agitation conditions, 
extraction time, and the use of an internal standard are all considered throughout the investigation 
and in the development of possible hematocrit effect correction methods.  
In reference to untargeted analysis, Chapter 5 includes an evaluation of SPME in fibre 
configuration as an analytical tool in metabolomics studies of brain tissue. As part of the 
assessment, different available extraction phases (C18, HLB and MM), desorption conditions, 
washing step strategies, and extraction times are discussed based on the metabolite features 
detected after extraction from cow brain homogenate. Lastly, the application of SPME for the in 
vivo monitoring of metabolic changes in rat brains after deep brain stimulation is presented in 
Chapter 6. Interesting results in terms of determination of dysregulated metabolites and lipids in 
groups of control and treated animals are shown, and a discussion about the biological relevance 
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of such findings is also presented. Chapter 7 summarizes the main contribution of this work and 
provides future directions to be considered in regards to the applicability of SPME towards the 























Chapter 2: High throughput targeted analysis in plasma using thin-film solid phase 
microextraction 
 
2.1. Preamble and introduction  
2.1.1. Preamble 
This chapter of the thesis is already published as an article under the title “High throughput 
quantification of prohibited substances in plasma using thin-film solid phase microextraction” by 
Nathaly Reyes-Garcés, Barbara Bojko and Janusz Pawliszyn., J. Chromatogr. A 2014, 1374, 40-
49. The content of the article is being reprinted in this thesis with permission of Elsevier, and in 
compliance with Elsevier and University of Waterloo policies. 
I, Barbara Bojko, authorize Nathaly Reyes-Garcés to use the material for her thesis. 
2.1.2. Introduction 
One of the ultimate goals in doping control is the development of a simple, fast, reliable and 
comprehensive analytical methods for biological matrices such as blood and urine. Due to the 
complexity of such matrices, as well as the diversity of prohibited substances listed by the World 
Antidoping Agency (WADA), sample preparation is often a challenging task.120 Currently, 
WADA has stipulated minimum required performance levels only for the detection and 
identification of prohibited substances in urine samples.121 However, analytical determinations in 
blood (plasma/serum) as a means to obtain complementary information to urinalysis results have 
been garnering a wealth of interest.122–126 Some advantages of blood analysis in doping control 
include finding intact unknown doping substances, determining temporal information regarding 
drugs prohibited in-competition only, and detecting if an athlete is participating in blood doping 
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practices.122,125,126 Sample preparation procedures reported for analysis of prohibited substances in 
blood, serum, and plasma include protein precipitation, solid phase extraction (SPE) and more 
recently, dried blood spots (DBSS).122,127–130 Several studies using these sample preparation 
methods for comprehensive screening of human and equine plasma/blood have been reported in 
recent years.123,124,131–137 Despite these approaches being effective, they can be time-consuming, 
unsuitable in some cases for automation, and prone to ion suppression/enhancement effects. 
Regarding instrumentation, undoubtedly, liquid chromatography coupled to mass spectrometry 
(LC-MS) has become the preferred method in sports drug testing due to its flexibility compared to 
gas chromatography-mass spectrometry (GC-MS) and to immunological assays.126,138–140 For these 
reasons, simple and effective sample preparation protocols suitable for automation and compatible 
with LC-MS based methods are highly desired. Recently, the introduction of thin-film solid phase 
microextraction (SPME) in an automated configuration has opened up a new alternative in sample 
preparation for bioanalysis. Biocompatible SPME coatings prepared by immobilizing various 
sorbents with polyacrylonitrile have demonstrated great performance in the extraction of drugs 
from complex matrices. By taking advantage of this technology, a comprehensive protocol for 
automated quantitative urinalysis of doping agents was recently introduced.80 In that work, more 
than 100 compounds of different classes and polarities were simultaneously extracted from urine 
samples using a C18-polyacrylonitrile (PAN) extraction phase and the Concept 96 automated 
sample preparation station. By using the 96 SPME thin-films that the aforementioned system can 
handle, the optimized method was able to provide throughput of less than 2 min per sample. 
Furthermore, the proposed automated SPME method allowed satisfactory sample clean-up since 
negligible absolute matrix effects were observed for the majority of the compounds. Considering 
the good performance of the proposed method, and by taking advantage of the biocompatibility of 
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the SPME extraction phases, a new high throughput SPME-based protocol for plasma analysis is 
introduced herein. Twenty-five compounds of a wide range of polarities (logP from -2 to 6.8), 
including different prohibited drug classes and some metabolites such as benzoylecgonine, 
morphine-3β, and 6β glucuronide, were selected for this study. Given that SPME only extracts an 
amount of analyte proportional to its free concentration, the method was carefully optimized, 
taking into account the binding that some compounds might experience due to the high protein 
content of plasma. For this purpose, simultaneous SPME pre-conditioning and sample pre-
incubation under a controlled temperature were enabled by modifying the software of the Concept-
96 autosampler. With the aim of covering a broad range of compounds in a single extraction, a 
thin-film SPME coating made of hydrophilic-lipophilic balance (HLB) Oasis particles 
immobilized with polyacrylonitrile (PAN) was chosen. To the best of our knowledge, this is the 
first time that such SPME coating is used in a multi-residue bioanalytical application.  
2.2. Experimental 
2.2.1. Materials and supplies 
Amphetamine, methamphetamine, 17-α-trenbolone, morphine, benzoylecgonine, codeine, 
codeine-d3, oxycodone-d3, cannabidiol-d3, methadone-d3, stanozolol, (±)11-nor-9-carboxy-Δ9- 
tetrahydrocannabinol (THC) (THCCOOH), (±)11-nor-9-carboxy-Δ9-THC-d3 (THCCOOH-d3), 
cortisol-d4, morphine-3β-glucuronide, morphine-6β-glucuronide, morphine-3β-glucuronide-d3, 
(±)11-nor-9-carboxy-Δ9-THC glucuronide (THCCOOH-glu), and (±)11-nor-9-carboxy-Δ9-THC 
glucuronide-d3 (THCCOOH-glu-d3) standards were purchased from Cerilliant Corporation (Round 
Rock, TX, USA). Nikethamide, propranolol, metoprolol, clenbuterol, exemestane, bisoprolol, 
budenoside, dexamethasone, furosemide, salbutamol, prednisolone, strychnine and testosterone-
d3 were purchased from Sigma-Aldrich (Oakville, ON, Canada). Salbutamol-d3 was purchased 
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from CDN isotopes (Pointe-Claire, Quebec, Canada). Toremifene and GW501516 were purchased 
from Toronto Research Chemicals (Toronto, ON, Canada).  
Sodium chloride, potassium chloride, potassium phosphate monobasic, sodium phosphate dibasic, 
formic acid, and polyacrylonitrile (PAN) were also purchased from Sigma-Aldrich (Oakville, ON, 
Canada). N,N-dimethyl formamide (DMF) was purchased from Caledon Labs (Georgetown, ON, 
Canada). Modified polystyrene divinylbenzene (PS-DVB) was obtained from Macherey-Nagel 
(Düren, Germany), Oasis hydrophilic-lipophilic balance 30 μm sorbent particles (HLB) were 
obtained from Waters (Milford, MA, USA), and Discovery silica-based C18 5 µm particles were 
obtained from Supelco (Bellefonte, PA, USA). Polypropylene Nunc U96 deep well plates were 
purchased from VWR international (Mississauga, ON, Canada) and bare stainless steel blades 
were obtained from Professional Analytical System (PAS) Technology (Magdala, Germany). LC-
MS grade acetonitrile, methanol, and water were obtained from Fisher Scientific.  
2.2.2. Working solutions 
A stock methanolic solution (20 µg mL-1) containing all analytes was prepared and further 
dilutions were done as required. A stock solution (8 µg mL-1) containing multiple deuterated 
compounds as internal standards was prepared in methanol. 
2.2.3. Plasma samples  
Different lots of potassium (K2) ethylenediaminetetraacetic acid (EDTA) pooled human plasma 
from healthy donors were purchased from Lampire Biological Laboratories (Pipersville, PA, 
USA). A phosphate-buffered saline solution (PBS) (pH 7.4) was prepared by adding 8.0 g of 
sodium chloride, 0.2 g of potassium chloride, 0.2 g of potassium phosphate monobasic, and 1.44 
g of sodium phosphate dibasic to 1 L of nanopure water. 
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2.2.4. Thin-film SPME devices 
Various coating chemistries in thin-film SPME format were prepared by immobilizing different 
SPE sorbents (C18, PS-DVB and HLB) with a PAN-DMF solution according to the procedure 
already reported by Mirnaghi et al.88 The only exception to the original protocol was the curing 
temperature, which was decreased from 180 to 150 °C. 
2.2.5. Sample preparation: automated Concept 96-blade SPME system 
Automated SPME extractions were carried out using the Concept-96 system (Professional 
Analytical Systems (PAS) Technology, Magdala, Germany). This robotic sample preparation unit 
has been described in detail elsewhere.81,141 A typical SPME protocol using this automated station 
involves preconditioning, extraction, washing and desorption steps. In this work, a simple 
modification of the controlling software allowed for the simultaneous pre-incubation of samples 
at a given temperature (extraction station) and pre-conditioning of SPME devices (preconditioning 
station).  
The SPME method was developed and optimized in terms of coating selection, pH control, 
extraction time and temperature, type of desorption solvent used, and desorption duration. A recent 
work on doping control using SPME demonstrated the suitability of C18 coatings for the extraction 
of a wide range of doping substances from urine samples.80 Due to the high protein content in 
plasma, and consequently the decrease of free concentrations of drugs that typically exhibit high 
protein binding, it was critical to evaluate the performance of different coating chemistries at such 
conditions. For optimization of the SPME method, both plasma and PBS standards were prepared 
by spiking analytes from stock solutions, keeping the organic solvent content constant at 1%. 
Spiked plasma aliquots were pre-incubated in the fridge overnight to allow complete binding 
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before extraction. Sample preparation involved mixing 1080 µL spiked plasma aliquots with 10 
µL internal standard solution and 120 µL of 1 M phosphate buffer (pH = 7). Subsequently, samples 
were homogenized in the 96-well plate at constant agitation for 30 min before starting the SPME 
procedure. Optimum SPME conditions were set as follows: pre-conditioning of SPME devices in 
1:1 methanol:water (1500 µL) for 30 min and simultaneous plasma samples pre-incubation at 30 
°C, then 90 min extraction at 30 °C, 10 s washing step in deionized water (1500 µL), and 20 min 
desorption in 4:1 methanol:acetonitrile with 0.1% formic acid (1200 µL). Agitation rate was set at 
1500 (revolutions per minute) rpm. It is worth emphasizing that the total incubation time of plasma 
aliquots after adding buffer and internal standard solution was 1 h. 
2.2.6. LC-MS/MS conditions 
Samples were run on a LC-MS system consisting of an Accela pump, an Accela autosampler and 
a triple quadrupole mass spectrometer TSQ vantage equipped with a heated electrospray (H-ESI) 
source (Thermo Scientific, San Jose, USA). Chromatographic separation was carried out using a 
Kinetex pentafluorophenyl core shell column (1.7 µm, 2.1 mm x 10 mm) connected to a PFP 
security guard ultracartridge (Phenomenex, Torrance, CA, USA). The mobile phases used were 
water with 0.1% formic acid (A), acetonitrile with 0.1% formic acid (B) and methanol with 0.1% 
formic acid (C). Mobile phase gradient conditions were as follows: hold at 90% A, 5% B, and 5% 
C for 0.5 min, linear increase of both solvents B and C to 50% in 9.5 min, linear increase of C to 
62.5 % and decrease of B to 37.5% in 5 min. Lastly, the column was re-equilibrated for 2 min at 
the starting conditions. The overall run time was 17.3 min, the flow rate was 400 µL min-1 and the 
column temperature was maintained at 35 °C. The injection volume was 10 µL in full loop 
injection mode. MS conditions were set as follows: spray voltage = 1300 V, vaporizer temperature 
= 275 °C, sheath gas = 45 units, auxiliary gas = 30 and capillary temperature = 280 °C. Samples 
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were run in positive and negative selected reaction monitoring (SRM) mode. Optimum collision 
energy and S-lenses conditions were determined for each compound by using direct infusion of 
standards (please refer to Table 2.1 and Table 2.2). Due to the multiple transitions monitored in 
this particular method, MS data was collected by defining acquisition windows based on 
chromatographic retention time. Xcalibur software (2.0.7 SP1) was employed for data acquisition 
and processing. 
Table 2.1. Optimum MS/MS parameters and chromatographic conditions for the selected target 

















Amphetamine 5.94 136.099 
65.138 36 
5.5 7 36 
91.114 17 
Methamphetamine 6.88 150.112 
91.12 19 
6 7.5 45 
119.139 9 
Nikethamide 3.76 179.1 
80.127 29 
3 4.5 76 
108.102 18 
Salbutamol 3.26 240.143 
148.103 18 
2.7 4 59 
166.116 12 
Salbutamol-d3 3.26 243.16 
151.123 18 
2.7 4 64 
169.138 12 
Propranolol 12.08 260.123 
116.138 17 
11.5 13 89 
183.116 17 
Metoprolol 8.0 268.14 
77.105 50 
7.5 9 94 
116.146 18 
Trenbolone 6.80 271.133 
165.106 56 
5.5 7.5 97 
199.17 24 
Clenbuterol 8.62 277.068 
132.1 30 
8.2 9.5 70 
203.049 15 
Morphine 2.78 286.119 
152.092 61 
2.2 3.5 110 
165.101 40 
Benzoylecgonine 5.53 290.133 
77.141 47 
4.8 5.8 93 
168.164 18 
Testosterone-d3 7.40 292.248 
97.135 22 
6.5 8.5 93 
109.137 25 




Codeine 4.87 300.105 
152.092 64 
4 6 104 
165.102 42 
Codeine-d3 4.87 303.149 
165.096 41 
4 6 104 
215.138 25 
Methadone-d3 16.0 313.214 
105.091 29 
13.8 17.3 87 
268.224 13 
Bisoprolol 9.45 326.16 
74.126 27 
8.5 10.5 102 
116.135 17 
Stanozolol 8.62 329.229 
81.108 44 
8 9.5 130 
95.115 38 
Strychnine 6.97 335.155 
156.126 45 













8 9.5 95 
302.282 18 
Prednisolone 5.72 361.145 
147.078 24 
5 6.5 59 
325.243 6 
Cortisol-d4 5.97 367.196 
121.046 28 
5 6.5 102 
331.254 14 
Dexamethasone 6.67 393.199 
266.226 27 
6 7.5 64 
373.226 5 
Toremifene 15.90 406.21 
70.157 36 
14.5 17.3 108 
72.167 24 
Budesonide 7.86 431.222 
147.069 30 
6.5 8.5 78 
323.215 13 
GW501516 9.76 454.091 
188.079 46 
9 10.3 108 
257.068 29 
Morphine-3β-glu 1.1 462.147 
201.101 42 
0.5 2.3 101 
286.149 29 
Morphine-6β-glu 1.49 462.147 
201.101 42 














7.5 9 90 
348.239 12 
Cannabidiol-d3  318.146 
123.041 33 




Oxycodone-d3  319.118 
244.13 28 






0.5 2.3 101 
289.168 29 
 
Table 2.2. Optimum MS/MS parameters and chromatographic conditions for the selected target 






























































































2.3. Results and discussion 
Target analytes were selected for plasma method development according to various xenobiotics 
reported in the literature as likely to occur in blood in case of positive doping.123,124 With the aim 
of expanding the range of drug chemical properties, glucuronide forms of morphine and 
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THCCOOH were also included in the target compound list. Although 17-β-trenbolone might 
prevail in plasma in case of positive doping, 17-α-trenbolone was used as model compound based 
on availability of the standard. Overall, the studied compounds represented several drug classes 
such as narcotics, stimulants, steroids, hormones (including an aromatase inhibitor and a selective 
estrogen modulator), a metabolic modulator (GW501516), cannabinoids, beta-blockers, beta-
agonists, other anabolics, diuretics and glucocorticosteroids, and offered a wide range of polarities, 
with logP values ranging from -2 to 6.8. 
2.3.1. Coating selection and desorption conditions 
The first part of the SPME method development involved coating selection. It is worth noting that 
the performance of SPME depends on the affinity of the analytes towards a given extraction phase 
at a defined set of experimental conditions. At equilibrium, the affinity of analytes towards the 
coating is represented by the fiber coating/sample matrix distribution constant. Based on these 
reasons, when selecting a SPME coating for a complex matrix such as plasma, both the affinity of 
the analytes towards the extraction phase, and the selectivity of the coating towards the target 
compounds versus possible matrix interferences should be considered.142 In addition, multiple 
proteins occurring in plasma constitute a binding matrix that depletes the free concentration of 
compounds exhibiting significant protein-drug interactions. Since the amount of analyte extracted 
using SPME is proportional to the free analyte concentration in the matrix at the end of the 
extraction process, substances characterized by high protein binding are expected to exhibit higher 
limits of quantification. As such, and considering the broad range of polarities of the drugs selected 
for this study, the selection of an extraction phase able to provide sufficient coverage for all 
compounds was a crucial step in the present work.  Previously, Boyacı et al. reported the evaluation 
of C18, mixed mode, phenyl boronic acid (PBA), and PS-DVB coatings for the extraction of more 
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than 100 doping substances from synthetic urine.80 Although the PS-DVB coating exhibited better 
extraction efficiency for most of the compounds spiked in urine, the authors selected C18 as the 
extraction phase due to its lower carryover but still sufficient coverage. Considering the reusability 
of the SPME devices herein used, carryover is an important aspect that should be carefully 
addressed. Optimum SPME conditions should ensure not only satisfactory extraction recoveries, 
but also maximum desorption efficiency and no-cross contamination. For the purposes of the 
current work, the performance of C18, PS-DVB, and HLB coatings to extract the target compounds 
from plasma was investigated. Figure 2.1 shows the absolute recoveries obtained for the different 
extraction phases when a mixture of 2:2:1 acetonitrile:methanol:water with 0.1% formic acid was 
used as desorption solvent. As can be seen in Figure 2.1, for this particular set of analytes, HLB 
showed the best performance in terms of analyte coverage. Highly polar compounds such as 
morphine 3β and 6β glucuronide, as well as non-polar compounds such as toremifene and 
THCCOOH were successfully extracted. Because of its hydrophilic N-vinylpyrrolidone and 
lipophilic divinylbenzene functionalities, HLB displays balanced analyte coverage and shows 
recoveries comparable with those exhibited by C18 coating, even for less polar compounds. In 
addition, HLB did not exhibit significant carryover at the initial desorption conditions selected for 
the coating evaluation (data not shown). Indeed, the decreased free concentration of some 
compounds due to high protein binding reduces chances of carryover at moderate or high 
concentrations. Another advantage of selecting HLB as the SPME extraction phase is its 
characteristic wettability, which facilitates its interaction with aqueous matrices. Based on these 
reasons, the HLB coating was chosen as the SPME extraction phase for this method. The next step 
of the SPME method development involved selection of desorption solvent and optimization of 
desorption time. Various desorption solvents were evaluated, including the desorption solution 
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selected by Boyacı et al., (2:2:1 acetonitrile:methanol:water with 0.1% formic acid), as well as 
other solutions comprised by different proportions of methanol, acetonitrile and water acidified 
with formic acid at 0.1%. Results in terms of carryover for each desorption solvent tested are 
presented in Table 2.3. 
 
Figure 2.1. Comparison of C18, HLB and PS-DVB coatings performance in the extraction of 
various drugs from plasma spiked at 100 ng mL-1 (logP values in brackets). Extraction time was 
set at 75 min and the sample volume was 1200 μL (9:1 plasma:buffer). 
 
Ideally, a desorption solution for SPME should offer minimum carryover, as already emphasized, 
and be compatible with the LC conditions, ensuring good chromatographic separation. As a matter 
of fact, general SPE protocols recommend methanol for elution of a wide range of analytes retained 
in HLB cartridges. However, in SPME configuration, and for this particular application, methanol 
showed a moderate carryover for some non-polar compounds such as GW501516 and THCCOOH. 
It was observed that by introducing some percentage of acetonitrile in the desorption solution,  
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Table 2.3. Carryover found for different solvent compositions (all desorption solvents tested were 
acidified with 0.1% formic acid). Results obtained from the second desorption after extracting 
from a PBS solutions spiked at 100 ng mL-1. Desorption volume and time were 1200 μL and 60 


























Morphine-3β-glu 8.7 3.9 4.6 10.0 17.6 - 5.1 
Morphine-6β-glu 3.0 3.0 3.7 3.1 3.9 7.6 3.4 
Morphine 4.0 3.5 5.2 3.6 3.0 5.1 3.6 
Salbutamol 3.4 3.1 3.5 3.0 3.0 5.3 3.0 
Nikethamide 2.0 2.7 2.4 2.2 2.7 3.2 2.5 
Codeine 4.4 3.7 5.8 4.0 3.1 4.8 3.5 
Benzoylecgonine 2.3 1.9 3.4 2.2 2.1 2.7 1.9 
Amphetamine 4.8 4.6 5.6 4.6 4.4 6.4 5.0 
Prednisolone 2.4 3.5 4.8 2.6 2.6 3.3 3.1 
Methamphetamine 4.5 3.9 5.5 3.9 3.3 4.7 3.7 
Dexamethasone 3.2 3.0 5.2 2.1 2.2 2.4 2.3 
Trenbolone 4.1 5.4 11.6 3.5 3.4 3.2 3.8 
Strychnine 6.2 3.8 8.5 5.4 3.1 5.8 3.9 
Testosterone 4.3 4.4 10.7 3.4 3.5 3.3 3.6 
Formoterol 6.0 4.9 7.9 4.4 3.6 6.4 4.1 
Metoprolol 4.3 3.8 5.9 3.4 3.0 3.8 3.3 
Exemestane 4.8 5.8 13.6 3.4 3.5 2.7 3.8 
Budenoside 4.8 5.3 12.3 3.1 3.0 2.8 3.6 
Clenbuterol 6.1 4.7 7.5 4.3 3.5 4.9 3.8 
THCCOOH-glu 5.6 5.3 11.9 3.7 3.7 6.5 3.3 
Stanozolol 6.7 4.6 13.1 4.4 4.1 5.3 3.6 
THCCOOH 14.3 8.8 26.0 6.7 4.9 6.8 5.1 
Bisoprolol 4.5 3.9 6.2 3.5 3.3 3.9 3.3 
Cocaine 6.1 4.9 8.1 5.5 4.3 5.0 4.5 
GW501516 18.0 14.5 35.9 9.1 5.4 5.6 6.7 
Propranolol 7.5 5.0 9.8 4.8 3.6 5.4 4.2 
Toremifene 12.2 5.2 12.6 6.7 3.7 4.4 4.8 
 
carryover of those compounds decreased. Conversely, by increasing water content in the 
desorption solvent, desorption efficiency of several non-polar compounds was worsened. For this 
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reason, and as a compromise between desorption efficiency and chromatographic resolution, 1200 
µL of a mixture of 4:1 methanol:acetonitrile acidified with 0.1% formic acid was found as 
optimum. Following the selection of desorption solvent, it was necessary to determine the optimum 
desorption time. Considering the composition of the selected desorption solvent, which is 100% 
organic, fast equilibration between the target analytes extracted on the SPME coating and the 
selected desorption medium was expected due to the dramatic decrease in the coating/medium 
distribution constant. For this reason, 10, 20 and 45 min were tested as desorption times. As can 
be seen in Figure 2.2, no significant differences were observed between desorbed amounts at 20 
and 45 min. In addition, the same carryover values found after 20 min desorption were observed 
at 45 min (data not shown). Conversely, 10 min showed smaller desorption amounts for some 
analytes, as well as a higher carryover level. Based on these findings, 20 min was selected as  
 
Figure 2.2. Comparison of desorption efficiency at 10, 20 and 45 min (n = 4 pins and 1200 µL of 
desorption solution (4:1 methanol:acetonitrile with 0.1% formic acid)). Extractions were 
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desorption time, and an additional cleaning step was added to ensure no carryover. Cleaning of the 
blades was carried out by desorbing the blades in a 2:1:1 methanol:acetonitrile:isopropanol 
solution for 30 min. It is worth emphasizing that desorption and cleaning conditions herein 
optimized allowed for negligible carryover of the target compounds. However, confirming an 
adverse analytical finding in a real doping case with this methodology might require reporting that 
only new or disposable SPME samplers were used.  
 
2.3.2. Extraction conditions: pH, temperature, time and selection of internal standards 
Once the SPME coating was selected and desorption conditions were carefully optimized, other 
extraction parameters such as pH, extraction time and temperature were also considered. It is worth 
emphasizing that the main goal of the current work was to simplify the sample preparation required 
to extract a wide range of analytes present in complex matrices such as plasma. Bearing this is 
mind, minimum modifications to the sample matrix were considered. As already stated, SPME is 
able to extract an amount of analyte proportional to its free concentration. Since pH and 
temperature can influence the degree of binding of a given substance in plasma,143,144 controlling 
these variables was necessary in the development of this SPME method. For instance, 
physiological pH in plasma varies from 7.35 to 7.45. However, upon storage or sample preparation, 
plasma pH shifts more than 1 unit towards alkaline values, affecting protein-binding measurements 
and even causing degradation of some pH-labile compounds.145 As an effective means to stabilize 
plasma pH during sample preparation, Fura et al. reported the use of buffer concentrations above 
0.5 M and plasma:buffer ratios greater than 10:1. In this study, 1 M phosphate buffer in 9:1 
plasma:buffer proportion was used to control plasma pH during the sample preparation process. 
Temperature control was possible by taking advantage of the Concept-96 system extraction stage. 
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This unit consists of an orbital shaker equipped with a heating surface that ensures uniform 
temperature distribution along the 96-wells tray (see Figure 2.3).  
 
Figure 2.3. Concept 96 blade system with uniform temperature control on the extraction station. 
The effect of temperature on the amount extracted was evaluated at 25, 30 and 37 °C in both PBS 
and plasma, while keeping the extraction time constant at 75 min. Table 2.4 shows results 
corresponding to the amounts extracted at different temperatures from both sample matrices. As 
can be seen in Table 2.4, no significant differences were observed in the amount extracted from 
PBS for most of the compounds at the investigated temperatures. In other words, these results 
showed that increasing the temperature from 25 to 37 °C did not affect the fiber/sample distribution 
coefficient, or the affinity of the HLB coating towards the majority of studied compounds. Only 
toremifene and GW501516, which are characterized for a high lipophilicity, exhibited a slight 
increase in the amount extracted as extraction temperature was increased. A possible explanation 
for this observation might be related to the temperature effect on the extraction kinetics, given that 
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Table 2.4. Evaluation of the effect of temperature on the amount extracted from PBS and plasma spiked at 100 ng mL-1 and mixed 
with 1 M buffer (9:1 plasma:buffer). Extraction time was fixed at 75 min (n=4 pins). 
Compound 
PBS Plasma 
25 ˚C 30˚C 37˚C 25˚C 30˚C 37˚C 
ng RSD, % ng RSD, % ng RSD, % ng RSD, % ng RSD, % ng RSD, % 
Morphine-3β-glu 6.0 9 6.2 6 6.1 5 7.2 6 8.3 11 8.5 9 
Morphine-6β-glu 15.3 11 16.0 8 16.0 5 11.8 29 15.8 14 15.3 12 
Morphine 58.5 9 61.1 8 58.2 4 56.6 10 61.2 11 55.4 11 
Salbutamol 41.9 10 43.0 9 42.6 4 40.5 9 43.0 9 38.9 9 
Nikethamide 69.7 9 72.3 8 73.4 5 60.6 13 64.2 13 59.1 12 
Codeine 75.9 8 80.2 7 79.0 2 69.6 8 75.9 9 68.9 9 
Benzoylecgonine 66.8 12 69.7 9 72.2 6 54.4 12 58.2 14 54.8 13 
Amphetamine 66.6 9 66.8 8 65.0 2 61.5 8 64.7 9 56.4 8 
Prednisolone 67.6 6 67.0 7 69.3 8 7.9 10 12.9 7 22.1 4 
Furosemide 67.0 4 66.4 4 64.9 10 3.4 11 3.9 11 3.9 16 
Methamphetamine 75.7 6 77.4 8 77.4 2 72.7 8 77.9 10 71.6 8 
Dexamethasone 81.4 6 86.0 7 90.4 2 38.1 7 45.1 9 45.4 6 
Trenbolone 91.1 7 94.5 6 98.6 1 29.1 8 34.7 6 35.9 5 
Strychnine 84.1 6 88.8 6 82.8 1 43.2 7 52.2 7 53.5 6 
Metoprolol 85.7 7 90.4 6 93.4 1 77.4 7 85.4 9 80.8 6 
Exemestane 86.6 9 90.7 6 96.9 1 23.2 12 29.0 3 30.5 4 
Budenoside 82.1 7 87.8 6 92.1 2 25.3 8 29.5 12 30.6 8 
Clenbuterol 88.4 7 92.4 6 94.5 0 53.6 5 60.9 7 60.0 5 
THCCOOH-glu 32.4 24 35.7 31 38.3 26 6.6 6 8.2 14 8.3 9 
Stanozolol 76.5 6 78.4 5 79.1 2 3.1 13 4.0 7 4.8 8 
THCCOOH 71.3 7 79.2 6 80.6 5 2.2 2 2.6 19 2.6 10 
Bisoprolol 83.5 6 89.3 7 92.5 2 63.0 6 69.6 7 66.9 6 
GW501516 63.2 7 74.5 7 68.2 2 1.4 11 1.4 6 1.4 9 
Propranolol 92.4 7 96.5 6 96.3 1 40.2 8 48.2 8 52.7 5 
Toremifene 26.6 11 30.9 7 39.8 14 0.8 13 0.8 6 0.8 11 
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at 75 min and 25 °C these two compounds were not likely at equilibrium conditions. It is also 
worth noting that these compounds are prone to get attached on the plastic walls of the 96 well 
tray due to their high hydrophobicity. Hence, concentration of such analytes in PBS available for 
SPME extraction may be affected. A reduction in secondary interactions of those compounds with 
plastic and an improvement in their solubility in PBS is expected by increasing the extraction 
temperature. Conversely, results observed in plasma demonstrated that an increment of only five 
degrees in the extraction temperature produced a statistically significant increase in the amounts 
extracted for some of the studied drugs. Prednisolone, for instance, was greatly affected by 
temperature changes, with 8, 13 and 22 ng extracted by SPME at 25, 30 and 37 °C, respectively. 
As already documented by several authors, the binding affinity of multiple drugs towards plasma 
proteins is a function of temperature.143,144,146 Indeed, in the literature, differences of up to 50% 
have been reported for unbound drug fractions determined at room temperature (25 °C) and at 37 
°C.143 To the best of our knowledge, studies of the effect of temperature on prednisolone protein 
binding have not been reported previously. However, it has been documented that raising the 
temperature from 37 to 41 °C produces an increase of 80% in serum-free cortisol, an endogenous 
steroid hormone that exhibits competitive protein binding towards prednisolone.147–149 For these 
reasons, and to avoid jeopardizing method accuracy and reproducibility, 30 °C was selected as the 
extraction temperature. In cases where temperature control is not possible and SPME procedures 
for samples and matrix calibration points are not performed simultaneously, using an appropriate 
internal standard that closely mimics the binding behavior of the target analytes is highly 
recommended. 
After choosing adequate temperature and pH conditions, the determination of an appropriate 
extraction time for the proposed method was undertaken. Due to the wide variety of target analytes 
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selected for this study, the extraction time was selected based on a compromise between sufficient 
sensitivity and satisfactory throughput. For this purpose, solutions of all target analytes were 
prepared in PBS and plasma at 100 ng mL-1 (final concentration after adding buffer was 90 ng mL-
1). Extractions were performed at 15, 30, 45, 60, 75, 90, 105 and 120 min. As shown in Figure 2.4, 
two general trends were observed: compounds with low binding, generally those more polar, 
exhibited similar extractions profiles in PBS and plasma at the same extraction conditions. On the 
other hand, compounds characterized by high binding towards plasma proteins, such as stanozolol, 
were able to reach an extraction amount plateau within 30 min in PBS, while in plasma an 
increasing trend in the amount extracted was observed even after 120 min extraction. This behavior 
occurs due to the complexity of the system (plasma), where multiple types of binding interactions 
take place; more in-depth studies required to fully understand this phenomenon are ongoing, and 
will be reported in the near future. As an acceptable balance between throughput and sensitivity, 
90 min was selected as the extraction time. Although the selected extraction time involves pre-
equilibrium SPME conditions for plasma analysis, satisfactory precision was ensured, as the 
Concept-96 system allows accurate and automated control of stirring, temperature and extraction 
time conditions. 
Aiming to account for possible pin-to-pin variations, instrumental fluctuations, as well as for 
differences among plasma samples, deuterated drugs of different binding affinities,150–153 polarities 
and moieties were introduced as internal standards (Table 2.5). Due to the high protein binding 
behavior that some of the studied substances might exhibit in plasma, the final concentration of 
internal standard in the samples was fixed at 100 ng mL-1.81  
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A general schematic summarizing optimum SPME conditions for plasma analysis is presented in 
Figure 2.5. Once internal standard solution and buffer were added to plasma samples, 
homogenization of samples was conducted for 30 min prior to starting the SPME procedure. 
 
Figure 2.4. Extraction time profiles in PBS and plasma for metoprolol (logP 1.6) and stanozolol 
(logP 3.81) (n=4). 
 
Table 2.5. Internal standards used in the proposed SPME method. 
Internal standard logPa Protein binding, %b 
Morphine-3β-glucurunide-d3 -2.02±0.78 10
c 
Codeine-d3 1.19 7 - 25 
Salbutamol-d3 0.64 NA 
Oxycodone-d3 1.43 45 
Testosterone-d3 3.32 98 
Cannabidiol-d3 7.03 NA 
Cortisol-d4 1.43 95 
THCCOOH-d3 6.36 92.0 ± 8.7
d 
THCCOOH-glucuronide-d3 NA 96.4 ± 3.0
 d 
NA (not available) 
a Data taken from Chemspider 150 
bData taken from Drugbank 151 
c152 










































































































Figure 2.5. Summary of optimized SPME conditions for the analysis of prohibited substances in 
plasma. 
 
2.3.3. Absolute and relative matrix effects 
After determining optimum experimental parameters for SPME, it was important to evaluate the 
selectivity and reliability of the proposed protocol. The typical approach employed to determine 
drugs in plasma samples is protein precipitation, which is an exhaustive technique. However, the 
lack of selectivity of this sample preparation method may lead to undesired ion suppression or 
enhancement effects caused by interferences that can get dissolved in the extraction solvent. 
Absolute matrix effects for the studied compounds were estimated by comparing absolute peak 
areas of blank plasma extracts obtained at optimum SPME conditions (n=5) and neat desorption 
solvent, both spiked at the same concentration level (50 ng mL-1).154 As can be seen in Table 2.6,  
1080 µL of plasma
+15 µL of IS solution 
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Table 2.6. Absolute and relative matrix effects found for the proposed method. 
Compound  
(Ionization mode) 











% Lot A Lot B Lot C Lot D Lot E 
Morphine-3β-glu (+) 
 -
2.02±0.78 Morphine-3β-glu-d3 5 -1000 0.0077 0.0077 0.0072 0.0072 0.0066 0.0072 0.0004 6.2 99 
Morphine-6β-glu (+) 
 -
1.60±0.77 Morphine-3β-glu-d3 5 - 1000 0.019 0.017 0.017 0.016 0.017 0.017 0.0011 6.4 108 
Morphine (+) 0.89 Codeine-d3 1 - 250 0.0069 0.0070 0.0069 0.0067 0.0059 0.0067 0.0004 6.7 112 
Salbutamol (+) 0.64 Salbutamol-d3 0.25 - 1000 0.011 0.011 0.010 0.010 0.010 0.010 0.0006 6.3 110 
Nikethamide (+) 0.33 Oxycodone-d3 0.5 - 250 0.027 0.026 0.024 0.022 0.021 0.024 0.0023 9.8 110 
Codeine (+) 1.19 Codeine-d3 0.5 - 1000 0.013 0.013 0.012 0.012 0.011 0.012 0.0007 6.0 114 
Benzoylecgonine (+) 2.26 Morphine-3β-glu-d3 1 - 250 0.37 0.36 0.34 0.33 0.35 0.35 0.0164 4.7 110 
Amphetamine (+) 1.76 Salbutamol-d3 0.5 - 100 0.0090 0.0084 0.0086 0.0082 0.0078 0.0084 0.0004 5.2 111 
Methamphetamine (+) 2.07 Salbutamol-d3 0.5 - 100 0.032 0.028 0.031 0.027 0.026 0.029 0.0026 9.0 112 
Strychnine (+) 1.93 Codeine-d3 1 - 250 0.013 0.014 0.014 0.013 0.013 0.013 0.0008 5.8 118 
Exemestane (+) 3.7 Testosterone-d3 1 - 100 0.0079 0.0072 0.0080 0.0075 0.0071 0.0075 0.0004 5.4 110 
Trenbolone (+) 2.27 Testosterone-d3 1 - 100 0.0073 0.0072 0.0068 0.0065 0.0061 0.0068 0.0005 7.2 109 
Metoprolol (+) 1.6 Oxycodone-d3 0.25 - 500 0.012 0.012 0.012 0.011 0.011 0.012 0.0007 5.8 111 
Stanozolol (+) 3.81 Testosterone-d3 0.5 - 250 0.011 0.014 0.011 0.011 0.009 0.011 0.0016 14.4 103 
Clenbuterol (+) 2.33 Oxycodone-d3 0.5 - 500 0.043 0.043 0.043 0.041 0.039 0.042 0.0017 4.1 97 
Bisoprolol (+) 1.89 Oxycodone-d3 0.5 - 500 0.063 0.064 0.063 0.061 0.058 0.062 0.0023 3.7 104 
GW501516 (+) 4.81 Cannabidiol-d3 10 - 500 0.23 0.24 0.21 0.18 0.23 0.22 0.0243 11.0 103 
Propranolol (+) 3.48 Oxycodone-d3 1 - 500 0.050 0.049 0.045 0.045 0.044 0.047 0.0028 6.0 112 
Toremifene (+) 6.8 Cannabidiol-d3 25 - 1000 0.057 0.031 0.060 0.060 0.064 0.055 0.0133 24.4 109 
Budenoside (-) 2.18 No internal standard 1 - 500 341.8 342.7 305.4 311.4 252.4 310.7 36.8 11.8 117 
Dexamethasone (-) 1.83 No internal standard 0.5 - 500 7502.4 7574.5 7554.2 7206.7 6773.1 7322.2 340.9 4.7 110 
Prednisolone (-) 1.62 Cortisol-d4  5 - 250 0.015 0.015 0.015 0.013 0.013 0.014 0.0010 7.2 114 
Furosemide (-) 2.03 THCCOOH-d3  5 - 500 0.013 0.010 0.012 0.012 0.014 0.012 0.0016 13.6 110 
THCCOOH-glu (-) NA THCCOOH-glu-d3 10 - 500 0.015 0.014 0.015 0.016 0.014 0.015 0.0007 5.1 152 
THCCOOH (-) 5.14 THCCOOH-d3  1 - 500 0.013 0.012 0.011 0.012 0.010 0.011 0.0012 10.3 104 
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absolute matrix effects for all target compounds were within 99 and 120%. The only compound 
that exhibited a significant ion enhancement effect was THCCOOH-glucuronide (150%). As 
already discussed elsewhere, PAN-based biocompatible SPME coatings are able to provide 
sufficient selectivity towards small compounds, avoiding protein attachment or co-extraction of 
several interferences.83 Results herein shown demonstrated that the HLB SPME coating provides 
efficient sample clean-up for a wide range of compounds when extracted from a complex matrix 
such as plasma. Certainly, the open bed geometry of SPME surpasses clogging issues typically 
encountered when using SPE for such type of samples. In addition, these findings demonstrated 
that the HLB extraction phase in SPME configuration might be a convenient sample preparation 
approach for screening and quantification purposes. This can be particularly useful when 
considering the potential occurrence of unknown prohibited substances and the need of 
retrospective analysis in some doping control cases. Relative matrix effects were also investigated 
according to the procedure proposed by Matuszewski et al., 2003.154 Table 2.6 presents the slopes 
of the calibration curves (area drug/area IS vs. nominal concentration) prepared in pooled plasma 
from different lots (n=5). Considering the principles of SPME, where the amount of analyte 
extracted is proportional to its unbound fraction at the end of the extraction process, biased 
quantitative results might be expected when dealing with significant variations in plasma protein 
levels among different samples. As seen in Table 2.6, the relative standard deviations of the slopes 
of the studied compounds were mostly below 7%. RSD values above 9% were mainly observed 
for compounds with a high logP such as toremifene, GW501516 and THCCOOH, which also 
display a high binding affinity towards plasma proteins. Other compounds characterized by high 
protein binding, such as budenoside and stanozolol, also showed higher RSD values. However, in 
general, RSDs for the slopes of all the model compounds were below 15%, and only toremifene 
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exhibited a relative standard deviation above 20%. An observed decrease in relative matrix effects 
might be expected by using deuterated analogues for each compound.  
2.3.4. Method validation 
The proposed method was evaluated according to the guidelines stipulated by the Food and Drug 
Administration (FDA).155 Calibration points were prepared at 0.25, 0.5, 1, 5, 10, 25, 50, 75, 100, 
250, 500 and 1000 ng mL-1 by spiking plasma aliquots with 1% of stock standards prepared in 
methanol. Weighted calibration curves were constructed using 1/x as a weighting factor. Although 
concentration levels in the order of hundreds of parts per billion (ppb) are not likely to occur for 
many of the studied drugs, it was important to investigate the linearity of the proposed method in 
a wide range of concentrations. Accuracy, as well as intra and inter-day precision were evaluated 
at five different concentrations levels: 1.6, 15, 35, 70, and 200 ng mL-1. Limit of quantitation 
(LOQ) was defined as the lowest concentration at which the back-calculated value deviated less 
than 20% from the nominal value, the precision of the measurements at such concentration level 
was below 20%, and the signal-to-noise ratio was at least 10:1. Table 2.7 shows method validation 
results for all the target compounds at optimized SPME conditions. As can be seen, good linearity 
(R2> 0.99) for the broad set of studied compounds was achieved in a wide range of concentrations. 
LOQ values for all the analyzed substances were in the low ppb range, except for toremifene, 
GW501516, and THCCOOH-glu, which are characterized by high protein binding and 
lipophilicity. Improved LOQ values can be attained by decreasing the volume of desorption 
solvent, and even increasing the extraction time. In cases of limited sample availability, smaller 
plasma volumes or even diluted plasma can always be used. Intra and inter-day accuracy values 
were in the ranges of 85 to 124 and 87 to 130% for all the studied compounds, respectively. In 
terms of inter-day precision, only four compounds, which had previously shown LOQ values of 
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Morphine-3β-glu 5 0.9995 - 97 98 105 96 - 5.3 8.0 5.5 5.8 - 96 94 108 99 - 4.8 7.4 6.1 6.6 
Morphine-6β-glu 5 0.9947 - 99 98 103 88 - 7.9 6.3 4.9 7.8 - 98 93 109 90 - 7.0 8.3 8.0 11.8 
Morphine 1 0.9983 99 103 104 109 94 8.6 5.8 7.4 9.7 5.9 95 101 100 113 96 8.2 5.2 7.8 8.8 11.3 
Salbutamol 0.25 0.9994 109 98 98 107 99 3.6 4.0 7.7 2.8 6.2 106 95 93 105 101 14.2 5.8 8.6 3.8 6.0 
Nikethamide 0.5 0.9976 90 93 91 93 94 12.1 3.9 5.5 6.0 8.5 91 92 88 95 95 10.6 6.7 6.8 7.4 13.6 
Codeine 0.5 0.9996 102 97 97 107 100 6.9 4.3 7.2 6.5 3.8 102 94 94 109 100 10.2 5.4 7.5 5.8 6.0 
Benzoylecgonine 1 0.9953 91 100 96 98 98 19.1 5.3 9.0 7.3 8.7 98 93 91 100 95 17.8 8.3 10.0 5.9 8.5 
Amphetamine 0.5 0.9988 101 97 100 112 - 3.4 8.8 10.0 14.5 - 94 95 99 120 100 7.8 7.1 8.1 13.6 - 
Methamphetamine 0.5 0.9981 116 104 103 109 - 3.3 4.5 6.9 3.6 - 105 100 99 113 101 10.5 6.3 7.6 6.0 - 
Strychnine 1 0.9973 113 116 118 123 102 4.6 3.5 8.7 8.7 7.4 95 112 114 130 105 18.7 8.6 10.3 9.9 9.0 
Exemestane 1 0.9976 124 107 105 108 - 8.8 6.3 7.3 4.5 - 107 101 98 110 - 17.7 8.2 9.9 6.5 - 
Trenbolone 1 0.9915 124 115 108 107 - 10.5 4.7 9.3 2.9 - 104 104 98 101 - 20.1 11.9 13.9 9.1 - 
Metoprolol 0.25 0.9989 108 98 97 109 101 6.6 5.3 4.4 6.7 11.2 103 98 95 108 105 7.5 5.1 4.6 6.0 10.1 
Stanozolol 0.5 0.9952 104 100 99 101 95 7.9 4.5 6.9 6.4 10.0 100 96 91 97 101 12.4 11.0 13.1 10.7 10.0 
Clenbuterol 0.5 0.9987 98 93 93 104 95 6.4 4.0 5.0 6.6 7.8 97 98 95 109 101 5.8 7.1 4.8 8.0 10.9 
Bisoprolol 0.5 0.9987 100 95 94 105 97 6.1 5.8 5.3 7.8 7.3 97 97 94 108 101 5.5 5.5 4.2 6.6 8.8 
GW501516 10 0.9927 - 103 102 106 90 - 2.9 8.9 3.2 17.2 - - 101 105 96 - - 8.2 9.3 15.3 
Propranolol 1 0.9995 109 103 103 112 97 5.5 3.6 8.2 4.0 8.1 99 102 100 116 102 11.0 4.4 7.8 5.7 9.9 
Toremifene 25 0.9968 - - 111 119 106 - - 7.2 8.2 10.9 - - 110 115 102 - - 9.5 12.4 12.0 
Budenoside 1 0.9937 87 93 90 93 85 6.8 14.2 15.5 11.8 19.9 93 93 88 90 87 19.0 14.9 14.9 12.6 18.4 
Dexamethasone 0.5 0.9929 96 101 100 102 88 4.2 2.8 3.8 3.6 17.1 93 94 92 93 87 13.8 12.3 11.9 11.6 16.2 
Prednisolone 5 0.9941 - 95 100 110 97 - 11.8 11.7 4.7 7.3 - 89 94 107 101 - 17.7 12.5 5.8 8.4 
Furosemide 5 0.9940 - 106 105 110 101 - 13.2 15.3 14.5 6.8 - 101 98 106 101 - 11.1 14.4 11.8 5.5 
THCCOOH-glu 10 0.9914 - 94 107 121 109 - 6.6 9.0 4.2 6.0 - 91 100 122 111 - 7.5 10.3 6.2 5.4 
THCCOOH 1 0.9976 118 100 97 105 96 3.4 4.1 6.1 2.2 9.8 112 98 94 103 101 11.0 6.3 8.0 4.1 11.5 
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1 ng mL-1, exhibited RSDs above 15% at 1.6 ng mL-1. At 200 ng mL-1, only budenoside and 
dexamethasone showed inter-day RSDs higher than 15%. Satisfactory figures of merit observed 
for the studied glucuronide compounds revealed that SPME is a suitable approach for the direct 
analysis of such metabolites without requiring an additional hydrolysis step. This might be of 
especial utility in cases where glucuronide standards are available, a poor yield after enzymatic 
hydrolysis is expected, or information about the concentrations of a given drug and its glucuronide 
form is required. 
SPME is an equilibrium-based sample preparation technique where a small amount of extraction 
phase is exposed to the sample matrix. A common misconception among potential SPME users 
involves potential saturation of the coating in direct immersion mode due to the presence of 
multiple substances in the sample media. It is worth emphasizing that extraction in SPME depends  
on the extraction phase/sample matrix partition coefficient, and achieving an exhaustive recovery 
is not necessarily the ultimate goal of this microextraction technique. A recent work where SPME 
and SPE were thoroughly compared from their fundamental aspects has been recently published.156 
In this work, it was experimentally verified that for the same set of compounds, breakthrough 
volume affects SPE, whereas it does not have any effect on SPME quantitation. In this sense, using 
SPME for the determination of multiple substances of diverse chemistries and varying 
concentrations is highly convenient, provided that there is no limitation in terms of breakthrough, 
and that efficient sample clean-up can be easily attained.  
 
2.4. Conclusions 
The herein proposed methodology demonstrated its suitability for high-throughput determination 
of a wide range of compounds in complex matrices such as plasma with minimum sample 
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handling. Rewarding results in terms of matrix effects evidenced the satisfactory performance of 
this sample clean-up approach. The HLB extraction phase used for this study was demonstrated to 
be a versatile coating in cases where analysis of multiple compounds of varying physicochemical 
characteristics is required. LOQs were within 0.25 and 10 ng mL-1 for most of the studied 
compounds; however, further improvement might be attainable by introducing solvent evaporation 
and reconstitution steps in the automated sample preparation workflow. Satisfactory results for 
figures of merit such as inter and intra-day precision and accuracy were also found. Although the 
method herein presented was developed using LC-MS/MS analysis, comprehensive plasma 
screening might be feasible by combining the proposed sample preparation methodology and full 
scan high resolution MS. By incorporating a sample pre-incubation feature at controlled 
temperature conditions, it is possible to normalize bound concentrations, reduce chances of error 
due to temperature fluctuations, and facilitate automated drug-binding studies.  
Overall, the most important advantages of the proposed method compared to typical approaches 
(e.g. SPE and protein precipitation) can be listed as follows: requirement of minimum sample pre-
treatment, satisfactory selectivity of the SPME extraction phase towards small compounds, no 
concerns regarding sorbent breakthrough in multi-residue analysis and/or clogging of cartridges, 
and suitability of full automation and high throughput sample preparation.  On the other hand, 
weak points of this protocol rely on the relative large volume of sample needed to completely 
cover the thin-film coating (>500 µL), the high limits of detection/quantitation expected for those 
compounds that exhibit high protein binding, and the lack of pre-concentration when the same 
sample and desorption volumes are used.  
This SPME-based analytical workflow can be further expanded for the analysis of other biological 
samples in applications where sufficient coverage for a broad range of analytes is required. Even 
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though the reusability of biocompatible SPME coatings in thin-film format has been already 
demonstrated, future directions foresee the introduction of single use thin-film devices in order to 




















Chapter 3: Solid phase microextraction devices prepared on plastic support as potential 
single-use samplers for bioanalytical applications 
 
3.1. Preamble and introduction 
3.1.1. Preamble 
This chapter of the thesis is already published as an article under the title “Solid phase 
microextraction devices prepared on plastic support as potential single-use samplers for 
bioanalytical applications” by Nathaly Reyes-Garcés, Barbara Bojko, Dietmar Hein and Janusz 
Pawliszyn., Anal. Chem. 2015, 87, 9722–9730. The content of the article is being reprinted in this 
thesis with permission of the American Chemical Society, and in compliance with the American 
Chemical Society and University of Waterloo policies. 
I, Barbara Bojko, authorize Nathaly Reyes-Garcés to use the material for her thesis. 
I, Dietmar Hein, authorize Nathaly Reyes-Garcés to use the material for her thesis. 
3.1.2. Introduction 
Solid phase microextraction (SPME) has demonstrated unquestionable advantages as an 
alternative sample preparation approach over traditional methods for several applications (e.g. 
liquid-liquid extraction and protein precipitation). Minimum solvent use, integration of sampling 
and sample preparation steps, simple operation, and suitability for on-site and in vivo 
determinations are just some of the important benefits of using SPME. Indeed, the introduction of 
biocompatible coatings suitable for direct extraction of diverse compounds from complex matrices 
has led to an expansion in SPME applications, especially in the field of bioanalysis.73,74,102,157–159 
These coatings, which consist of a biocompatible binder used to immobilize solid phase extraction 
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(SPE) particles and other sorbents, have demonstrated great selectivity towards small molecules, 
minimum or negligible protein fouling, and sufficient stability even for long-term reusability (140 
extractions from plasma).83,88  
Biocompatible SPME coatings are available in two main configurations: fibers and thin-films. The 
term “thin-film” is used to designate another geometry of SPME, in which devices consisting of a 
large coated surface area and a thin coating thickness (large extraction phase surface area-to-
volume ratio) provide better sensitivity than traditional SPME fibers without sacrificing analysis 
time (short equilibration times).75 Both, fiber and thin-film SPME devices, have been subjected to 
automation for high throughput analysis in the 96-well plate format; however, the enhanced 
sensitivity offered by thin-film geometry is preferred in several cases (e.g. in vitro biofluids 
analysis). Various studies reporting on the suitability of high-throughput thin-film SPME for 
analytical determinations in different matrices have been published recently.84,160,161 In the area of 
bioanalysis, some recently reported applications of thin-film SPME include for instance the 
determination of tranexamic acid and rocuronium bromide in plasma, and the analysis of multiple 
doping substances in both urine and plasma samples.80,90,162 Although, as already emphasized, the 
robustness of these biocompatible devices allows for reusability even in complex matrices, in some 
cases (e.g. doping analysis), it is certainly preferable, if not mandatory, to use disposable or single-
use samplers. In this sense, exploring alternative materials for the construction of SPME devices, 
as well as simplifying the manufacturing process itself, are key factors to facilitate the widespread 
acceptance of this sample preparation method.  
The introduction of novel materials in the fabrication of SPME samplers has been mainly directed 
towards finding alternative and cost-effective coating types.87,163,164 However, broadening the 
current list of substrate materials used to immobilize different SPME extraction phases can also 
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provide unique opportunities. While self-supported SPME samplers (e.g. polydimethylsiloxane 
sheet pieces (PDMS)) are available for selected applications,75,165 a solid substrate is typically 
required as base for application of the SPME coating, as well as to define the device geometry 
(e.g. wire or monofilament type of substrate for traditional SPME fibers, flat supports for thin-
films and blade spray devices, and a metallic mesh for SPME-transmission mode).79,166,167 Fused 
silica, StableFlex™, and metal non-ferrous alloys such as nitinol have been all used as fiber cores 
for gas chromatography (GC)-amenable SPME coatings (Table 3.1), while  stainless steel and 
nitinol are currently employed as substrate materials of choice to immobilize biocompatible 
extraction phases.87,163,164 Despite the satisfactory performance of biocompatible SPME samplers 
manufactured on such supports, certain applications will definitely benefit from the introduction 
of biocompatible substrates that are cheaper to manufacture, in addition to being more flexible, 
and easier to mold. For example, while the original in vivo SPME approach involves the use of 
traditional fibers by exposing them directly to the bloodstream or by inserting them in different 
types of tissue, 21,56,115,168 the development of devices for less invasive in vivo applications, such 
as saliva and mucosa analysis, might require alternative support materials. 
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(thin-films) 
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Various requirements should be fulfilled when looking for substitute materials to manufacture 
SPME devices for bioanalysis. First of all, the material should be biocompatible, suitable for 
sterilization, and able to handle temperatures normally employed to cure the polymeric binders 
used for SPME coatings. Once applied, the coating should be sufficiently stable on the substrate, 
and ideally, the coated material should not release any type of interferences, neither in the sample 
nor in the desorption medium. Substitute support materials for SPME should also offer good 
chemical resistance, low moisture absorption, affordability, and be easily accessible. Several 
materials, including metals and polymers, are used to manufacture various commercially available 
medical devices.169,170 Among this list of medical grade materials, thermoplastics represent an 
important group of polymers that are widely used for the production of healthcare 
components.169,170 Given that these plastics display many of the features required for the 
preparation of SPME samplers, in this work, polybutylene terephthalate (PBT) was tested as a 
potential support for application of SPME biocompatible extraction phases. For this purpose, 
coating preparation conditions were modified according to the new support material 
characteristics, and thin-film SPME devices were prepared using two different PBT geometries: 
rounded and flat. In this study, an SPME coating made of hydrophilic-lipophilic balanced particles 
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(HLB) and polyacrylonitrile (PAN) was selected due to its suitability to extract a wide range of 
compounds.162 A thorough evaluation of the newly prepared samplers in terms of stability, 
reproducibility, and performance in the extraction of seventeen doping substances from various 
biological matrices (urine, plasma, and whole blood) is herein presented. The model compounds 
chosen for this work covered logarithmic octanol-water partition coefficients (log P) values 
ranging from 0.33 to 6.56, and included drugs bearing different structural moieties. Figures of 
merit corresponding to determinations of total concentrations of the selected analytes spiked in 
different biofluids are also reported. Lastly, this work presents a discussion regarding the impact 
of sorbent type on coating wettability; a comparison of water contact angles measured on HLB-
PAN, C18-PAN, and only-PAN coatings provided remarkable evidence on the advantages of using 
HLB-PAN as SPME coating for the analysis of aqueous matrices.  
3.2. Experimental section 
3.2.1. Materials and supplies 
A 250 mL flask-type sprayer, formic acid, PAN, potassium chloride, sodium chloride, potassium 
phosphate monobasic, and sodium phosphate dibasic were obtained from Sigma-Aldrich 
(Oakville, ON, Canada). Oasis hydrophilic-lipophilic balance 30 μm sorbent particles (HLB) were 
obtained from Waters (Milford, MA, USA). Discovery silica-based C18 5 µm particles were gently 
provided by Supelco Sigma-Aldrich (Bellefonte, PA, USA). N,N-dimethyl formamide (DMF) was 
purchased from Caledon Labs (Georgetown, ON, Canada). PBT rounded pieces (1.7 mm diameter) 
were obtained from Professional Analytical System (PAS) Technologies (Magdala, Germany), and 
PBT film (300 mm width, 2 m length, 0.5 mm thickness) was purchased from Goodfellow 
(London, UK). Polypropylene Nunc U96 deep well plates were obtained from VWR international 
70 
 
(Mississauga, ON, Canada) and LC-MS grade solvents (acetonitrile, methanol, and water) were 
purchased from Fisher Scientific. 
The following compounds were selected as model analytes to evaluate the SPME-HLB-PBT 
devices: amphetamine, 17-α-trenbolone, benzoylecgonine, bisoprolol, clenbuterol, codeine, 
exemestane, GW501516, methamphetamine, metoprolol, morphine, nikethamide, propranolol, 
salbutamol, stanozolol, strychnine, and toremifene. Codeine-d3, oxycodone-d3, cannabidiol-d3, 
methadone-d3, (±)11-nor-9-carboxy-Δ9-THC-d3 (THCCOOH-d3),  testosterone-d3 and salbutamol-
d3 were used as internal standards. Further details about compounds suppliers are provided in 
Chapter 2.  
3.2.2. Preparing thin-film SPME devices on PBT support 
Rounded PBT pieces were trimmed to 53 mm length. In the case of SPME-HLB-PBT devices on 
flat support, rectangular PBT pieces with a 0.5 mm thickness (10 x 8 cm) were cut using a 
conventional paper trimmer. Prior to the application of the coating, the area to be coated was 
uniformly sanded using commercial sandpaper (first using a sandpaper of a medium macro grit 
(P150) and then using one of ultra-fine micro grit (1500)). All PBT pieces were cleaned with 
methanol and acetonitrile (20 min in each solvent under sonication), and then left to dry at room 
temperature.  
For the coating procedure, a slurry was prepared by mixing approximately 0.7 g of HLB particles, 
3 mL of DMF, and 10 mL of 7% (w/w) PAN/DMF solution (prepared by mixing PAN with DMF, 
and heating the obtained solution at 90 ˚C for 1 h). A 2 cm length coating was applied by spraying 
uniform layers of slurry and curing each layer at 125 ˚C for 2.5 min (14 cycles in total) (Figures 
3.1A, 3.1B and 3.1C). From the coated rectangular pieces, SPME-HLB-PBT samplers with a 2.3 
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mm width were cut using a paper trimmer as well. Six of these devices were over-coated with PAN 
by dipping them in 7% PAN solution, as reported in the literature.171 Finally, twelve SPME-HLB-
PBT devices on flat support (6 of them over-coated with PAN) were arranged to ensure 
compatibility with the Concept 96 system, as shown in Figure 3.1D. All the SPME devices were 
cleaned in a solution of 2:1:1 v/v methanol:acetonitrile:isopropanol for 120 min.  
To characterize the prepared devices, scanning electron microscopy (SEM) images were taken 
using a LEO 1530 field emission (Carl Zeiss NTS GmbH, Germany), and microscope pictures 
were taken using an Olympus SZX10 stereomicroscope system equipped with a SC30 digital 
camera (Olympus, Japan).  
The previously described coating procedure was also followed to apply HLB-PAN, C18-PAN and 
only-PAN (without sorbent particles) coatings on flat PBT pieces (2 x 10 cm). These coated PBT 
pieces were subsequently used to investigate the wettability of these extraction phases. The 
wettability of these three coatings was assessed by measuring the contact angle of 30 µL water 
drops according to the sessile drop method. Images were acquired every 2 s, and contact angle 
measurements were collected using Axisymmetric Drop Shape Analysis (ADSA). 
3.2.3. Sample preparation for LC-MS/MS analysis 
An initial assessment of PBT as a substrate for the manufacture of thin-film SPME devices was 
carried out with the rounded pieces (Figures 3.1A and 3.1B). For this purpose, phosphate buffer 
solution (PBS) and three different biological matrices (urine, plasma, and whole blood) were used 
to test the plastic devices. Aliquots (1080 µL) of each matrix were spiked with methanolic stock 
solutions containing the model compounds. The organic solvent content was kept below 1% in all 
cases. Once spiked, sample pre-incubation was allowed for 1 h under constant vortex agitation 
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conditions to ensure proper equilibration between the model compounds and the different tested 
matrices. Table 3.2 summarizes sample preparation parameters selected for urine, plasma, and 
blood analysis. These experimental conditions were chosen based on previous work done in our 
group.80,162 As can be seen, the same parameters used for plasma analysis were employed for 
extraction from whole blood, except for an additional washing step that was introduced after pre-
conditioning, and three 5 s wash steps conducted after each extraction. In addition, a higher 
concentration of internal standard was used for blood and plasma samples compared to urine 
samples with the aim of compensating for low recoveries due to matrix binding effects. Since the 
number of SPME-HLB-PBT samplers on rounded PBT support was limited, matrix matched 
calibration curves were constructed for each biological fluid using one device per calibration level 
(0.1, 0.25, 0.5, 1, 5, 10, 25, 50, 75, and 100 ng mL-1). Accuracy and precision were evaluated at 
1.6, 15, 35, and 70 ng mL-1, using three devices per concentration level. Limits of quantification 
(LOQ) were determined as the lowest concentration points at which both deviations from nominal 
concentration values and relative standard deviations were below 20% for each individual 
compound. All steps of the SPME method were carried out at room temperature, and uniform 
stirring was conducted by placing the vials in a multi-tube vortex agitator. SPME-HLB-PBT 
devices on flat PBT support were employed to evaluate the robustness of the coating immobilized 
on the selected substrate. For this purpose, consecutive extractions from plasma and whole blood 
spiked with six of the model compounds were performed using a set of 12 films arranged in the 
Concept 96 system (Figure 3.1 D). For this part of the study, experimental conditions were kept as 
already described for whole blood analysis, except for extraction time and desorption volume, 
which were set at 60 min and 1200 µL, respectively. All extracts were analyzed using liquid 
chromatography-tandem mass spectrometry (LC-MS/MS).  
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3.2.4. LC-MS/MS conditions 
All the extracts were run using an LC-MS/MS system comprised by an Accela autosampler, an 
Accela pump and a triple quadrupole mass spectrometer TSQ vantage with a heated electrospray 
ionization source operating in positive mode (Thermo Scientific, San Jose, USA). For 
chromatographic separation, a pentafluorophenyl core shell column (1.7 µm, 2.1 mm × 10 mm) 
with guard (PFP security guard ultracartridge) was employed (Phenomenex, Torrance, CA, USA). 
A ternary mobile phase system consisting of 0.1% formic acid (A), acetonitrile with 0.1% formic 
acid (B) and methanol with 0.1% formic acid (C) was used for LC separation. Gradient elution 
conditions were set as follows: A, B and C were held at 90, 5 and 5%, respectively, for 0.5 min, B 
and C were linearly increased to 50% in 6.5 min, then C was increased to 75% and B decreased to 
25% in 5 min and held for 3.5 min. Finally, the column was kept at the initial gradient composition 
for 2 min. The column temperature was maintained at 35 ˚C, the total run time was 17.5 min, and 
the column flow was set at 0.3 mL/min. Samples were stored in the autosampler at 5 ˚C and the 
injection volume was 10 µL. MS analysis was carried out using selective reaction monitoring 
(SRM) mode (please refer to Table 2.1 in Chapter 2) and conditions were optimized by doing 
direct infusion of the standards.  Other parameters were the following: spray voltage = 1300 V, 
vaporizer temperature = 275◦C, sheath gas = 45 units, auxiliary gas = 30 and capillary temperature 
= 280◦C. 
Table 3.2. Summary of experimental conditions selected for SPME. 
Parameter Urine Plasma Whole blood 
Sample volume 1080 µl 
Phosphate buffer (pH = 7) 120 µL (2 M buffer)  120 µL (1 M buffer) 
74 
 
Parameter Urine Plasma Whole blood 
Internal standard 
Spiked in buffer at 
200 ng mL-1 
15 µL of 8 µg mL-1 solution 
Preconditioning 
30 min in 1500 µL of 
1:1 methanol:water 
30 min in 1500 µL of 1:1 
methanol:water + 10 s wash in 
nanopure water 
Extraction time 90 min 
Washing 





3 times each in 1500 µL of 
nanopure water for 5 s  
Desorption 
20 min in 600 µL of 4:1 methanol: acetonitrile 
acidified with 0.1% formic acid 
 
3.3.Results and discussion 
3.3.1. Characterization of PAN-HLB coating prepared on plastic and evaluation of PBT as 
a support for SPME 
The optimized procedure for preparing thin-film PAN-based SPME coatings on a stainless steel 
support has been already reported.88 In that study, spraying over a previously etched surface and 
curing at 180 ˚C for 2 min were found to be optimum conditions. Due to the characteristics of the 
material selected as a new support for SPME devices, modifications to the already reported 
protocol were necessary. First of all, since etching with concentrated acid was not feasible, the 
plastic surface was only sanded with regular sandpaper (as indicated in section 3.2.2). This step 
was taken with the aim of improving the adherence of the biocompatible coating on PBT. 
Secondly, considering that the maximum temperature for long term use of PBT is 125 ˚C, the 















Figure 3.1. Rounded thin-film SPME devices prepared as described (A), microscope pictures of 
the HLB coating applied on the rounded plastic pieces (B), SEM image of the morphology of the 
coating on PBT support using 30x magnification (C) and SPME-HLB-PBT devices (on flat PBT 
support) in an arrangement compatible with the Concept 96 system (D). 
 
As can be seen in both the microscope picture and SEM image presented in Figures 3.1B and 3.1C, 
a uniformly coated surface was obtained. The robustness of the coated plastic devices was tested 
by exposing them to water, methanol, and acetonitrile for a total period of 20 h under constant 
vortex agitation. No noticeable changes in the coating structure were observed, and no detachment 
of the coating from the plastic surface occurred. These findings demonstrated the stability of the 






conditions for the coating procedure. Provided that no etching with concentrated hydrochloric acid 
is required, a simplified and greener coating application approach can be established. 
After verifying the stability of the SPME coating on PBT, inter-device reproducibility was also 
assessed. Satisfactory results were obtained for 20 rounded devices employed to extract from 
spiked PBS, showing RSD values below 13% for all the tested compounds (Figure 3.2). However, 
it is worth noting that the rounded shape of the plastic support may have hindered the uniform 
application of the SPME coating by spraying. Although 13% was an acceptable RSD value, better 
results were obtained when a flat support was used. 
 
 
Figure 3.2. Inter-device relative standard deviation values (RSDs, %) obtained from coated 
rounded PBT pins (n=20) for various drugs. Extractions were performed from PBS spiked at 50 






























Following the initial positive results obtained for the new coated material, an evaluation was 
conducted regarding possible interferences arising from the substrate that may be introduced into 
the sample or desorption media. For this purpose, an initial assessment of the background provided 
by the SPME coating prepared on the PBT support was carried out. Various new SPME-HLB-
PBT devices were desorbed in 4:1 methanol:acetonitrile (v/v) acidified with 0.1% formic acid for 
20 min. Prior to blank desorption, a cleaning step was performed by exposing the plastic devices 
to a mixture of organic solvents (2:1:1 v/v methanol:acetonitrile:isopropanol) under vortex 
agitation conditions for 120 min. Extracts were then run in full scan mode and compared with 
solvent blanks and extracts from the new HLB-PAN coatings prepared on a regular stainless steel. 
As can be seen in Figure 3.3, no significant differences were observed among the background 
signals obtained for all blanks. As a second means of verifying the absence of interferences coming 
from the proposed devices, absolute matrix effects were estimated according to the procedure 
proposed by Matuszewski et al.154 Extracts obtained from the desorption of blank SPME-HLB-
PBT samplers were spiked with the target compounds at 50 ng mL-1, and their response (peak area) 
was compared with the one from standards prepared in neat solvent at the same concentration 
level. Likewise, extracts from urine and plasma blanks obtained with SPME-HLB-PBT devices (n 
= 6) were post-spiked and compared with neat standards as well. As shown in Table 3.3, no 
absolute matrix effects coming from the devices prepared on the PBT support were found for all 
the studied compounds. In addition, no significant matrix effects (80 – 112%) were observed for 
the compounds spiked in urine and plasma blank extracts. These results demonstrated the stability 
of the SPME coatings on the polymeric support, while proving the absence of possible 
interferences that might be released upon contact between the coated PBT and the sample medium 




Figure 3.3. Blanks run in positive full scan mode (100 – 1000 m/z) using TSQ vantage. A cleaning 
step was performed by exposing the rounded coated PBT devices to a mixture of organic solvents 
(2:1:1 v/v methanol:acetonitrile:isopropanol) for 60 min under vortex agitation conditions. 
 
Table 3.3. Evaluation of absolute matrix effects in blank solution coming from desorption of new 
plastic HLB devices, and in extracts of blank urine and plasma obtained with such plastic devices 
(n=6, extracts spiked at 50 ng mL-1 and analyzed in positive ionization mode). 
Compound 
Absolute matrix effects, %  






Morphine 99 106 93 
Salbutamol 100 107 112 
Nikethamide 101 108 108 
Codeine 99 107 88 
Benzoylecgonine 96 110 107 
Amphetamine 95 103 102 
Methamphetamine 100 105 101 
Trenbolone 97 103 81 
Strychnine 94 94 88 
Metoprolol 98 91 95 
Exemestane 95 97 87 
Clenbuterol 99 92 94 
Stanozolol 94 92 93 
RT: 0.00 - 21.00
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TIC  MS 
blank_hlb_pl
astic_4
Blank of plastic pin coated with 
HLB (without cleaning). 
Blank of plastic pin coated with 
HLB after performing a cleaning 
step. 
Blank of HLB coating on stainless 
steel support 
Blank of solvent 
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Bisoprolol 99 89 79 
GW501516 101 103 103 
Propranolol 99 99 90 
Toremifene 103 107 102 
 
3.3.2. Using SPME devices on polymeric support for the analysis of doping substances in 
urine, plasma, and blood 
 
3.3.2.1.Urine and plasma analysis 
The proposed rounded PBT devices were used for the analysis of urine and plasma samples 
according to the experimental conditions provided in Table 3.2. As can be seen in Table 3.4, 
rewarding figures of merit were obtained when using SPME-HLB-PBT devices in both matrices. 
Satisfactory results were observed for most analyzed drugs, with good linearity (R2 > 0.99), 
accuracy (80 – 120%), and precision (RSD < 7%) measures. As expected, less polar compounds 
such as toremifene (logP 6.56) and GW501516 (logP 6.46) exhibited higher LOQ values in plasma 
than in urine due to protein binding effects. On the other hand, polar compounds such as salbutamol 
(log P 0.64) and morphine (log P 0.89), which are not significantly affected by protein binding 
interactions, showed the same LOQ values in both matrices. Indeed, the LOQ value for a given 
analyte is directly correlated to the absolute SPME recovery, which, in turn, depends on several 
parameters, namely, the extraction time, the convection conditions, the coating volume, and the 
affinity of the compound for the matrix components and for the SPME coating. Although in SPME 
a small amount of analyte proportional to the analyte concentration in the sample is extracted, 
depending on the previously listed factors and on the proportion between coating and sample 
volumes, exhaustive, or almost exhaustive extraction can take place. For some of the model 
compounds, this can be reflected in the higher enrichment factors (EF, analyte concentration in the 
extract/analyte concentration in the sample) estimated in urine compared to those EFs calculated  
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Table 3.4. Figures of merit for urine and plasma analysis using rounded SPME-HLB-PBT devices. 
Compound  
(logP)a 








Accuracy %, (RSD, n=3) 
1.6 















Morphine (0.89) 0.1 0.9984 100 (0.1) 89 (1.0) 102 (1.4) 102 (0.4) 0.1 0.9958 116 (0.1) 107 (1.1) 92 (3.8) 110 (2.0) 
Salbutamol (0.64) 0.1 0.9952 103 (0.1) 87 (0.7) 97 (0.9) 98 (1.7) 0.1 0.9936 109 (0.1) 104 (0.5) 103 (2.7) 108 (3.7) 
Nikethamide (0.33) 0.5 0.9895 103 (0.1) 81 (1.5) 90 (1.7) 85 (1.7) 0.5 0.9986 100 (0.1) 102 (1.2) 100 (3.2) 104 (5.3) 
Codeine (1.19) 0.1 0.9977 101 (0.1) 87 (0.5) 103 (1.1) 101 (1.0) 0.1 0.994 109 (0.1) 104 (0.4) 105 (2.7) 109 (3.9) 
Benzoylecgonine 
(2.71) 0.5 0.9978 99 (0.1) 86 (1.8) 114 (0.8) 107 (3.0) 1 0.9993 87 (0.3) 110 (2.5) 107 (3.9) 113 (3.2) 
Amphetamine (1.76) 0.25 0.9935 95 (0.1) 82 (1.4) 88 (1.6) 94 (3.8) 0.25 0.9919 105 (0.2) 104 (0.7) 112 (3.1) 99 (2.5) 
Methamphetamine 
(2.07) 0.1 0.9928 94 (0.1) 84 (2.1) 89 (1.4) 94 (3.4) 0.25 0.9909 105 (0.2) 103 (0.9) 115 (2.5) 98 (4.2) 
Strychnine (1.93) 0.5 0.9959 94 (0.1) 85 (1.9) 103 (1.6) 99 (4.6) 5 0.9935 - 121 (0.7) 94 (3.8) 116 (5.5) 
Exemestane (3.11) 1 0.9975b 107 (0.1) 87 (0.8) 88 (1.1) 108 (3.2) 1 0.9922 118 (0.2) 106 (1.0) 112 (2.2) 111 (4.7) 
Trenbolone (2.27) 1 0.9958b 104 (0.2) 74 (0.6) 81 (0.5) 98 (7.8) 1 0.9922 107 (0.1) 105 (1.0) 105 (4.4) 105 (4.8) 
Metoprolol (1.88) 0.25 0.9940 102 (0.1) 84 (0.6) 102 (1.9) 88 (2.3) 0.25 0.9982 107 (0.1) 107 (0.4) 112 (3.1) 109 (4.6) 
Stanozolol (4.42) 0.1 0.9997b 94 (0.1) 81 (0.5) 87 (1.0) 105 (2.7) 5 0.9843 - 95 (0.4) 102 (3.2) 93 (4.4) 
Clenbuterol (2.61) 0.1 0.9906 102 (0.1) 86 (1.0) 106 (1.7) 95 (1.6) 1 0.9968 79 (1.3) 123 (1.5) 105 (2.9) 118 (5.7) 
Bisoprolol (1.89) 0.1 0.9953 93 (0.1) 82 (1.1) 103 (2.2) 86 (3.5) 0.5 0.9951 79 (1.0) 116 (0.7) 118 (2.7) 112 (5.7) 
GW501516 (6.46) 0.1 0.9963 96 (0.4) 80 (1.8) 80 (4.9) 96 (3.9) 5 0.9940 - 98 (0.5) 98 (3.2) 103 (1.7) 
Propranolol (3.48) 0.1 0.9913 91 (0.1) 74 (2.0) 93 (1.7) 86 (3.1) 5 0.9952 - 110 (0.9) 101 (3.4) 112 (2.1) 
Toremifene (6.56) 1 0.9959 105 (0.2) 75 (1.3) 72 (4.8) 96 (6.5) 5 0.9976 - 85 (2.0) 101 (3.4) 118 (5.3) 
Regression coefficients were calculated using LOQ values and 100 ng mL-1 as the lowest and highest calibration points, respectively.  
alog P values were taken from Chemspider150 




Table 3.5. Enrichment factors calculated in the different matrices evaluated. 
Compound 
Enrichment factors (Cextract/Csample) 
Urine (RSD, %) Plasma (RSD, %) Blood (RSD, %) 
Morphine 0.56 (6) 0.52 (6) 0.62 (4) 
Salbutamol 0.65 (2) 0.21 (6) 0.33 (1) 
Nikethamide 1.03 (3) 0.80 (5) 0.90 (9) 
Codeine 0.90 (7) 0.71 (7) 0.85 (3) 
Benzoylecgonine 0.59 (7) 0.51 (6) 0.42 (7) 
Amphetamine 0.89 (9) 0.39 (7) 0.61 (1) 
Methamphetamine 1.10 (9) 0.60 (8) 0.73 (3) 
Strychnine 1.10 (5) 0.28 (12) 0.53 (4) 
Exemestane 1.41 (3) 0.22 (9) 0.27 (20) 
Trenbolone 1.34 (4) 0.32 (10) 0.47 (11) 
Metoprolol 1.20 (4) 0.69 (13) 0.96 (4) 
Stanozolol 1.59 (6) 0.02 (12) 0.06 (12) 
Clenbuterol 1.33 (8) 0.52 (10) 0.86 (5) 
Bisoprolol 1.12 (7) 0.75 (11) 0.97 (6) 
GW501516 1.44 (7) 0.01 (16) 0.02 (10) 
Propranolol 1.42 (6) 0.29 (7) 0.20 (10) 
Toremifene 1.22 (12) 0.01 (14) 0.04 (12) 
 
in plasma or in whole blood (Table 3.5). In regards to urine results, it is also worth emphasizing 
that the LOQs determined complied with or were lower than the minimum required performance 
levels (MRPL) stipulated by WADA. For instance, the LOQ value determined for clenbuterol, the 
compound with the lowest MRPL (0.2 ng mL-1), not only fulfills WADA requirements but also 
allows for a quantification that is two times lower than the drug MRPL. Indeed, the observed 
differences between the LOQ values presented in this work and those already reported by BoyacI 
et al.80 and Reyes- Garcés et al.162 can be attributed to a reduction in the desorption solvent volume 
(600 μL instead of 1200 μL), a distinct SPME coating volume (coated stainless steel blades vs. 
coated rounded devices) and, in the case of urine, the use of HLB particles instead of C18. Figure 
3.4 shows representative chromatograms corresponding to extracts obtained from the different 





Figure 3.4. Representative SRM chromatograms corresponding to extracts obtained from urine, 
plasma and whole blood spiked at LOQ levels. Salbutamol (A), methamphethamine (B), stanozolol 












3.3.2.2.Whole blood analysis 
Due to the high content of proteins and the presence of red blood cells, using whole blood as a 
matrix is more challenging and subsequently less common than analyzing serum and plasma. 
Based on the already discussed results corresponding to urine and plasma, the suitability of SPME-
HLB-PBT devices for whole blood analysis was also investigated.  
A previous study published by Mirnaghi and Pawliszyn in 2012 reported irreversible attachment 
of red blood cells to C18-PAN thin-film SPME devices when they undergo direct immersion in 
whole blood using the Concept 96 workstation system.171 As a feasible solution to this problem, 
and looking toward coating reusability in an automated fashion, a modified extraction phase 
consisting of an external layer of PAN over a C18-PAN coating was proposed.171 This approach 
considerably improved the coating compatibility with blood and enabled its reusability for multiple 
extractions in such a complex matrix. However, it is worth emphasizing that the presence of the 
extra PAN layer leads to a decrease in extraction kinetics, and therefore affects method sensitivity, 
especially at pre-equilibrium conditions. Figure 3.5 shows a comparison of the absolute recoveries 
obtained for six of the model compounds, using SPME-HLB-PBT devices prepared on flat support 
with and without a PAN over-coating (applied by dipping). As can be seen, a decrease of more 
than 70% for some of the analytes was found due to the over-coating PAN layer. Given that in this 
case, potential application of the proposed devices as single use samplers is being considered, a 
different approach to test the rounded PBT coated pieces in whole blood analysis was taken. 
The typical SPME workflow was modified by introducing three additional washing steps, as 
described in Table 3.2. A washing step was implemented after preconditioning in order to remove 
any excess organic solvent remaining on the coating. This prevented possible protein precipitation 
or cell disruption from occurring on the extraction phase when the wet SPME coating got in contact 
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with the whole blood matrix. Three wash steps of 5 s were also conducted after direct blood 
extraction (each wash step was performed in a new vial with clean water). It is worth highlighting 
that an evaluation of four different washing approaches (10 s static, 10 s with vortex agitation, two 
washing steps of 5 s with vortex agitation and three washing steps of 5 s with vortex agitation) 
showed that three consecutive washing steps did not cause any significant losses for any of the  
 
Figure 3.5. Comparison of absolute recoveries found using HLB thin-films with and without PAN 
over-coating applied by dipping. Extractions were performed from PBS spiked at 70 ng mL-1. The 
extraction time was 60 min.  
 
studied compounds for SPME devices coated with HLB particles (see Figure 3.6). Indeed, the 
washing step should be carefully optimized according to the SPME coating selected and the 
analytes of interest. For example, in the case of the HLB-PAN, it is expected to observe high 
affinity toward compounds bearing on their structures lone electron pairs and able to display π-π 

























Without PAN over-coating With PAN over-coating
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HLB-PAN coating when used for the extraction of basic (e.g. clenbuterol, bisoprolol, and 
propranolol) and steroidal analytes (e.g. 17-α-trenbolone and stanozolol) from PBS are in 
agreement with other reports where the properties of HLB as SPE sorbent were investigated.174,175 
It is also worth to emphasize that, among the model compounds, salbutamol presented the lowest 
absolute recovery. Albeit for this compound a lower distribution coefficient is predictable due to 
its high hydrophilicity and degree of ionization, reproducible recoveries, even after several 
washing steps, were still attained. 
 
 
Figure 3.6. Evaluation of the effect of four different washing step approaches (10 s static, 10 s 
with vortex, two 5 s steps with vortex and three 5 s steps with vortex) on the final amount desorbed 
from rounded SPME-HLB-PBT devices (n = 4). Extractions were performed from PBS spiked at 




































































































































































10 s, static 10 s, vortex twice 5 s, vortex three times 5 s, vortex
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 ng mL-1 
R2 









Morphine (0.89) 0.1 0.9984 107 (0.1) 102 (1.0) 99 (1.4) 108 (6.0) 
Salbutamol (0.64) 0.1 0.9992 102 (0.1) 100 (0.3) 95 (0.7) 105 (5.0) 
Nikethamide (0.33) 0.5 0.9993 110 (0.1) 101 (1.3) 91 (1.2) 106 (2.3) 
Codeine (1.19) 0.1 0.9992 101 (0.1) 98 (0.3) 95 (0.5) 105 (5.5) 
Benzoylecgonine (2.71) 0.5 0.9992 122 (0.2) 109 (2.0) 102 (1.7) 117 (10.6) 
Amphetamine (1.76) 1 0.9994 86 (0.1) 101 (0.7) 94 (1.9) 106 (4.6) 
Methamphetamine (2.07) 1 0.9987 83 (0.1) 104 (1.1) 95 (1.6) 108 (2.9) 
Strychnine (1.93) 5 0.9980 - 103 (0.3) 97 (1.0) 103 (5.4) 
Exemestane (3.11) 1 0.9988 87 (0.2) 94 (0.8) 95 (0.1) 104 (5.6) 
Trenbolone (2.27) 1 0.9994 88 (0.1) 94 (0.5) 90 (0.9) 100 (6.8) 
Metoprolol (1.88) 0.25 0.9970 97 (0.1) 99 (0.3) 94 (1.2) 100 (6.0) 
Stanozolol (4.42) 5 0.9944 - 105 (2.2) 99 (3.5) 110 (5.4) 
Clenbuterol (2.61) 1 0.9982 80 (0.1) 102 (0.3) 95 (0.8) 102 (5.7) 
Bisoprolol (1.89) 0.25 0.9964 94 (0.1) 98 (0.5) 92 (0.5) 99 (6.4) 
GW501516 (6.46) 5 0.9945 - 95 (0.5) 91 (2.6) 98 (5.2) 
Propranolol (3.48) 5 0.9958 - 106 (0.9) 94 (0.4) 102 (7.5) 
Toremifene (6.56) 5 0.9956 - 102 (1.8) 88 (3.1) 107 (10.0) 
Regression coefficients were calculated using the LOQ value and 100 ng mL-1 as the lowest and 
highest calibration points, respectively. 
a log P values were taken from Chemspider150 
 
By following this modified SPME procedure, analytical figures of merit in whole blood were 
investigated. As can be seen in Table 3.6, satisfactory results in terms of linearity, LOQ, accuracy, 
and precision were obtained for all prohibited drugs under analysis. These findings also reflected 
the absence of irreversible fouling which, as already reported by several authors, can affect the 
kinetics of extraction with SPME.176–178 SEM images and microscope pictures of the HLB coating 
after exposure to blood for 90 min (Figure 3.7) confirmed that irreversible protein attachment on 
the coating surface did not take place. In this regard, it is important to note that the feasibility of 
using the proposed devices for direct immersion in whole blood without any PAN over-coating 
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layer may be related to the agitation conditions, the composition of the slurry employed to prepare 
the devices (lower SPE particles/PAN solution ratio compared to previous reports88), as well as 














Figure 3.7. Microscope picture and SEM images (30x magnification) taken from SPME-HLB-
PBT devices after being exposed for 90 min to whole blood.  
 
support. In point of fact, shear stress imparted by blood flow conditions has been reported as a 
critical factor in determining whether a device is blood compatible.179–182 The vigorous agitation 
provided by the multi-tube vortex system, together with the rounded shape and the specific 
dimensions of the coated devices (2.0 mm diameter), might have led to different shear conditions 
from those normally encountered when using the Concept 96 under its typical operational 
88 
 
configuration. Another aspect that should be also taken into account is that the evaluation of plastic 
devices was carried out in vials. Whole blood, when exposed to an open environment for a 
substantial period of time, as it occurs when using the Concept 96 system, is more prone to undergo 
alterations compared to blood that remains capped in a vial during the extraction process.181 For 
this reason, additional considerations should be taken into account when expecting an antifouling 
SPME extraction phase at such conditions (e.g. using SPME coatings with an extra layer of PAN). 
Overall, the results demonstrated high blood compatibility for both the coating and support 
employed at the selected experimental condition for the proposed devices. 
The presence of an absolute matrix effect after extracting from whole blood was assessed in the 
same manner reported for urine and plasma (Table 3.7). As presented in Table 3.7, no significant 
ion suppression/enhancement was found for any of the evaluated compounds at the selected 
experimental conditions. Indeed, using vortex stirring for the washing steps provided very 
effective cleaning/removal of possible interferences due to the strong agitation provided by the 
vortex. As a second approach to verify the performance of the plastic SPME devices in terms of 
analytical specificity at the tested conditions, transition ratios were also calculated for all the 
evaluated biofluids. In quantitative analysis using mass spectrometry, the ratio between qualifier 
and quantifier transition signals should be the same for both the standards and biological 
samples.183 Results presented in Table 3.8 evidenced an overall satisfactory performance of the 
proposed methodology for the majority of the model compounds. Only trenbolone extracted from 
blood showed a significant deviation from the ratio calculated in standard; however, this may be 









Blank blood extract 
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counts RSD, % 
Average 
area counts RSD, % 
Morphine + 790613 6.8 746645 6.5 106 
Salbutamol + 1752803 6.4 1683275 7.4 104 
Nikethamide + 1770978 9.4 1698455 12.0 104 
Codeine + 901379 6.6 865793 6.5 104 
Benzoylecgonine + 2123832 5.5 2011989 5.7 106 
Amphetamine + 613793 7.8 597718 9.7 103 
Methamphetamine + 1472182 7.4 1403228 8.4 105 
Strychnine + 982709 4.9 892247 5.0 110 
Exemestane + 294528 3.8 284409 4.6 104 
Trenbolone + 294309 6.9 290659 7.0 101 
Metoprolol + 810327 7.8 807978 8.2 100 
Stanozolol + 2112271 4.9 2073968 5.3 102 
Clenbuterol + 2884970 6.2 2804007 7.6 103 
Bisoprolol + 4809840 6.2 4617177 6.8 104 
GW501516 + 13394571 5.0 12500394 4.8 107 
Propranolol + 3172468 6.0 3189958 7.6 99 
Toremifene + 3873108 6.6 3851666 3.3 101 
 
Table 3.8.  Transition ratios calculated from standards and from the tested matrices. Values were 
calculated by dividing the qualifier transition signal by the quantifier transition.  Concentrations 
of up to 3 times LOQ values were considered for this calculation. 
Compound 
Transition ratios Qual/Quant Deviation from standard, % 
Standard Urine Plasma Blood Urine Plasma Blood 
Morphine 0.71 0.74 0.80 0.69 5 14 2 
Salbutamol 0.24 0.24 0.29 0.29 2 22 21 
Nikethamide 0.26 0.26 0.22 0.26 1 13 1 
Codeine 0.82 0.89 0.76 0.87 8 6 7 
Benzoylecgonine 0.31 0.29 0.30 0.29 7 4 8 
Amphetamine 0.24 0.26 0.20 0.25 7 19 3 
Methamphetamine 0.26 0.20 0.24 0.24 25 10 10 
Strychnine 0.68 0.64 0.58 0.71 6 15 5 
Exemestane 0.72 0.68 0.82 0.75 4 14 5 
Trenbolone 0.95 0.90 0.93 1.73 5 2 83 
Metoprolol 0.66 0.74 0.71 0.78 13 9 19 
Stanozolol 0.45 0.35 0.46 0.49 21 3 11 
Clenbuterol 0.44 0.34 0.42 0.42 22 4 4 
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Bisoprolol 0.16 0.14 0.16 0.17 16 1 7 
GW501516 0.26 0.25 0.26 0.26 4 1 2 
Propranolol 0.92 0.92 0.88 0.93 0 5 0 
Toremifene 0.10 0.10 0.09 0.09 1 12 9 
 
3.3.3. Assessment of HLB-PAN coating wettability 
 
Figure 3.8. Water contact angles for HLB-PAN, C18-PAN and only-PAN coatings. Images were 
acquired every 2 s over a 10 min period. 
Surface wettability has been traditionally conceived as an essential parameter in the design of 
materials with efficient resistance to protein fouling.184,185 However, a direct relationship between 
low water contact angles (increasing wettability) and negligible protein adsorption or material 
biocompatibility has not been found in all the studied cases.179,185–187 Despite this, determining the 
degree of wettability of PAN-based SPME coatings may provide important information 
considering the aqueous nature of biofluids. Indeed, easily wettable extraction phases are expected 
to facilitate the sample-coating interaction during the extraction process. Figure 3.8 shows the 
water contact angle variation over time found for HLB-PAN, C18-PAN and only-PAN coatings. 
Prior to the contact angle measurements, the HLB-PAN and C18-PAN surfaces were conditioned 
in a 1:1 methanol:water solution for 10 min, wiped with Kimwipes, and allowed to dry for 
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tested surfaces, HLB particles imparted a high degree of wettability to the coating. On the other 
hand, C18 conferred significant hydrophobicity to the extraction phase, yielding estimated water 
contact angles above 100˚ over the entire measurement time. In relation to SPME extraction 
phases, these results suggest that using HLB combined with PAN, or even using other wettable 
materials, may provide improved performance compared to other sorbents, such as C18, when 
dealing with biological samples. As such, the development of SPME devices intended for spot 
sampling or even for in vivo sampling, where convection is certainly restricted, may need to 
include the determination of coating wettability as an important criterion.  
3.3.4. Evaluation of the robustness and reusability of SPME thin-film devices prepared on 
plastic substrate using high-throughput configuration. 
After verifying the suitability of PBT as a substrate for SPME devices, the robustness of the PAN-
based coatings prepared on the new support was evaluated through multiple extractions from 
plasma and whole blood. Although there are cases where single-use samplers are certainly 
required, other analytical applications might be more flexible, and reusable SPME devices are a 
most convenient and cost-effective option. To validate the suitability of the new device for multiple 
use applications, SPME-HLB-PBT samplers made on flat support (with and without over-coating) 
were arranged in a Concept 96-compatible fashion, as shown in Figure 3.1D. Given that these 
devices were prepared by coating a PBT surface that was subsequently cut into smaller pieces, an 
initial assessment of inter-thin-film reproducibility was carried out. As can be seen in Table 3.9, 
RSD values below 7 and 3.5% (n=6) were found for SPME devices with and without PAN over-
coating, respectively. In addition to carrying out an assessment of inter-device reproducibility, 
SPME-HLB-PBT samplers were physically inspected by taking microscope pictures of the 





Figure 3.9. Microscope pictures of PAN-HLB thin-films obtained by cutting pieces of 2.3 mm 
width from a coated flat PBT rectangular piece (8 x 10 cm).  
 
images of the lateral view of the devices confirm that good attachment was achieved between the 
PAN-based coatings and the PBT surface. It is worth highlighting that even after undergoing a 
cutting process, the SPME coating remained firmly adhered to the polymeric material. Regarding 
reusability, no statistical differences were observed between recovery values obtained in the first 
and twentieth trials performed in plasma (Figure 3.10). In the case of whole blood, propranolol 
and stanozolol showed a slightly lower recovery during the first extraction when compared to all 
subsequent experiments. This observed outcome may be due to the extra layer of PAN applied to 
the HLB coating which, in addition to slowing down the extraction kinetics, might require that the 
overcoated HLB coating receive more extensive conditioning in comparison to coatings without 
this over-coating; however, this effect was observed only for the two least polar drugs tested. 
Overall, the obtained results suggest that using PBT as a substrate may provide the same coating 
robustness and stability obtained with the use of etched stainless steel.  
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Table 3.9.  Average absolute recoveries obtained when using HLB thin-films prepared on PBT 
support to extract from PBS spiked at 70 ng mL-1 (n=6 thin-films). 
Compound 
No overcoated Overcoated 
Abs. recovery, % RSD, % Abs. recovery, % RSD, % 
Salbutamol 38.7 5.2 5.0 7.1 
Codeine 83.2 4.4 8.4 5.1 
Stanozolol 75.5 1.5 45.9 6.6 
Clenbuterol 91.7 2.9 12.1 2.3 
Bisoprolol 93.9 1.2 10.0 2.9 


















Figure 3.10. Evaluation of the stability and robustness of the HLB-PAN coating applied on PBT 
support. Consecutive extractions were performed from plasma (A) and whole blood (B) spiked at 
70 ng mL-1 and mixed with 1 M phosphate buffer in a 9:1 ratio (sample:buffer) (n=6). Extractions 































































In this work, the suitability of PBT as a support to manufacture SPME devices that could be 
potentially employed as disposable samplers was demonstrated. Robust PAN-HLB coatings, free 
of background interferences and able to stand exposure to organic solvents for long periods of 
time, were attained by following a modified coating preparation procedure. Since no etching with 
hydrochloric acid was required, a greener manufacturing process with a reduced production of 
chemical waste was possible. Rewarding figures of merit were found when these SPME samplers 
were used for quantitative analysis of multiple doping substances in urine, plasma, and whole 
blood. LOQ values determined in urine met or were below the MRPL requirements set by WADA. 
In the case of plasma and whole blood, LOQ levels were in the low ng mL-1 which is within the 
range of expected concentrations in such matrices.124 Absence of an absolute matrix effect in 
extracts obtained from the three tested biofluids proved that the SPME-HLB-PBT devices 
provided satisfactory sample clean-up. Indeed, whole blood analysis was facilitated by utilizing 
rounded SPME-HLB-PBT devices together with the implementation of multiple washing steps 
and vortex agitation conditions. HLB-PAN was demonstrated to be a more easily wettable coating 
than C18-PAN, which may be an important criterion to consider when developing disposable 
devices for spot sampling. The high stability of the biocompatible coating applied on PBT 
permitted the cutting of smaller portions from an already large coated piece, which may be 
convenient in cases where tailor-made sizes are needed. Although these devices were developed 
considering the concept of single-use, they can be re-used in applications where carryover at trace 
levels does not represent a serious concern. Overall, the introduction of alternative materials, such 
as polymeric substrates, may represent an important opportunity for new advances in the 
commercialization and acceptance of SPME in the bioanalytical field. Besides traditional fiber and 
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flat thin-film configurations, the development of other SPME geometries may be facilitated by 
integrating new materials as supports, and by taking advantage of technologies such as 3-D 



















Chapter 4: The effect of hematocrit on solid phase microextraction 
 
4.1.Preamble and introduction 
4.1.1. Preamble 
The results presented in this chapter have not yet been published in any journal. Nathaly Reyes-
Garcés designed the experiments, conducted all the experimental work, processed the data, and 
wrote the corresponding discussion herein presented. Md. Nazmul Alam also participated in the 
data interpretation and discussion. 
4.1.2. Introduction 
Many bioanalytical studies and clinical tests rely on the quantitative determination of small 
molecules in whole blood samples. Given the complexity of this type of matrix, developing simple 
analytical workflows that can provide satisfactory results while remaining compliant with health 
regulations can be a challenging undertaking. Whole blood is comprised of two main components: 
plasma and blood cells. Blood plasma is an aqueous solution of solubilized proteins, low and high 
molecular weight components, metabolites, mineral salts, and ions. Plasma has a relatively simpler 
composition than whole blood, which makes it a commonly-used matrix for many routine 
bioanalytical determinations, the most representative case of which being the therapeutic 
monitoring of multiple drugs. The second main component of whole blood is the cells, which can 
be classified into three main types: red blood cells (erythrocytes, ~96%), white blood cells, and 
platelets.188 Hematocrit (Hct) is a term that refers to the fraction of blood volume made up of red 
blood cells, and its typical values are within the ranges of 40 – 50% for men, and 36 – 44% for 
women.189 However, Hct levels can fall outside of these ranges in particular cases, such as 
individuals living at high altitudes, newborns, or anemic people.14 Although plasma and serum are 
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the specimens of choice for several standardized analytical procedures, the direct analysis of whole 
blood is required in certain instances (e.g. the determination of immunosuppressive drugs). Hence, 
understanding and evaluating Hct’s effect on whole blood analysis should always be a matter of 
consideration.  
Numerous sample preparation methodologies for analyzing small compounds (<1500 Da) in whole 
blood using liquid chromatography coupled to mass spectrometry have been reported in the 
literature.11,73,190–195 Among such approaches, liquid-liquid extraction (LLE) and protein 
precipitation (PP)—which, in some cases is followed by cleaning steps involving online or offline 
solid-phase extraction—are perhaps the most commonly used strategies. For substances that 
display a high affinity for red blood cells, the use of additives that induce hemolysis and the release 
of compounds from erythrocyte membranes (e.g. zinc sulfate) have been reported as effective 
means of normalizing the sample matrix composition.196–198 Nonetheless, the use of appropriate 
internal standards is always recommended in order to ensure satisfactory method accuracy and 
precision. Due to the highly-invasive nature of traditional blood collection, alternative blood micro 
sampling strategies have been garnering much interest. For instance, dried blood spots (DBSS), 
which is a well-established sampling and whole-blood-analysis methodology, has been broadly 
reported in several applications due to its low invasiveness.12,123,134,193,195,199 In DBSS, a small drop 
of whole blood is placed on filter paper, allowed to dry, and subsequently analyzed by desorbing 
fixed-diameter discs punched out from the dried spots. Prior studies have found that Hct’s effect 
on DBSS analysis is mostly associated with the variable spreading pattern that blood samples 
exhibit when spotted onto DBSS cards;14,189,193 the viscosity of blood samples is directly related to 
their Hct values, and samples with higher Hct values produce smaller spot radii. Other critical 
factors in determining the degree of bias in DBSS measurements are the analyte characteristics 
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and the paper type. The best strategy for overcoming Hct’s impact in relation to variable blood 
spreading is to analyze whole spots of volumetrically-applied blood.14,16,193 The incorporation of 
appropriate internal standards via spraying prior to DBSS extraction has proven to be a feasible 
way of mitigating the variations related to matrix effects or recoveries.200,201 Another absorptive-
based approach recently introduced to overcome the Hct issues associated with DBSS is 
volumetric absorptive microsampling (VAMS),194 which uses an absorptive polymeric material 
immobilized on a pipette tip to collect fixed volumes of blood via wicking. Several studies have 
demonstrated that VAMS devices are able to collect reproducible blood volumes independent of 
their Hct levels. 194,202,203 However, some issues with VAMS have also been reported, particularly 
in relation to bias in the determination of blood concentrations, low recoveries at high Hct levels, 
and interoperator variability. 202,203 Further evaluation of VAMS is still required as it is still a 
relatively new microsampling approach.   
Solid phase microextraction (SPME) is a non-exhaustive extraction technique that uses a matrix-
compatible coating structure, which enables the analysis of complex samples, such as plasma and 
even whole blood. In fact, the literature contains several prior studies that document SPME’s 
usefulness as a sample preparation approach for such matrices prior to LC-MS or direct MS 
instrumental analysis.73,162,166,204–206 Interestingly, SPME’s applicability is not only limited to ex 
vivo determinations; indeed, several studies have documented its suitability for in vivo blood 
analysis in different animal models.103,104,168,207–211 In regards to the principle of SPME, it is worth 
mentioning that the extraction and pre-concentration of analytes occurs by directly exposing a 
defined amount of a biocompatible extraction phase to the sample matrix for a given period of 
time. The amount of analyte collected during the extraction process is proportional to the analyte’s 
concentration and depends on the analyte’s affinity for the biocompatible coating and for the 
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sample matrix at the extraction conditions. Considering that the SPME matrix compatible coating 
is highly selective for small compounds and that a washing step is carried out after the extraction, 
the presence of proteins, salts, and other interferences that could affect the instrumental analysis is 
easily avoided. In regards to the extraction mechanism, it is worth emphasizing that, in SPME, the 
uptake of analytes from the sample media to the coating material happens via free analyte 
concentration.212 Therefore, if we consider a complex system, such as blood, where multiple co-
existing phases can display an affinity for a given target compound, the amount of analyte extracted 
by the SPME probe will be correlated to the free concentration of analyte at the end of the 
extraction.  As a matter of fact, parameters such as lipophilicity, charge, molecular weight, 
diffusion coefficient, and structural moieties govern the distribution of any compound into 
different blood compartments.213 Likewise, such parameters strongly determine the affinity that a 
target analyte exhibits for a particular SPME coating. In addition to the analyte’s physicochemical 
characteristics, there are other factors that play an important role in the microextraction process; 
for example, extraction time, extraction phase characteristics, temperature, and convection 
conditions all determine the final recovery provided by an SPME device. Given that red blood 
cells comprise a significant portion of a whole blood sample, this work aims to investigate how 
varying Hct levels affect the amount of analyte extracted by SPME devices. For this purpose, ten 
drugs with different polarities and physicochemical properties were chosen as model compounds, 
and blood samples with three different Hct levels (20%, 45%, and 70 %) were selected as sample 
matrices. The effects of the coating type, sample convection, and extraction time were also taken 
into consideration.   
4.2.Experimental section 
4.2.1. Materials and supplies 
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Methamphetamine, stanozolol, codeine, codeine-d3, (±)11-nor-9-carboxy-Δ9-THC (THCCOOH), 
(±)11-nor-9-carboxy-Δ9-THC-d3 (THCCOOH-d3), oxycodone-d3, testosterone-d3, cannabidiol-d3 
and methadone-d3 standards were obtained from Cerilliant Corporation (Round Rock, TX, USA). 
Nikethamide, propranolol, metoprolol, clenbuterol, exemestane, and salbutamol were purchased 
from Millipore Sigma (Oakville, ON, Canada), and salbutamol-d3 was purchased from CDN 
Isotopes (Pointe Claire, Quebec, Canada). Sodium chloride, potassium chloride, potassium 
phosphate monobasic, sodium phosphate dibasic, and formic acid were also purchased from 
Millipore Sigma (Oakville, ON, Canada). LC-MS grade acetonitrile, methanol, and water were 
obtained from Fisher Scientific. 
Biocompatible SPME fibres (MM-F) coated with a mixed-mode extraction phase (C18 and 
benzene sulfonic acid functionalities, 1.5 cm coating length, 45 μm coating thickness, and a total 
diameter of 300 µm) were generously provided by Millipore Sigma (Bellefonte, PA, USA). SPME 
devices prepared on a plastic support with a hydrophilic lipophilic balanced (HLB) extraction 
phase (HLB-D) (2 cm coating length, 150 µm coating thickness, and 2 mm total diameter) were 
made as described in 204.  
Blood samples were purchased from Bioreclamation IVT (Westbury, New York, USA). These 
samples were from healthy donors (with K2-EDTA as anticoagulant), and had Hct levels that had 
been adjusted to 20%, 45%, and 70%.  
4.2.2. Working solutions 
A stock methanolic solution (20 µg mL-1) containing all analytes was prepared and further dilution 
was done as required. A stock solution (8 µg mL-1) containing different deuterated compounds as 
internal standards was prepared in methanol. 
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4.2.3. SPME procedure 
Prior to the experiments, the blood with adjusted Hct content was spiked with stock methanolic 
solutions containing all the analytes, while ensuring that the organic solvent content was kept 
below 1% in all cases. For the construction of the calibration curves, the spiked blood was pre-
incubated for at least 1 hour at constant agitation; for the determination of the extraction time 
profiles, blood incubation was allowed overnight. Before the extractions, MM-F and HLB-D were 
first pre-conditioned in a 1:1 (v/v) methanol:water solution for 30 min using vortex agitation at 
1500 (revolutions per minute) rpm. Subsequently, all devices were rinsed in ultrapure water for 10 
s to remove any remaining organic solvent from the coating surface. In order to guarantee a stable 
sample pH over the entire extraction process, 1080 µL of spiked blood aliquots were mixed with 
120 µL of 1 M phosphate buffer adjusted at a pH of 7. Furthermore, 15 µL of internal standard 
solution were added to the samples used for the calibration curve experiments. The extractions 
were then carried out by immersing both types of SPME devices into the sample matrix for a pre-
set period of time at constant agitation conditions. To construct the calibration curves, the 
extraction time was set at 90 min, the calibration range was set between 5 and 100 ng mL-1 for all 
target analytes, and four calibration curve replicates were constructed on two consecutive days. 
Time points of 15, 30, 60, 90, 120 and 180 min were selected for the extraction time profiles, and 
all the extractions were conducted in triplicates. The agitation parameters were set as follows: 
vortex agitation was set at 1500 rpm for the HLB-D, and orbital shaking agitation was set at 400 
rpm for the MM-F. Once the extraction step was completed, three consecutive rinsing steps in 
water (5 s each) were performed following the procedure reported by Reyes-Garcés et al.204 After 
the rinsing step, it was verified that no blood cells remained attached to the matrix-compatible 
coating. Finally, desorption of the devices was carried out for 20 min at 1500 rpm in 300 and 600 
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µL of desorption solution (4:1 methanol:acetonitrile) for MM-F and HLB-D, respectively. To 
determine the amount of analyte extracted by the SPME devices in each experiment, an 
instrumental calibration curve (from 0.1 to 150 ng mL-1) was prepared using the same solvent 
composition that was used for the desorption solution. 
4.2.4. LC-MS/MS conditions and data processing 
All the collected extracts and the instrumental calibration curve were run using LC-MS/MS 
conditions already reported.204 Briefly, the LC-MS/MS system was comprised of an Accela 
autosampler, an Accela pump, and a TSQ vantage triple quadrupole mass spectrometer with a 
heated electrospray ionization source operating in positive mode (Thermo Scientific, San Jose, 
USA). Chromatographic separation was attained using a Kinetex pentafluorophenyl core shell 
column (1.7 µm, 2.1 mm x 10 mm) that had been connected to a PFP security guard ultracartridge 
(Phenomenex, Torrance, CA, USA), and LC separation was achieved using a mobile phase system 
consisting of 0.1% formic acid (A), acetonitrile with 0.1% formic acid (B), and methanol with 
0.1% formic acid (C). The gradient elution conditions were set as follows: A, B, and C were held 
at 90%, 5%, and 5 %, respectively, for 0.5 min; B and C were then increased linearly to 50% over 
the course of 6.5 min; C was then increased to 75% and B was decreased to 25% over the course 
of 5 min and held for 3.5 min. Finally, the column was kept at the initial gradient composition for 
2 min. The column temperature was kept at 35 ˚C, the total run time was 17.5 min, and the column 
flow was set at 0.3 mL min-1. Samples were stored in the autosampler at 5 ˚C, and the injection 
volume was 10 µL. MS analysis was conducted using selective reaction monitoring (SRM) mode 
(Table 4.1), and the conditions of each compound were optimized by directly infusing the 
standards. The following transitions were selected for the deuterated compounds that were 
employed as internal standards: salbutamol-d3: 243.16 151.12; codeine-d3: 303.15 165.10; 
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oxycodone-d3: 319.12  259.15; methadone-d3: 313.21  105.10; testosterone-d3: 292.25  
97.14; and THCCOOH-d3: 348.16  302.28. Other parameters were set as follows: spray voltage 
= 1300 V; vaporizer temperature = 275˚C; sheath gas = 45 units; auxiliary gas = 30 units; and 
capillary temperature = 280˚C.  
4.2.5. Data analysis 
Xcalibur software (2.0.7 SP1) was employed for data acquisition and processing. For the purpose 
of this study, the slopes of the calibration curves constructed for each compound with different 
Hct levels were statistically compared. Statistical analysis was carried out using one-way ANOVA, 
one-tail t-test (equal and unequal variances), and relative standard deviations (RSDs). 
4.3.Results and discussion 
Table 4.1. Model compounds with their corresponding physicochemical properties and MS/MS 
detection parameters. Analytes are listed in order of hydrophobicity. 
Compound 
SRM transition 
Collision energy, S-lenses 
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64, 104  
MW: 299.36 












2.07 10 – 20  
Clenbuterol 
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15, 70  
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2.61 89 - 98215 
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3.48 > 90 
Stanozolol 









18, 90  
MW: 344.45 
6.36 92.0 ± 8.7153 
NA= not available 
In order to elucidate the effect that various Hct levels can have on SPME recovery rates, an 
analyte’s affinity for the main blood components (aqueous phase, proteins, and red blood cells) 
should be taken into consideration. For this reason, analytes with distinct physicochemical 
properties were selected for this work because they can be expected to display variable affinities 
for blood constituents (Table 4.1). In addition to using various model compounds, two 
experimental setups were employed: MM-F at 400 rpm and HLB-D at 1500 rpm. Although both 
types of SPME devices have been documented as being suitable and biocompatible for the analysis 
of whole blood,83,104,204 the mechanical attachment of macromolecules is usually observed in the 
case of MM-F under aggressive agitation conditions and long extraction times. Consequently, an 
orbital shaker operating at 400 rpm was chosen as the agitation setup for MM-F extractions. In the 
case of HLB-D, satisfactory results for whole blood analysis were already found when using vortex 
agitation at 1500 rpm; therefore, the same parameters were kept.204 Although high agitation speeds 
such as 1500 rpm are likely to induce lysis in red blood cells—and therefore changes in the Hct 
content during the extraction216—the main purpose of the evaluation was to assess the overall 




Table 4.2 presents the results corresponding to the calculated slopes for each of the model analytes 
in blood samples with different Hct levels as determined by the two different experimental setups. 
It is worth emphasizing that slope calculation was selected as parameter for investigating Hct effect 
because it is a well-accepted approach for assessing relative matrix effects.154 As shown in Table 
4.2, different outcomes were found depending on the analyte and the experimental conditions; 
therefore, in order to simplify things, we classified the observations into four different cases. In 
the first case (Case I), no statistically significant Hct effect was observed for any of the study 
conditions (MM-F at 400 rpm and HLB-D at 1500 rpm). Interestingly, salbutamol, nikethamide, 
codeine, and methamphetamine, which are all characterized as being relatively polar and/or for 
having low protein-binding affinities, were categorized in this first group. In order to explain the 
obtained results, parameters such as the polarity and affinity of an analyte for the matrix 
components and the extraction phases should be taken into account. With regards to an analyte’s 
polarity, it is important to emphasize that highly-polar compounds typically display shorter 
equilibration times due to their low affinities for SPME coatings (low K values). This is confirmed 
by Equation 1, where the equilibration time in SPME is expressed as a function of the boundary 
layer thickness (𝛿𝑠), the distribution constant (K), the thickness of the SPME coating (L), the 
diffusion coefficient of the analyte in the sample matrix (𝐷𝑠), and the coating capacity (Г𝑚𝑎𝑥).
217 
𝑡𝑒𝑞 ≈ 𝑡95% =
𝛿𝑠𝐾𝐿
𝐷𝑠Г𝑚𝑎𝑥
         (1) 
In this context, it is worth mentioning that, when extractions are performed at conditions close to 
equilibrium, the amount of analyte collected is mostly determined by the analyte’s distribution 
constant. Conversely, when the extraction process is interrupted at an earlier stage, the diffusion 
of the analytes in the sample matrix plays a more important role. Since 90 min was chosen as the    
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Table 4.2. Slopes of the calibration curves constructed using blood with different Hct levels in the range between 5 and 100 ng mL-1 
(no internal standard). 
Compound (case) 
Slopes (n=4)a (average ± standard deviation) 
MM-F, 400 rpm HLB-D, 1500 rpm 
20% Hct 45% Hct 70% Hct RSD % 
b 
F c 20% Hct 45% Hct 70% Hct RSD% b F c  
Salbutamol (I) 0.018 ± 0.003 0.016 ±0.006 0.017 ± 0.004 4.0 0.090  0.25 ± 0.02 0.24 ± 0.037 0.23 ± 0.02 3.0 0.230  
Nikethamide (I) 0.042 ± 0.004 0.044 ± 0.004 0.039 ± 0.004 6.6 0.017  0.71 ± 0.06 0.73 ± 0.110 0.75 ± 0.06 3.0 0.238  
Methamphetamine (I) 0.058 ± 0.005 0.053 ± 0.009 0.048 ± 0.003 9.5 2.865 0.55 ±0.04 0.54 ±0.071 0.54 ±0.04 1.0 0.022 
Codeine (I) 0.034 ± 0.002 0.030 ± 0.004 0.029 ± 0.002 8.0 3.090 0.69 ±0.06 0.69 ±0.051 0.69 ±0.07 0.1 3.41e-4 
Propranolol (II) 0.047 ± 0.002 0.036 ± 0.003 0.027 ± 0.003 26.0 61.138  0.56 ± 0.05 0.57 ± 0.057 0.58 ± 0.04 2.0 0.232  
Metroprolol (II) 0.077 ± 0.008 0.064 ± 0.008 0.053 ± 0.006 19.0 11.108 0.83 ±0.08 0.85 ±0.099 0.88 ±0.08 3.0 0.243 
Clenbuterol (II) 0.072 ±0.004 0.059 ±0.005 0.045 ±0.004 14.0 36.232 0.69 ±0.04 0.70 ±0.044 0.73 ±0.05 3.0 1.031  
Exemestane (III) 0.034 ±0.005 0.023 ±0.001 0.013 ±0.003 45.0 37.719 0.31 ±0.05 0.28 ±0.027 0.21 ±0.03 20.0 7.597 
THCCOOH (IV)d 0.010 ±0.002 0.011 ±0.001 0.012 ±0.001 9.6 1.370 0.026 ± 0.001 0.032 ±0.0062 0.036 ±0.002 16.2 8.851 
Stanozolol (IV) 0.040 ± 0.006 0.036 ±0.003 0.034 ±0.004 7.7 1.539 0.047 ±0.004 0.053 ±0.0060 0.066 ±0.007 18.0 11.865 
 
a Average slopes calculated from the equation y=mx+b, where y is the amount extracted in ng and x is the concentration spiked in blood. 
b inter-slope RSD estimated from the values obtained for each Hct level. 
c F crit = 4.256 (α=0.05), if F > F crit the null hypothesis that the three slopes are equal is rejected (one-way ANOVA). 




















Figure 4.1. Extraction time profiles for salbutamol (a and b), propranolol (c and d), exemestane (e 
and f), THCCOOH (g and h). Plots on the left side summarize results for MM-F at 400 rpm, and 


















































































































































































































extraction time for the Hct effect assessment, it was relevant for the interpretation of the results to 
determine at what point of the extraction process the comparison was being conducted. As shown 
in Figure 4.1A, a relatively polar compound like salbutamol was close to reaching equilibrium 
after 90 min of extraction using MM-F at 400 rpm. This means that variations in the analyte’s 
diffusivity due to differences in the matrix viscosity will not have an important effect on the 
analyte’s uptake. Moreover, as can be seen in the same plot, minimal differences were found in 
the profiles constructed at the three Hct levels. Considering salbutamol’s high polarity and low 
protein binding, variable levels of matrix constituents are not expected to greatly affect SPME 
recoveries as a result of decreasing the analyte’s free concentration. In the case of HLB-D, a 
slightly different situation was observed for the same compound. As can be seen in Figure 4.1B, 
although there is an overlap in the constructed time profiles for blood adjusted at different Hct 
levels, a plateau in the extracted amounts of salbutamol was not achieved, even after 180 min of 
extraction at high-speed agitation. These results can be explained based on HLB’s much higher 
affinity for polar analytes and the thicker HLB-D coatings that permit the extraction of much larger 
amounts of analyte. Under such experimental conditions, the stronger affinity that HLB-D displays 
for the target analytes—compared to the one exhibited by the matrix constituents—will contribute 
to lessening the differences that can occur in SPME recoveries due to variations in the matrix 
composition. It is also noteworthy that the convection parameters in the HLB-D experiments were 
significantly higher than those in the MM-F extractions. Faster agitation conditions allow for a 
decrease in the thickness of the boundary layer, which in turn accelerates the mass transfer process 
occurring from the sample matrix to the SPME coating. Given this principle, the combination of 
improved convection conditions and HLB-D’s strong extraction capacity will result in a reduced 
Hct effect in the extraction of analytes that do not show a specific affinity for erythrocytes. In the 
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case of compounds such as methamphetamine and codeine, which are less polar than salbutamol 
and nikethamide but still meet the conditions to be classified as Case I, it is noteworthy that the 
slopes of the calibrations curves constructed with MM-F showed higher RSD values (9.5% and 
8%) than those obtained with HLB-D (1% and 0.1%). In fact, when MM-F was used, the slopes 
for methamphetamine and codeine were statistically higher in blood adjusted at 20 % Hct than for 
blood adjusted at 70% Hct (methamphetamine (20% vs 70% Hct): one-sample t(6)=3.52, p-
value<0.01; codeine (20% vs 70% Hct): one-sample t(6)=4.42, p<0.01). Since these compounds 
are slightly hydrophobic, and considering the fact that codeine binds to the red blood cell plasma 
membrane, the presence of variable levels of matrix components is likely to alter the concentration 
of analytes available for SPME extractions.218 Interestingly, this effect becomes more pronounced 
when devices with weaker affinities and lower extraction capacities, such as MM-F, are employed 
for extraction. In light of the discussed results, it is clear that the affinity of target analytes for the 
coating and the matrix components has a highly-significant effect on the final SPME recoveries 
when analyzing blood with different Hct levels.  
In order to explain the experimental findings corresponding to Case II, the same rationale regarding 
various analytes’ affinities for coatings and for matrix constituents should be taken into 
consideration. As can be seen in Table 4.2, Case II analytes had different outcomes that were 
dependent on the SPME experimental parameters. On the one hand, a pronounced decrease in the 
slopes as a function of erythrocyte levels was observed in the experiments conducted with MM-F; 
on the other hand, the statistical comparison of the slopes showed no Hct effect for extractions 
carried out with HLB-D (propranolol: F(2,9)=0.232, p-value=0.80; metoprolol: F(2,9)=0.243, p-
value=0.79; clenbuterol: F(2,9)=1.031, p-value=0.40). The lack of observed differences when 
HLB was used can be attributed to the high convection conditions, as well as the fact that, as was 
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discussed in relation to Case I, HLB-D has a much higher affinity for the target analytes than MM-
F and matrix components. Moreover, since the Case II analytes are overall less polar than those in 
Case I, they can be expected to have a higher degree of interaction with matrix components (lower 
free concentrations) and larger K values, and therefore longer equilibration times (Equation 1). 
Figure 4.1C presents the extraction time profile constructed for propranolol using MM-F at 400 
rpm. As can be seen, the recoveries corresponding to the profile in 20% Hct blood are considerably 
higher than those obtained for the other two Hct levels. This outcome can be explained based on 
the fact that higher concentrations of matrix components—in this case, red blood cells—lead to 
lower concentrations of propranolol available for SPME extraction; thus, lower amounts of 
propranolol are collected at 70% Hct. Given that MM-F lacks sufficient extraction capability for 
inducing the release of bound analytes in order to further enhance the extraction recoveries, such 
experimental conditions tend to exhibit a significant Hct effect. Moreover, taking into account that 
the extraction process is still close to the linear regime at 90 min, it is possible that differences in 
the analyte’s diffusivity as a function of matrix viscosity could be partly responsible for variations 
in the uptake rate.219 Although equilibrium is far from being reached at 90 min in HLB-D (Figure 
4.1D), its high affinity for propranolol and the high convection conditions largely mitigate any 
effect that variable Hct levels can have on the final recoveries. Indeed, HLB’s high capacity for 
adsorption is able to deplete the analyte’s free concentration and induce the release of bound 
analytes back to their free forms, thereby increasing the total recovery. While possible changes in 
the matrix composition due to vigorous agitation216 should be considered when explaining the 
different recoveries obtained using the two experimental setups, the results that will be presented 
in the next case clearly indicate that red blood cells remain a significant compartment after 90 min 
of vortex agitation.  
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In the third case noted in this study (Case III), a similar Hct effect for both MM-F and HLB-D was 
found; that is, the amount of analyte extracted decreased in proportion to the blood erythrocyte 
levels. This particular behavior was observed for exemestane, a relatively non-polar steroidal 
compound (Figures 4.1E and 4.1F). As shown in Table 4.2, extractions conducted with both MM-
F and HLB-D produced smaller calibration curve slopes for 70% Hct blood than for the ones 
calculated at 20% (MM-F (20% vs 70% Hct): one-sample t(5)=7.25, p<0.01; HLB-D (20% vs 70% 
Hct): one-sample t(4)=3.37, p<0.05). In the case of MM-F, a more pronounced variation was 
observed in the slopes of the calibration curves constructed at the different Hct levels due to the 
previously described effects of lower coating affinity and slower agitation. To the best of our 
knowledge, there is no information in the literature regarding the partitioning of exemestane into 
red blood cells. In fact, stanozolol, another steroidal compound that was used as a model analyte 
in this study, did not exhibit the same Hct effect. In order to confirm that exemestane was being 
partitioned into the erythrocytes, the recoveries of extractions from 70% Hct blood and fully-
hemolyzed 70% Hct blood were compared using HLB-D. Complete blood hemolysis was achieved 
by storing pre-spiked 70% Hct blood for two hours at -80 °C (i.e. freeze and thaw). As shown in 
Figure 4.2, the recovery of exemestane increased by approximately 60% when extracted from 
hemolyzed blood; this confirms that this drug is being partitioned into the red blood cells. Based 
on these results, it is evident that exemestane’s affinity for the matrix is much higher than that of 
other model analytes categorized in the previous cases such that even pronounced differences are 
observed when HLB-D are used. Therefore, the use of an internal standard that displays the same 
affinity for red blood cells is crucial to ensuring the successful analysis of exemestane in blood 




Figure 4.2. Relative recoveries obtained after extracting from 70% Hct blood (hemolyzed vs. non-
hemolyzed). These experiments were conducted using HLB-D at 1500 rpm and an extraction time 
of 90 min. 
Similar to Case II, two different trends that were dependent on the SPME experimental conditions 
were observed in Case IV. Interestingly, the model compounds that were categorized within this 
last case are highly lipophilic and capable of significant protein binding. The slopes for these 
analytes were significantly higher at 70% Hct content when the extractions were carried out using 
HLB-D at 1500 rpm (THCCOOH (20% vs 70% Hct): one-sample t(5)=-8.58, p<0.01; stanozolol 
(20% vs 70% Hct): one-sample t(6)=-4.89, p<0.01) (Table 4.2). On the contrary, no statistical 
differences in the slopes were observed for the calibration curves constructed with MM-F 
(THCCOOH: F(2,8)=1.371, p-value=0.31; stanozolol: F(2,9)=1.539, p-value=0.27). One of the 
model compounds that exhibited this behavior was THCCOOH, the main secondary metabolite of 
THC. THCCOOH is a considerably non-polar analyte (logP 6.38) with 92.0 ± 8.7% protein 
binding.153 In addition, according to previous studies, THCCOOH’s distribution into red blood 
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significantly higher than its concentration in whole blood (blood-to-plasma ratio = 0.65).153 
Therefore, if we take into account that the volume of plasma is substantially less at 70% Hct than 
at 20% and 45% Hct, we can anticipate that a higher free analyte concentration will be available 
for SPME extractions at 70% Hct than at the other two Hct levels. This trend is reflected in the 
slopes for THCCOOH that were obtained with HLB-D (Table 4.2), and in its extraction time 
profile (Figure 4.1H). A similar behavior was also observed in the slopes for stanozolol that were 
constructed under the same conditions. Stanozolol is also known for being highly lipophilic (logP 
4.43), but, to the best of our knowledge, there have been no prior studies that have analyzed its 
distribution in different blood components. With respect to the results obtained using MM-F, we 
hypothesize that the concentration available for SPME extractions, the convection conditions, and 
the diffusion of analytes all played an important role in the final outcome. As can be seen in Figure 
4.1G, the THCCOOH uptake in MM-F is still in its linear regime at 90 min due to the slow 
convection and the compound’s high affinity for the coating. Hence, the analytes’ diffusion has a 
more significant effect on the extraction process than it does in cases where extractions are closer 
to equilibrium. In addition, it is important to consider that the flux of analyte from the sample 
matrix towards the coating (or analyte uptake) is proportional to the concentration gradient 
between the coating surface and the sample. Since a higher concentration of analyte is available 
for SPME extractions at 70% Hct, a higher uptake rate can be expected due to the concentration 
gradient. Based on this information, the estimated slopes for MM-F represent a combination of 
both the variation in analyte diffusion at different sample viscosities, and the changes in analyte 
uptake rates due to the concentrations available for SPME extractions at different Hct levels.  
As has been discussed so far, the Hct effect in SPME is completely dependent on the analytes of 
interest, and different outcomes can be obtained by changing the experimental conditions. 
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Parameters such as an analyte’s physicochemical properties (lipophilicity, molecular weight, 
diffusivity, etc), distribution constants, convection conditions, and, to some extent, sample 
viscosity are all important in determining how Hct differences affect SPME recoveries. 
Nevertheless, as in any other sample preparation approach, the use of internal standards represents 
the best way to account for any matrix variability. Table 4.3 presents the slopes after internal 
standard correction for those cases where F>Fcrit. Unfortunately, none of the available deuterated 
standards exhibited the same affinity for red blood cells shown by exemestane; as such, we could 
not provide the corrected data for that compound.  As can be seen in Table 4.3, the RSD values 
corresponding to the corrected slopes of those analytes that were significantly affected by variable 
red blood cell content were rewarding. Interestingly, compounds that were not necessarily 
deuterated analogues of the target analytes were able to provide adequate correction. Several 
studies in which SPME was used to analyze multiple substances in biofluids have described the 
use of a small set of internal standards as a practical and cost-effective strategy for correcting all 
of the target analytes.80,162,204 However, as has been noted above, the behavior of a given analyte 
in a specific matrix depends on several factors, and a proper assessment of an internal standard’s 
suitability at various Hct levels is required when dealing with real blood samples. Indeed, although 
a given internal standard can effectively correct for extraction variations in a single blood lot, this 
does not necessarily mean that the same internal standard will properly account for varying Hct 
content. 
Further investigation should be conducted into alternative strategies for overcoming the Hct effect 
observed in SPME. These strategies may focus on full red blood cell lysis via a combination of 
using additives (e.g. zinc sulfate or organic solvents) or freezing and the addition of appropriate 
internal standards, preferably deuterated analogues. In the case of in vivo blood sampling, special 
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attention should be given to the Hct effect when external calibration curves are used for 
quantitation, as no internal standard can be introduced into the samples. 




Slopes (n=4)a (average ± standard deviation) 
20 % Hct 45 % Hct 70 % Hct RSD 
% 
Fb 
Propranolol, MM-F  
(Methadone-d3) 
0.018 ±0.002 0.019 ±0.001 0.017 ±0.001 5.4 2.538 
Metroprolol, MM-F 
(Methadone-d3) 
0.0053 ±0.0002 0.0054 ±0.0002 0.0055 ± 0.0003 1.2 0.331 
Clenbuterol, MM-F 
(Methadone-d3) 
0.024 ±0.001 0.024 ±0.001 0.023 ±0.001 3.1 3.058 
THCCOOHb, HLB-D 
(THCCOOH-d3) 




0.41 ±0.05 0.42 ±0.02 0.46 ±0.03 5.9 1.653 
 
a Average slopes calculated from the equation y=mx+b, where y is the ratio area analyte/area 
internal standard and x is the concentration spiked in blood. 
b F crit = 4.256 (α=0.05), if F > F crit the null hypothesis that the three slopes are equal is rejected 
(one-way ANOVA). 
cThe lowest concentration level was 25 ng mL-1. 
 
4.4.Conclusions 
In this study, the effect of varying levels of Hct on SPME recoveries was investigated by using 
distinct model compounds and two different experimental setups. As expected, the observed effect 
was dependent on the analyte’s characteristics and the extraction parameters. For instance, variable 
Hct levels did not show any effect on the recovery of polar compounds with low protein affinities 
(e.g. salbutamol) under any of the study conditions. However, the extraction of more hydrophobic 
analytes, such propranolol, was strongly affected by the red blood cell content only when MM-F 
117 
 
was used at 400 rpm. Similarly, for compounds such as methamphetamine, codeine, propranolol, 
metoprolol and clenbuterol, the use of HLB-D with high convection conditions produced 
negligible differences in the SPME recoveries from blood adjusted at various Hct levels. This 
demonstrated that an analyte’s relative affinity for the matrix and the extraction phase is critical 
when matrices with varying compositions are analyzed. Other model analytes, such as exemestane 
and THCCOOH, exhibited a negative and positive correlation, respectively, between the SPME 
recoveries and the Hct content due to their opposite affinity for red blood cells. Lastly, despite 
variations in analyte recovery due to different erythrocyte contents, it was possible to correct for 
relative matrix effects by using appropriate internal standards. Overall, since each analyte can 
display different Hct effects, variable red blood cell levels within the final experimental conditions 












Chapter 5: Evaluation of solid phase microextraction as a sample preparation tool for 
untargeted analysis of brain tissue 
 
5.1.Preamble and introduction 
5.1.1. Preamble 
The results presented in this chapter have yet to be published in any journal. Nathaly Reyes-Garcés 
and Dr. Ezel Boyacı equally contributed to the experimental work, the data processing, and the 
discussion herein presented. The chromatographic conditions employed for the analysis of lipids 
were provided by the research group led by Prof. Dajana Vuckovic from Concordia University as 
part of a collaborative project funded by Brain Canada. The results presented in this chapter are 
part of an ongoing research project which commenced in August 2015. Nathaly Reyes-Garcés was 
the sole writer of the text presented here. 
5.1.2. Introduction 
Metabolomics platforms, particularly those based on mass spectrometry (MS), have been 
garnering a wealth of interest in the biomedical field in recent years.221–224 Both targeted and 
untargeted metabolomics approaches have opened up a range of possibilities towards the 
elucidation of biochemical pathways affected under particular conditions (e.g. disease and 
treatment). Indeed, the last decade has evidenced a growing number of published studies 
documenting the use of MS-based metabolomics to investigate a wide variety of medical 
conditions, such as different types of cancer, diabetes, neurological diseases, coronary heart 
disease, and cystic fibrosis, among others.225–230 As for the experimental workflows developed for 
such investigations, diverse analytical strategies applicable to different study cases have been 
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described and reviewed in detail.34–36,191,231,232 In this regard, parameters such as matrix specimen 
(type and availability), required metabolite coverage (targeted or untargeted approach), cohort 
size, and instrument availability play a critical role when choosing a set of experimental conditions 
for a particular metabolomics study. While biofluids (e.g. plasma, serum, blood, urine, saliva, 
exhale breath condensate, cerebrospinal fluid) are most commonly selected as matrices of choice 
due to the meaningful information they can impart as well as their relative ease of 
collection,33,40,45,191 in specific cases, the utilization of tissue specimens as matrix cannot be 
avoided despite the invasiveness of tissue sampling procedures, as certain information, such as 
site-specific information, can only be gathered through such means.2,33,34 In metabolomics 
investigations, the successful isolation of metabolites of interest from such complex biological 
matrices constitutes a critical step in determining the quality of the gathered data. To this extent, 
it is imperative that factors such as the representativeness of the extracted metabolome for the 
biological state of the system under investigation (metabolism quenching), and the reproducibility 
of the recoveries over large numbers of samples be carefully considered during method 
development. The advantages and challenges associated with the sample preparation strategies 
most frequently used in the processing of biological specimens in metabolomics investigations 
have been reviewed by several authors.2,34,37,50,191 For studies involving biofluids, most commonly 
employed methodologies include the use of dilute-and-shoot and solvent precipitation for global 
metabolomics, whereas liquid-liquid extraction with different organic solvents (methanol, 
chloroform, and methyl tert-butyl ether mixtures) is the approach of choice when targeting 
lipids.2,36,191 With respect to tissue, although solvent-based extraction applications comprise the 
most utilized sample preparation methods for investigations involving this matrix, additional steps 
are required prior to the extraction process due to the high complexity of tissue samples. In typical 
120 
 
workflows, collected tissue samples are first rinsed with either water or buffer so as to avoid 
contamination or inclusion of artefacts stemming from blood and/or from anesthetics used during 
the sample collection process.34,46 Subsequently, samples are subjected to shock freezing with 
liquid nitrogen to ensure metabolism quenching, followed by homogenization of the frozen tissue 
to induce cell disruption.34,50 Finally, according to the metabolite coverage that is desired, the 
extraction step is carried out by employing one or various solvents (single phase, two-phase, or 
multi-step extractions). Single extraction steps combined with appropriate instrumental platforms 
are preferred in most cases; in addition to being less timing consuming, such methodologies are 
less prone to errors in comparison to two-phase or multi-step extractions. Naz et al. have 
comprehensively reviewed traditional analytical protocols for untargeted analysis of biological 
tissues.34 Undoubtedly, a common denominator among all sample preparation approaches for 
tissue handling is that they are time consuming and labor intensive. Considering the 
abovementioned limitations surrounding currently available analytical workflows for 
metabolomics studies that involve tissue analysis, new efforts must be sustained towards the 
development and implementation of alternative strategies capable of streamlining the analytical 
workflow, while ensuring the integrity of the metabolome.  
Solid phase microextraction (SPME) is a non-exhaustive extraction technique that integrates 
sampling and sample preparation in a single step.212 In the last decade, SPME has been successfully 
applied towards various metabolomics studies, including applications in the clinical field that have 
yielded promising results.113,115,158,208,233 In SPME, a small amount of extraction phase 
immobilized on the outer part of a solid support is used to extract either volatile (headspace) or 
non-volatile (direct immersion) compounds from a given sample matrix.212 Although several 
authors have reported application of headspace (HS) SPME-gas chromatography (GC)-MS for 
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metabolic profiling of volatile compounds,108,158,233,234 direct immersion (DI) SPME combined 
with liquid chromatography (LC)-MS analysis is generally preferred for untargeted studies, as it 
allows for analysis of a more comprehensive range of metabolites.235,236 Indeed, use of DI-SPME 
coupled with LC-MS has enabled determinations of multiple classes of metabolites encompassing 
a wide range of polarities.57,114,117 Furthermore, a comparative study between SPME, 
ultrafiltration, and solvent precipitation demonstrated that SPME was able to provide 
complementary information by reducing ionization suppression (SPME vs solvent precipitation) 
and through improved coverage of hydrophobic compounds (SPME vs ultrafiltration).114 
However, while these findings endorse the applicability of this technology for untargeted studies 
in the clinical field, further evaluations of SPME conditions in different matrices are still needed 
to further validate its implementation in such investigations. In addition to the abovementioned 
advantages, another positive characteristic of SPME is the advantage afforded by the 
biocompatibility of its sampling devices. LC-amenable SPME coatings, which are comprised of 
sorbent particles immobilized with a biocompatible binder, allow for high selectivity towards small 
molecules, avoid the co-extraction of proteins and other macromolecules, and do not induce 
adverse reactions when immersed in biological matrices (anti-fouling surface).83 Moreover, SPME 
biocompatible extraction phases are also suitable for in vivo analysis. Undoubtedly, one of the 
most attractive features of in vivo SPME as a tool in metabolomics is that it integrates sampling, 
extraction, and metabolism quenching in a single step, thus minimizing the likelihood of samples 
incurring the type of metabolome alterations associated with traditional procedures.57,208 On this 
note, it is worth emphasizing that the general DI-SPME workflow used for both in vivo and ex vivo 
analyses is significantly straightforward, only involving the following steps: i) conditioning and 
rinsing of the SPME coating (also sterilization if required); ii) exposure of the coating to the sample 
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matrix for a defined period of time; iii) quick rinsing of the SPME probe to remove any 
macromolecules loosely attached to the coating surface; iv) and desorption of the extracted 
metabolites into an appropriate solvent. This methodology is largely suitable for studies that 
require analysis of tissue specimens, as it simplifies the time-consuming steps of typical sample 
preparation workflows. Other advantages of SPME in tissue analysis include the viability of tuning 
the geometry of the device to target specific sampling sites, its low invasiveness in comparison to 
standard tissue sampling approaches, the non-destructive nature of the extraction procedure, and 
in particular for in vivo studies, the feasibility of monitoring the same subjects at multiple time 
points. Until now, only a few studies have reported application of DI-SPME for monitoring of 
metabolic changes in animal tissue, including muscle, lung, liver, and also brain 
specimens.115,116,237 In SPME brain analysis studies, the use of DI-SPME and LC-MS/MS enabled 
in vivo measurement of changes in neurotransmitters after fluoxetine administration. Remarkably, 
the results obtained by DI-SPME in this study were comparable to those obtained with 
microdialysis (MD), the technique of choice for in vivo monitoring of neurotransmiters.237 Among 
the many insights obtained through this study, its findings certainly support the applicability of 
SPME as a complementary tool to MD; as observed in that work, while SPME facilitates the 
extraction of non-polar metabolites such as lipids, MD favors the detection of more polar 
metabolites. Thus, the concomitant use of these techniques enables monitoring of a wider range of 
compounds, allowing for a more complete snapshot of a given system under study. Yet, despite 
the promising results reported in the few reports where tissue analysis was carried out by DI-
SPME, a complete assessment regarding the effect of different experimental conditions on the 
metabolic coverage of this technique has yet to be published. The currently presented work seeks 
to fill this gap by presenting an evaluation of SPME as a sample preparation tool in untargeted 
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brain studies. The work included an evaluation of the metabolite coverage provided by C18, MM, 
and HLB coatings after extraction from cow brain homogenate at static conditions, with 
parameters such as desorption solvent, features detected in different chromatographic modes, 
washing steps, and extraction time all taken into consideration. The findings of this work support 
the applicability of SPME in brain metabolomics studies, providing insightful information 
regarding the performance of DI-SPME in untargeted tissue analysis.  
5.2.Experimental 
5.2.1. Materials and supplies 
7 mm long C18 and mixed mode (C18 and benzene sulfonic acid functionalities, MM) fibers (45 
µm thickness) were kindly provided by Millipore Sigma (Bellefonte, PA, USA). 7 mm 
hydrophilic-lipophilic balanced (HLB) fibers were manufactured in-house by dipping nitinol wires 
multiple times in a slurry containing polyacrylonitrile (PAN) dissolved in dimethylformamide 
(DMF), and 5 µm HLB particles (40 µm coating thickness). Cow brain homogenate was selected 
as a model matrix for all experiments due to its ready commercial availability. All fibers were pre-
conditioned in 1:1 (v/v) methanol:water for at least 30 min prior to extraction. Following their 
conditioning, SPME fibers were rinsed with ultra-pure water to remove any excess organic solvent 
remaining on the coating surface. 
5.2.2. Investigation of SPME coating coverage and desorption conditions 
Cow brain homogenate was placed in 300 µL vials with the help of a disposable Luer lock syringe. 
All vials were carefully filled from the bottom to the top, ensuring no air pockets remained in the 
vial, as their presence could disturb the extraction process and potentially introduce errors to the 
data gathered. C18, HLB, and MM fibers (n=16 per coating type) were exposed to brain 
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homogenate for 30 min at room temperature and at static conditions. Each fiber was thoroughly 
wiped with a Kimwipe, then quickly dipped in ultra-pure water following extraction so as to 
remove adhering macromolecules and tissue debris from the coating surface. Desorption 
evaluations were carried out for four different desorption solvents: methanol, acetonitrile (ACN), 
1:1 (v/v) ACN:water, and 1:1 (v/v) isopropanol:methanol. The first three solvents were evaluated 
in terms of their desorption strength for metabolomics analysis, while 1:1 (v/v) 
isopropanol:methanol was selected to test the lipid coverage capacity of the selected coatings. In 
total, four fibers of each coating chemistry were used to test each desorption solvent. For methanol 
and ACN desorptions, solvent volume was set to 100 µL, with further dilution with 100 µL of 
water carried out after desorption of fibers so as to ensure good chromatographic retention. For 
1:1 (v/v) ACN:water and 1:1 (v/v) isopropanol:methanol, 200 µL of solvent was selected as 
desorption volume. All fibers were desorbed under constant vortex agitation (1500 rpm) for 1 hour.  
5.2.3. Evaluation of the washing step in SPME lipid analysis 
The effect of the washing step was assessed as a factor of analytical variability in SPME lipid 
extraction from brain tissue. Four different washing strategies were evaluated at 10 s vortex each: 
pure water, 10 % (v/v) acetone, 10 % (v/v) methanol, and 10 % (v/v) isopropanol. The rinsing step 
was carried out by employing a manual vortex agitator at 3200 rpm. For this experiment, C18 
fibers (n=5 for each washing strategy) were deployed in 30 min extractions carried out in both 
plasma and brain homogenate. The findings of this evaluation indicated the parameters 10 s vortex 
in 10 % (v/v) acetone to be the best rinsing strategy for lipid analysis; as such, this approach was 




5.2.4. Extraction time investigation 
Following investigations of coating coverage, desorption conditions, and washing step, extraction 
time profiles for all coating chemistries were constructed. C18, HLB, and MM fibers were used to 
extract from brain homogenate for 5, 10, 20, 30, and 40 min under static conditions. All extractions 
were carried out in a randomized order. Four fibers of each coating type were used per extraction 
point. Following desorption of HLB and MM fibers in 100 µL of methanol, all resulting extracts 
were submitted to instrumental analysis, using the chromatographic method for metabolomics 
analysis described in section 5.2.5. Conversely, following desorption of C18 fibers in 1:1 (v/v) 
isopropanol:methanol, obtained extracts were submitted to LC-MS analysis in accordance to the 
chromatographic method described in Section 5.2.5 for analysis of lipids. 
5.2.5. LC-MS analysis 
All extracts were run on a LC-MS system consisting of an Accela pump, an Accela autosampler, 
and an Orbitrap mass spectrometer Exactive equipped with a heated electrospray (H-ESI) source 
(Thermo Scientific, San Jose, USA). Chromatographic separation was carried out using one of two 
methods, targeting either small metabolites, or lipids. In accordance with previous work carried 
out in our group, separation and detection of small metabolites was conducted on a 
pentafluorophenyl (PFP) column, chosen due to its selectivity and satisfactory performance in 
retaining certain small polar compounds and non-polar metabolites with different moieties.114,238 
Summaries of settings selected for both LC-MS methods are provided in Tables 5.1 and 5.2. 
Xcalibur software (2.0.7 SP1) was employed for data acquisition. To ensure appropriate mass 
accuracy over the course of the sequence, the MS instrument was calibrated every two days using 
the Pierce™ LTQ Velos ESI Positive Ion Calibration Solution and the Pierce™ Negative Ion 
Calibration Solution (Thermo Scientific, San Jose, USA). Moreover, 391.2843, and 255.2329 m/z 
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were used as lock masses for positive and negative acquisition modes, respectively, corresponding 
to diisooctyl phthalate (a common plasticizer) and palmitic acid, common background 
contaminants present in electrospray analysis. A pooled quality control (QC) sample (prepared by 
mixing equal aliquots of each extract) was run multiple times across the instrumental sequence 
(about every ten injections) so as to ensure instrumental stability for all extracted features. Samples 
were run in a randomized manner as a means of avoiding sequence bias related to instrumental 
drift. Fibers and solvent blanks were also analyzed as controls of possible artefacts. 
Table 5.1. Chromatographic conditions employed for this study. 
Metabolites analysis114 Lipids analysis 
Column: Supelco Discovery HS F5, 2.1 x 
100 mm, 3 µm 
Column: Waters, XSelect CSH C18 Column, 
130Å, 3.5 µm, 2.1 mm X 75 mm 
Mobile phases 
A (positive): Water with 0.1 % (v/v) formic 
acid 
B (positive): ACN with 0.1 % (v/v) formic 
acid 
A (negative): 1 mM acetic acid 
B (negative): 1 mM acetic acid in ACN 
Mobile phases  
A: 40:60 methanol/water with 10 mM 
ammonium acetate and 1 mM acetic acid 
B: 90:10 isopropanol:methanol with 10 mM 
ammonium acetate and 1 mM acetic acid 
Gradient 


















Column temperature 25 oC Column temperature 55 oC 
Autosampler temperature: 5 °C Autosampler temperature: 5 °C 




Table 5.2. MS conditions for untargeted analysis of brain extracts. 
 MS conditions 
Electrospray voltage, kV 4000 (-2900 negative mode) 
Sheath gas, AU 30 
Auxiliary gas, AU 10 
Sweep gas, AU 5 
Capillary temperature, °C 300 
Vaporizer temperature, °C 300 
MS resolution High 50,000 at 2 Hz (FWHM* 200 m/z) 
Acquisition range, m/z 100 – 1000  
Automatic gain control Balanced 1e6 
Injection time 100 ms 
*Full-width at half maximum (FWHM) 
5.2.6. Data analysis 
Raw files were converted to mzXML files using the peak picking function (centroid data) from 
ProteoWizard MS Convert version 3.0. 10095 64 bits. Converted files were then processed using 
the platform XCMS online, which is available for free 
(https://xcmsonline.scripps.edu/landing_page.php?pgcontent=mainPage). Parameters employed 
in XCMS online were set as follows: feature detection was conducted using the centWave with 5 
ppm as the maximal tolerated m/z deviation; 7 s as the minimum peak width; and 120 s as the 
maximum peak width (other parameters were S/N=6, mzdiff=0.01, integration method through 
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descent on the Mexican hat filtered data, prefilter data=3, and prefilter intensity=100); retention 
time correction was carried out using the orbiwarp method (profStep=1); for feature alignment, 
bw=10 s, mzwid=0.015 m/z, minfrac=0.5; feature annotation (isotopes and adducts) was 
conducted using CAMERA (a package integrated in the XCMS online platform) at 5 ppm and 
0.015 as m/z absolute error. The software SIMCA P+ 14.0.0 (Umetrics, Umeå, Sweden) was 
employed for multivariate analysis of data. Principal component analysis (PCA) and orthogonal 
partial least squared – discriminant analysis (OPLS-DA) were carried out by employing the aligned 
data obtained from XCMS online. For PCA and OPLS-DA, the data was scaled using Pareto 
scaling. Metabolites corresponding to important metabolite features were putatively identified 
based on accurate mass (within 5 ppm) searches on different databases (METLIN and Human 
Metabolome Data Base). The identification process accounted for information regarding annotated 
adducts and isotopes detected at the same retention time.  Provided their availability, standards 
were then run to verify the identity of the metabolites.  
5.3.Results and discussion 
Several publications have reported the applicability of SPME for metabolomics studies of different 
biological matrices, including tissue.158 Although positive results in terms of sample clustering and 
metabolite coverage have been documented in the literature, an evaluation and subsequent 
optimization of experimental conditions aimed at maximizing the information obtained by SPME 
in applications involving tissue samples had yet to be presented.  
One of challenges in tissue analysis of brain is derived from the intrinsic complexity of this organ, 
as its intricate structure is mirrored in its rich chemical composition. Indeed, the brain is a 
heterogeneous organ divided into different regions with diverse biochemical functions that, in turn, 
are composed of various cell types, proteins, lipids, and small molecules. As metabolomics 
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applications have as their main goal the comprehensive capture of low molecular weight 
metabolites (<1000 Da) that represent the biological state of a given system, the development of 
any analytical workflow chosen for such a purpose should, ideally, be able to fulfill that 
requirement. In most comparisons of exhaustive extraction technologies versus microextraction 
techniques (such as SPME) it is anticipated that the former would likely outperform the latter in 
terms of metabolite recoveries and coverage. However, for in vivo metabolomics analysis, the 
simplicity and low invasiveness of this microextraction technique afford SPME a key advantage 
over traditional approaches. Moreover, the non-lethal and non-exhaustive nature of SPME enables 
multiple samplings of the same animal or biological system, thus allowing for paired tests or 
matched pair comparisons (same animal before and after a treatment), and facilitating 
metabolomics studies of a longitudinal nature. While cow brain homogenate was selected as model 
matrix for initial assessments and optimization of parameters, the final optimized conditions 
provided by this study are intended to be used for in vivo rat brain investigations. 
5.3.1. Assessment of SPME coverage for the analysis of brain tissue metabolome 
In the first part of this study, different SPME coating chemistries available for bioanalytical 
applications were evaluated in terms of metabolite coverage. In this context, HLB fibers (home-
made), commercial C18 fibers, and MM fibers (currently provided by Millipore Sigma Aldrich) 
were selected for this evaluation owing to their previously documented performances in 
bioanalytical studies. To date, most of the SPME-based metabolomics studies reported in the 
literature have employed MM fibers due to the wide coverage provided by their C18 and strong 
cationic exchanger (benzene sulfonic acid) functionalities.56,57,115,116 However, recent work carried 
out by our group has also demonstrated the advantages of using HLB for the analysis of a broad 
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range of compounds.117,118,162,204 Based on this, HLB was also included as one of the coating 
chemistries to be tested for untargeted brain studies.  
In addition to evaluating different coating types, several desorption solvents were compared. In 
SPME method development, the establishment of optimum desorption conditions for SPME 
constitutes a critical step in ensuring maximum sensitivity and satisfactory precision. Considering 
that the number of metabolites extracted from cow brain tissue via SPME is unknown, a 
comparison was conducted based on the relative intensities of detected metabolite features, the 
information provided by different desorption solvents, and the analytical precision of each set of 
conditions. Based on the fact that a metabolite feature corresponds to a detected ion that has a 
unique m/z and retention time, several metabolite features corresponding to isotopes, different 
adducts, and also in-source fragments are detected when a single metabolite or compound is 
analyzed via MS.  
Figures 5.1 and 5.2 depict results corresponding to the relative intensities of features detected after 
30 min extractions from cow brain homogenate, using the three aforementioned coating 
chemistries. For this initial comparison, following desorption of the probes in three different 
solvents (methanol, 1:1 (v/v) ACN:water, and ACN), obtained extracts were submitted to LC-MS 
instrumental analysis in both positive and negative modes in accordance with the described LC-
MS method for metabolomics analysis using a PFP column. Only those features having both 
pooled QC/fiber blank area intensity ratios above 5 and average intensities above 1000 were 
considered for the plots (2405 features in positive mode; 1294 features in negative mode). The 
obtained data was then further filtered based on information gathered from fiber blanks so as to 
avoid erroneous inclusions of artefacts originating from either the coatings or solvents as features 






Figure 5.1. Features detected per coating type at different desorption conditions (positive mode). 



















































































































Figure 5.2. Features detected per coating type at different desorption conditions (negative mode). 




















































































































calculating the total sum of areas for each metabolite feature (including all coatings and desorption 
solvents) and dividing it by 36 (4 fibers * 3 solvents * 3 coating types). The relative intensities for 
each feature, in turn, were calculated as a percentage of the total sum of areas of the same feature 
detected in all the extracts obtained per coating type. For example, the relative intensity for a 
feature X detected in methanol via C18 fiber #1 (F1) was calculated as follows: relative intensity 
of feature X (C18, F1, methanol)= (area feature X(C18, F1, methanol)/(∑areas feature X C18,methanol (F1,2,3 and 4) + 
∑areas feature XC18, 1:1(v/v)ACN:water (F1,2,3 and 4) + ∑areas feature XC18, ACN (F1,2,3 and 4)))*100. 
Considering that four replicates were carried out per coating-solvent pair, the data plotted in 
Figures 5.1 and 5.2 correspond to the averages of the relative intensities. As shown, ACN presented 
the poorest desorption strength for all tested coatings, with most of the features detected showing 
relative intensities below 5%. The observed findings thus support that as an SPME solvent, ACN 
was unable to significantly decrease the coating/elution media distribution constant for most of the 
extracted metabolites; therefore, ACN was discarded as an option among the desorption solvent 
possibilities. Methanol, on the other hand, showed the highest desorption efficiency for all tested 
extraction phases. In both positive and negative modes, all three evaluated coatings exhibited an 
overall increase in the number of features with relative intensities above 20% when methanol was 
used as desorption solvent. This trend was, however, more pronounced in the results obtained in 
negative mode. Lastly, the desorption efficiencies of the 1:1 (v/v) ACN:water solvent were shown 
to be superior to those obtained by ACN; however, based on the relative intensities obtained for 
all three solvents, methanol was concluded to yield the best elution performance among the tested 
solvents.  
Subsequent to this initial assessment, an evaluation was carried out to assess the performance of 
each coating in relation to its coverage as well as quality of data provided. For this purpose, 
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obtained data for each coating was filtered so as to only retain features with pooled QC/blank 
(solvent and fiber blanks) ratios above 5, pooled QC RSD values below 30 %, and intensities above 
3000. As shown in Figures 5.3 and 5.4, similar feature numbers matching the specified filtering 
conditions were found for all extracts in both positive and negative modes. This certainly confirms 
that carrying out evaluations of the coverage of a given extraction phase as well as of the 
performance of a desorption solvent based solely on the number of features attained through their 
application is insufficient for optimization of these parameters. Indeed, a cursory examination of 
these results (Figures 5.3 and 5.4) would certainly seem to indicate that any of the three coatings 
desorbed in any of the tested solvents would provide virtually the same information. With aims of 
gaining further clarification on the effect of each solvent on the extraction recoveries, ratios 
between the average intensities detected in methanol and in 1:1 (v/v) ACN:water were estimated. 
As presented in Table 5.3, the number of features with intensities 1.5 times higher in methanol  
 
Table 5.3. Comparison of feature intensities as a function of their desorption solvent (methanol 
vs. 1:1 (v/v) ACN:water). Only features with pooled QC/blank (solvent and fiber blanks) ratios 
above 5, RSD values below 30 %, and intensities above 3000 were taken into consideration for 
this comparison. 
 
Features with intensities 1.5 times 
higher in methanol 
Features with intensities 1.5 times higher 
in 1:1 (v/v) ACN:water 
C18, pos 161 72 
C18, neg 246 74 
HLB, pos 115 131 
HLB, neg 164 47 
MM, pos 81 142 






Figure 5.3. Ion maps corresponding to features detected in positive mode after extraction from 
brain homogenate with C18, MM, and HLB 7 mm fibers. Desorptions were carried out in methanol 
(left) and 1:1 (v/v) ACN:water (right). Only features having pooled QC/blanks (solvent and fiber 















C18, methanol, 684 features with intensities > 












C18, 1:1 acetonitrile:water, 703 features with 












HLB, 1:1 acetonitrile:water, 723 features with 












HLB, methanol, 694 features with intensities > 












MM, methanol, 681 features with intensities > 












MM, 1:1 acetonitrile:water, 718 features with 




Figure 5.4. Ion maps corresponding to features detected in negative mode after extraction from 
brain homogenate with C18, MM, and HLB 7 mm fibers. Desorptions were carried out in methanol 
(left) and 1:1 (v/v) ACN:water (right). Only features having pooled QC/blanks (solvent and fiber 
blanks) ratios above 5, RSD values below 30 % in the pooled QC, and intensities above 3000 were 
plotted. 
 
than in 1:1 (v/v) ACN:water was significantly larger for extracts of C18 (both positive and negative 
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C18, 1:1 acetonitrile:water, 519 features with 












HLB, methanol, 569 features with intensities > 











HLB, 1:1 acetonitrile:water, 513 features with 












MM, 1:1 methanol, 566 features with intensities 












MM, 1:1 acetonitrile:water, 558 features with 
intensities > 3000 and pooled QCs RSD < 30 % 
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features with 1.5 times higher intensities in 1:1 (v/v) ACN:water as compared with methanol was 
larger in HLB and MM extracts run in positive mode. While no marked differences were observed 
between methanol and 1:1 (v/v)ACN:water for HLB extracts, the obtained results seem to indicate 
that  use of 1:1 (v/v) ACN:water as solvent would yield better results for untargeted analysis in 
positive mode in cases where the MM coating is used.  
In addition to carrying out an assessment of solvent and coating performance with aims of 
identifying the combinations capable of yielding the highest number of features with the highest 
intensities, an investigation into the type of information attained by solvent type was carried out 
with aims of assessing whether the use of different solvents would introduce significant differences 
to the obtained information. To this end, principal components analysis (PCA) and orthogonal 
partial least squares discriminant analysis (OPLS-DA) were employed to analyze the data. As 
shown in Figure 5.5, clear clusterings of observations obtained according to type of desorption 
solvent used were found for both positive and negative modes. This evidently indicates that in 
SPME, significant differences in the composition of final extracts may occur due to selective 
desorption of extracted metabolites. To determine which features contributed to the observed 
differentiation, multivariate supervised analysis, more specifically OPLS-DA, was carried out 
(Figure 5.6) on the obtained data. Interestingly, the main discriminating features in the S-plots (|p1| 
> 0.05 and |p(corr)1| > 0.8) depicted in Figure 5.6 corresponded to polar metabolites eluting at 
retention times below 2 min and to non-polar compounds eluting at retention times close to 25 
min. The p1 axis provides information regarding the influence of each feature towards the observed 
separation between the two groups, while the p(corr)1 axis describes the reliability of each variable 
in the discrimination of the two groups.239 As shown in Figure 5.7, our results revealed that the use 




Figure 5.5. Principal component analysis (PCA) plots corresponding to C18, MM and HLB desorption extracts obtained in methanol 
and ACN:water in positive mode (left) and negative mode (right). Only features exhibiting pooled QC/blank (solvent blanks and fiber 
blanks) ratios above 5 and having pooled QC RSD values below 30 % were considered for these plots. 
 
1:1 (v/v) ACN:water 








Figure 5.6. OPLS-DA plots (left) and S-plots (right) corresponding to the comparison of 1:1(v/v) 
ACN:water (1) and methanol (2) extracts from all the coating types in positive (above) and 







Figure 5.7. Summary of the main features discriminating 1:1 (v/v)ACN:water and methanol 
extracts (from the S-plots). The markers represent the features with the highest intensities at each 
of the specified conditions.  
 
provided better recovery for certain polar metabolites. Among the non-polar discriminating 
features determined to contribute to the observed differentiation are lipids belonging to 
phosphatidylcholine (PC), phosphatidylethanolamine (PE), and glucosyl/galactosylceramide 
(Glc/galCer). In regards to polar metabolites, compounds having in their structure a purine base 
such as xanthine, inosine, guanosine, and deoxyguanosine were found to be present at much higher 
levels in 1:1 (v/v) ACN:water extracts (Figures 5.8 and 5.9). While the number of features 
exhibiting higher intensities was in general larger for extracts desorbed in methanol than for those 
in 1:1 (v/v) ACN:water, the findings of this investigation certainly evidence that certain 
metabolome information can be omitted from the final extract based on the solvent selected for 
desorption. As untargeted metabolomics studies aim to provide a thorough snapshot of the system 
under study, better metabolite coverage can then be attained by combining extracts from both 
















Pos, 1:1 acetonitrile:water Pos, methanol
Neg, 1:1 acetonitrile:water Neg, methanol
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Following the conclusion of desorption evaluations for 1:1 (v/v) ACN:water and methanol, a 
comparison of detected features by coating type was carried out. Indeed, the behaviour and affinity 
of each coating type for the broad range of metabolites found in brain tissue can be predicted based 
on the extraction phase chemistry of the coating. C18, for instance, is expected to show high 
affinity towards non-polar components, as its extraction mechanism occurs mostly through 
hydrophobic interactions. On the other hand, HLB and MM are expected to provide better 
recoveries for polar compounds and analytes with aromatic moieties (via pi-pi interactions) given 
the types of functionalities these coatings possess. HLB contains divinyl benzene and 
vinylpyrrolidone moieties that enable the extraction of both non-polar and polar compounds, 
whereas MM contains C18, and also a strong cation exchanger functionality (benzene sulfonic 
acid), which increases the affinity of the coating for polar charged metabolites. With this in mind, 
an initial comparison of experimental data obtained from brain extracts collected via C18 fibers 
versus data obtained via HLB and MM coatings was carried out, and the intensities of 
representative discriminating metabolite features were plotted, as seen in Figures 5.8 and 5.9. In 
regards to 1:1 (v/v) ACN:water extracts, our results showed that higher intensities were obtained 
for polar compounds such as niacinamide, phenylalanine, tryptophan, xanthine, arginine, and 
choline from extracts originating from MM and HLB fibers (Figure 5.8). Some of these 
compounds are not only polar, but also contain an aromatic functionality or a positive charge, 
which function to increase their affinity for HLB and MM coatings. Interestingly, several fatty 
acids also exhibited higher intensities in MM and HLB extracts obtained with 1:1 (v/v) 




Figure 5.8. Representative metabolites identified in brain extracts obtained with the three different 
coating types using 1:1 (v/v)ACN:water as desorption solvent (n=4 fibers). 
 
0 100000 200000 300000 400000
Choline (m/z 104.1072, +) x 1e2
Niacinamide (m/z 123.0554, +) x 1e2
Leucine (m/z 132.1020, +) x 1e2
Isoleucine (m/z 132.1020, +) x 1e2
Lysine (m/z 147.1128, +) x 1e2
Glutamate (m/z 148.0604, +) x 1e2
Methionine (m/z 150.0584, +) x 1e1
Xanthine (m/z 153.0407, +) x 1e2
Phenylalanine (m/z 166.0863, +) x 1e2
Uric acid (m/z 167.0204, -)
Arginine (m/z 175.1190, +) x 1e2
Tyrosine (m/z 180.0660, -) x 1e1
Phosphocholine (m/z 184.0734, +) x 1e2
Tryptophan (m/z 205.0973, +) x 1e2
Uridine (m/z 245.0769, +)
Inosine  (m/z 269.0881, +) x 1e1
Xanthosine (m/z 283.0685, -)
Guanosine (m/z 284.0990, +)
Fatty acid C20H32O2 (m/z 303.2331, -) x 1e2
Cytidine 2',3'-cyclic phosphate  (m/z 306.0497, +) x 1e1
N-Acetylneuraminic acid (m/z 310.1133, +) x 1e1
Fatty acid C22H32O2 (m/z 327.2331, -) x 1e1
Fatty acid C22H34O2 (m/z 329.2487, -)
Fatty acid C22H36O2 (m/z 331.2643, -) x 1e1
Deoxyguanosine (m/z 348.0704, +)
Peptide C15H26N4O6S (m/z 391.1646, +)
Peptide C18H31N5O8S (m/z 478.1967, +)
Peptide C22H39N5O9 x 1e1 (m/z 518.2822, +)
PE C39H76NO7P (m/z 702.5432, +) x 1e2
GlcCer C42H79NO8 (m/z 726.5878, +) x 1e2
PE/PC C41H78NO7P (m/z 728.5588, +) x 1e2
PE/PC C41H78NO8P (m/z 744.5537, +) x 1e2
GlcCer C42H81NO9 (m/z 744.5983, +) x 1e2
PE/PC C43H76NO7P (m/z 750.5431, +) x 1e2
Lipid [M-H]- MW 799.658 (m/z 798.6470, -)
Lipid [M-H]-  MW 827.689 (m/z 826.6782, -) x 1e1








Figure 5.9. Representative metabolites identified in brain extracts obtained with the three different 
coating types using methanol as desorption solvent (n=4 fibers). 
 
0 100000 200000 300000 400000
Choline (m/z 104.1072, +) x 1e2
Niacinamide (m/z 123.0554, +) x 1e2
Leucine (m/z 132.1020, +) x 1e2
Isoleucine (m/z 132.1020, +) x 1e2
Lysine (m/z 147.1128, +) x 1e2
Glutamate (m/z 148.0604, +) x 1e2
Methionine (m/z 150.0584, +) x 1e1
Xanthine (m/z 153.0407, +) x 1e2
Phenylalanine (m/z 166.0863, +) x 1e2
Uric acid (m/z 167.0204, -)
Arginine (m/z 175.1190, +) x 1e2
Tyrosine (m/z 180.0660, -) x 1e1
Phosphocholine (m/z 184.0734, +) x 1e2
Tryptophan (m/z 205.0973, +) x 1e2
Uridine (m/z 245.0769, +)
Inosine  (m/z 269.0881, +) x 1e1
Xanthosine (m/z 283.0685, -)
Guanosine (m/z 284.0990, +)
Fatty acid C20H32O2 (m/z 303.2331, -) x 1e2
Cytidine 2',3'-cyclic phosphate  (m/z 306.0497, +) x 1e1
N-Acetylneuraminic acid (m/z 310.1133, +) x 1e1
Fatty acid C22H32O2 (m/z 327.2331, -) x 1e1
Fatty acid C22H34O2 (m/z 329.2487, -)
Fatty acid C22H36O2 (m/z 331.2643, -) x 1e1
Deoxyguanosine (m/z 348.0704, +)
Peptide C15H26N4O6S (m/z 391.1646, +)
Peptide C18H31N5O8S (m/z 478.1967, +)
Peptide C22H39N5O9 x 1e1 (m/z 518.2822, +)
PE C39H76NO7P (m/z 702.5432, +) x 1e2
GlcCer C42H79NO8 (m/z 726.5878, +) x 1e2
PE/PC C41H78NO7P (m/z 728.5588, +) x 1e2
PE/PC C41H78NO8P (m/z 744.5537, +) x 1e2
GlcCer C42H81NO9 (m/z 744.5983, +) x 1e2
PE/PC C43H76NO7P (m/z 750.5431, +) x 1e2
Lipid [M-H]- MW 799.658 (m/z 798.6470, -)
Lipid [M-H]-  MW 827.689 (m/z 826.6782, -) x 1e1







eluting non-polar metabolites from C18, and not to actual differences in coating affinities. A 
similar trend was observed for several polar metabolites with respect to SPME extracts obtained 
in methanol. Again, compounds such as niacinamide, phenylalanine, and tryptophan showed 
higher intensities in HLB and MM brain extracts in comparison with those extracted via C18 fibers 
(Figure 5.9). Although these findings confirm that HLB and MM display high affinities for these 
types of polar compounds, decent peak areas for the same metabolites were nonetheless found for 
all extracts corresponding to the C18 fibers. Such a phenomenon can be explained by considering 
the presence of active silanol groups in the sorbent material, which enable secondary polar 
interactions. With respect to non-polar metabolites such as lipids and fatty acids, desorption in 
methanol was evidenced to provide an overall increase in their peak intensities. As can be seen in 
Figure 5.9, C18 extracts yielded the highest peak areas for several non-polar compounds in 
instances where methanol was used as the desorption solvent. This data supports the previous 
assertion that selective metabolite desorption occurs based on solvent composition, further 
validating the approach previously proposed in this chapter, which would see the use of more than 
one desorption solvent per coating type. To conclude the evaluation of coating coverage for 
metabolomics studies, an assessment of possible differences between HLB and MM in terms of 
information provided was conducted. To this end, features detected in HLB and MM extracts 
following their submission to PFP chromatography were compared via OPLS-DA loading S-plots 
(Figure 5.10). The results of this comparison demonstrated that although there are some differences 
in the intensities of several metabolite features such as those corresponding to niacinamide and 
tryptophan (Figures 5.8 and 5.9), in most cases, all filtered features can be easily detected with 
either coating types. In fact, only 12 features exhibited |p1| > 0.05 and |p(corr)1| > 0.8 in both 
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positive and negative modes. Further discussion regarding metabolite extraction kinetics will be 
provided in Section 5.3.3.  
 
 
Figure 5.10. OPLS-DA plots and S-plots corresponding to a comparison of HLB(1) and MM (2) 
extracts in positive (above) and negative (below) modes. Features highlighted have |p1| > 0.05 and 




Part of the initial assessment of different SPME coatings for brain metabolomics studies also 
involved inter-fiber variability determinations. This is a critical aspect of both targeted and 
untargeted metabolomics, as the analytical methodology of choice should guarantee that the 
differences observed between any two sample groups are due to biological changes, and not to 
experimental errors introduced in any of the steps of the workflow. Table 5.4 presents a summary 
of inter-fiber RSDs for features that had pooled QC/blank (solvent and fiber blanks) ratios above 
5, pooled QC RSDs below 30 %, and intensities above 3000. As can be seen, the use of methanol 
in the desorption of C18 extractions considerably improved the precision of the method for features 
detected in both positive and negative mode. This improvement is due to the strength of this solvent 
in regards to quantitative desorption of non-polar metabolites such as fatty acids, which are highly 
abundant in brain tissue. Similarly for HLB and MM, results showed that for negative mode, the 
use of methanol as a desorption solvent significantly increased the percentage of features with 
RSD values below 30%. Conversely, in positive mode, HLB showed better inter-fiber RSDs when 
1:1 (v/v) ACN:water was employed as desorption solution, whereas for MM fibers, no significant 
differences were observed between the two desorption solvents. Considering the complexity of the 
matrix, the fact that no internal standards were used, and that the extraction was conducted using 
7 mm-length fibers at static conditions, the encouraging results obtained in this study certainly 
support the applicability of SPME for untargeted in vivo brain studies. 
5.3.2. Assessment of SPME coverage for the analysis of lipids in brain tissue 
As a next step, the capability of SPME towards extraction of lipids from brain homogenate was 
investigated. For that purpose, 30 min extractions were carried out from brain homogenate via the 
three coating chemistries, followed by desorptions in 1:1 (v/v) methanol: isopropanol. 1:1 (v/v) 
methanol: isopropanol was selected for this evaluation due to its already tested efficiency in the 
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desorption of lipids from SPME fibers, as well as its demonstrated compatibility with the 
chromatographic conditions selected for lipid analysis.240 Figures 5.11 and 5.12 show data  
Table 5.4. Summary of RSD values estimated for features detected in positive and negative mode 
using the PFP method (n=4). Only features with pooled QC/blank (solvent and fiber blanks) ratios 
above 5, pooled QC RSDs below 30 %, and intensities above 3000 were considered. 














0 - 10 % 187 220 103 38 59 158 
10 - 20 % 197 232 289 136 225 145 
20 - 30 % 104 79 146 181 175 136 
30 - 40 % 57 25 90 94 102 105 
>  40% 160 129 98 247 158 139 
Total # of features 705 685 726 696 719 683 
% of features with 
RSDs below 30 % 
69 78 74 51 64 64 














0 - 10 % 105 268 68 122 114 184 
10 - 20 % 119 193 145 175 117 162 
20 - 30 % 43 51 119 119 67 110 
30 - 40 % 51 36 74 69 37 51 
>  40% 200 26 106 83 222 58 
Total 518 574 512 568 557 565 
% of features with 
RSDs below 30 % 
52 89 65 73 54 81 
corresponding to features detected in positive and negative modes using the chromatographic 
conditions for lipids analysis. Similarly to what was already reported in Section 3.1, the relative 
intensities plotted in Figures 5.11 and 5.12 correspond to the percentage represented by a given 
feature intensity over the total sum of peak areas of the same feature detected in all extracts. Thus, 
the relative intensity for feature X detected in the extract attained from the C18 fiber #1 (F1) was 
calculated as follows: relative intensity of feature X (C18, F1)= (area feature XC18, F1/( ∑areas 




Figure 5.11. Lipid-related features detected in positive mode for each coating type after extraction 
from brain tissue. Features were classified according to their average relative intensities (n=4 fibers 
per coating type). 
 
 
Figure 5.12. Lipid-related features detected in negative mode for each coating type after extraction 
from brain tissue. Features were classified according to their average relative intensities (n=4 fibers 













































































X in MM extractsF1, 2, 3 and 4))*100. Since four replicates were carried out per coating type, the data 
plotted in Figures 5.11 and 5.12 correspond to the averages of the relative intensities of the features 
obtained by coating type. As shown, among the three coatings evaluated, HLB exhibited the largest 
number of features in the highest ranges of relative intensities. C18 certainly yielded a comparable 
but slightly lower performance than HLB, while MM provided the largest number of features in 
the low range of relative intensities. As in the initial assessment of SPME for metabolomics 
analysis, only features having pooled QC/fiber blank ratios higher than 5 and average intensities 
above 1000 were considered. Interestingly, after applying the specified filtering criteria, 1688 
features still remained in positive mode, whereas 2646 features were kept in negative mode. With 
aims of further discerning the coverage capabilities and content of information provided by each 
coating, ion maps were plotted by utilizing only features having pooled QC/blank (solvent and 
fiber blanks) ratios above 5, pooled QC RSD values below 30 %, and intensities above 3000, as 
presented in Figures 5.13 and 5.14. As easily gathered through a comparison of Figures 5.13 and 
5.14 versus Figures 5.3 and 5.4, which represent mostly small metabolite features, SPME clearly 
displays significant capabilities towards extraction of lipids from brain tissue. As inferred by the 
experimental findings shown in Figures 5.11 and 5.12, HLB yielded the best performance in terms 
of relative intensities of features detected using the lipids analysis conditions. In view of this, 
comparisons between HLB and MM and between HLB and C18 were carried out. As shown in 
Table 5.5, in all cases, HLB exhibited the largest number of features with the highest intensities. 
These results suggest that HLB is able to provide balanced metabolite coverage as it facilitates the 
analysis of polar and small metabolites, while also yielding satisfactory results for extraction of 






Figure 5.13. Ion maps corresponding to lipid-related features detected in positive mode after 
extraction from brain homogenate for 30 min with C18, MM, and HLB 7 mm fibers, followed by 
desorption in 1:1 (v/v) methanol:isopropanol. Only features having pooled QC/blank (solvent and 














C18, lipidomics, 824 features with 
intensities > 3000 and pooled QC RSDs < 












HLB, lipidomics, 871 features with intensities > 












MM, lipidomics, 779 features with intensities > 







Figure 5.14. Ion maps corresponding to lipid-related features detected in negative mode after 
extraction from brain homogenate for 30 min with C18, MM, and HLB 7 mm fibers, followed by 
desorption in 1:1 (v/v) methanol:isopropanol. Only features having pooled QC/blank (solvent and 













C18, lipidomics, 2106 features with intensities > 












HLB, lipidomics, 2132 features with intensities > 












MM, lipidomics, 2064 features with intensities > 
3000 and pooled QC RSDs < 30%               
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Table 5.5. Comparison of detected lipid-related features by coating type. Only features with 
pooled QC/blank (solvent and fiber blanks) ratios above 5, RSD values below 30 %, and intensities 
above 3000 were taken into consideration. All ratios were calculated using peak areas. 
 Features with A/B 
ratios > 1.5 
Features with B/A 
ratios > 1.5 
Total number of 
compared features 
HLB (A) vs MM (B), pos 423 48 729 
HLB (A) vs MM (B), neg 1507 51 2019 
HLB (A) vs C18 (B), pos 160 66 729 
HLB (A) vs C18 (B), neg 125 92 2019 
C18 (A) vs MM (B), pos 414 126 729 
C18 (A) vs MM (B), neg 1506 93 2019 
 
comparison to extracts obtained via HLB, this coating should be still considered as a suitable 
coating for lipids studies, especially since it is commercially available. Interestingly, a comparison 
between the C18 and MM fibers provided by Millipore Sigma demonstrated that C18 offers better 
sensitivity for lipids as 57% and 75 % of the features detected with the chromatographic method 
for lipid analysis in positive and negative mode, respectively, exhibited higher intensities than 
those obtained via MM (Table 5.5).  
Following the above-discussed evaluation, which sought to assess the capability of the studied 
coatings to extract lipids based on the relative intensities of the detected lipid-related features 
obtained for each coating, an assessment of inter-fiber reproducibility was carried out for all three 
fibers. Table 5.6 presents results corresponding to RSD values calculated for lipid-related features, 
filtered using the same parameters defined in Figures 5.13 and 5.14. Conversely to what was 
observed for features detected using the PFP chromatographic method, in this part of the study, 
HLB showed the poorest performance in terms of inter-fiber precision for features obtained in both 
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positive and negative mode. While the goal of the evaluation discussed in this section pertains to 
lipid-related features, whereas the investigation discussed in Section 5.3.1 had as focus mostly 
metabolites of low molecular weight, the use of a different batch of HLB fibers could have 
certainly contributed to the high inter-fiber variability that is shown in Table 5.6. In regards to the 
inter-fiber reproducibility of C18 and MM coating types, the percentages of features detected in 
positive mode that presented RSD values below 30% were comparable. However, results obtained 
in negative mode showed that MM was superior to the two other coatings in this regard, as 76 % 
of the detected features by MM were in the lowest range of inter-fiber RSDs. 
Table 5.6. Summary of RSD values estimated for lipid-related features detected in positive and 
negative mode (n=4).  Only features with pooled QC/blank (solvent and fiber blanks) ratios above 
5, pooled QC RSDs below 30 %, and intensities above 3000 were considered for the calculations. 
Positive mode, # of metabolite features 
RSD, % C18  HLB MM 
0 - 10 % 67 53 39 
10 - 20 % 130 91 113 
20 - 30 % 220 103 189 
30 - 40 % 92 219 85 
>  40% 314 404 352 
Total # of features 823 870 778 
% of features with RSDs below 30 % 51 28 44 
Negative mode, # of metabolite features 
RSD, % C18 HLB MM 
0 - 10 % 70 36 188 
10 - 20 % 251 173 735 
20 - 30 % 397 276 638 
30 - 40 % 580 591 202 
>  40% 807 1025 294 
Total 2105 2101 2057 
% of features with RSDs below 30 % 34 23 76 
 
Several factors should be considered when aiming to investigate the sources of variability that 
could affect the precision of the developed method for extraction of lipids from brain tissue via 
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SPME. First of all, the high binding that lipids display for several matrix components will be 
reflected in considerably low free concentrations of lipids available for SPME extraction. The 
smaller extraction amounts expected for lipids in comparison to other small metabolites, in turn, 
could lead to high inter-fiber variations. Moreover, the risk of incurring non-specific binding due 
to the physical attachment of matrix components to the probe should be carefully considered. In 
such cases, any tissue debris remaining on the coating surface would be further extracted in the 
desorption step, introducing variations to the metabolite composition of the final extracts. With 
this in mind, the effect of an added post-extraction rinsing/cleaning step was evaluated for its 
impact on inter-fiber reproducibility. For this purpose, the feasibility of incorporating organic 
solvent into the washing step was explored based on recent work conducted in our group, wherein 
rewarding SPME method precision was attained by introducing acetone in a rinsing solution, 
which was utilized to rinse fibers following extraction of pesticides from avocado.241 To this end, 
acetone, isopropanol, and methanol were evaluated as additives in the washing step at a set 
proportion of 10 % (v/v). C18 fibers were used for this experiment in view of their satisfactory 
performance towards lipid extraction, their current availability in the market, and their high inter-
fiber variability in terms of lipid-related features, as was shown in Table 5.6. In order to further 
study the impact of convection and matrix type on inter-fiber RSD, in addition to carrying out a 
washing step evaluation using brain homogenate as matrix, plasma aliquots were also sampled 
under agitation conditions. Figure 5.15 depicts results corresponding to the washing step 
evaluation after extraction from both matrices. As can be seen, for extractions conducted in plasma, 
addition of acetone and methanol to the washing solution contributed to a decrease in the 
percentage of features with RSD values higher than 40 %. Indeed, the percentages of lipid-related 
features with RSD values below 30 % were 63%, 75%, and 54 % for acetone (10 %), methanol 
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(10 %), and water, respectively. In tissue extractions, it is evident that acetone (10 %) yielded the 
best results among the tested strategies, with 62 % of the detected features yielding RSDs below  
 
 
Figure 5.15. Evaluation of different washing solutions after 30 min extractions from plasma 
(above) and brain homogenate (below). RSD values were calculated based on peak areas detected 






















































































30 %. Isopropanol and methanol displayed similar outcomes, as 53 % of the detected features 
yielded RSD values below 30 % in both cases. While higher variation was observed in the washing 
step assessment for water in comparison to the results presented in Table 5.6, the use of a different 
batch of C18 fibers was suspected to contribute towards some of the observed variability. With the 
purpose of confirming our findings, the use of 10 % acetone as rinsing solution was evaluated once 
again by extracting from brain homogenate with a third batch of C18 fibers. As can be seen in 
Table 5.7, satisfactory results were obtained, with almost 80% of features detected in both positive 
and negative modes yielding RSD values below 30 %. Based on these and our previous findings, 
the use of acetone in the rinsing step was adopted as a strategy for analysis of lipids from brain 
tissue. 
Table 5.7. Second assessment of RSD values estimated for lipid-related features detected in 
positive and negative mode via C18 fibers (n=4).  Only features with pooled QC/blank (solvent 
and fiber blanks) ratios above 5, pooled QC RSDs below 30 %, and intensities above 3000 were 
considered for the calculations. 
RSD ranges C18, lipids, positive mode C18, lipids, negative mode 
0 - 10 % 71 115 
10 - 20 % 199 552 
20 - 30 % 174 380 
30 - 40 % 52 155 
>  40% 64 135 
Total 560 1337 
% of features with RSDs below 30 % 79 78 
 
As previously emphasized at the beginning of this chapter, final metabolite concentrations 
obtained via SPME are expected to be lower in comparison with those obtained through exhaustive 
sample preparation techniques. Based on the results presented so far, an average of 500 (HLB, 
MM) and 436 (HLB, MM) metabolite features with RSD values below 30 % can be measured via 
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independent SPME extractions, following the general metabolomics method in positive and 
negative mode, respectively. As for lipid-related features, 444 (C18) and 1047 (C18) features in 
positive and negative mode, respectively, meet the same criteria. Although a fair comparison with 
other methodologies reported in the literature for tissue analysis cannot be easily made, as the 
employed chromatographic conditions and instrumentation in such studies differ from those 
employed in this work, our results are nonetheless very encouraging, particularly in view of the 
simplicity of the SPME workflow and its applicability for in vivo studies. For instance, in a 
protocol using in-vial dual extraction for metabolite analysis from rat brain cerebellum, Ebshiana 
et al. reported a total of 1040, 1783, 1733, and 2603 metabolite features with RSD values below 
30 %, detected with reversed phase (RP) positive, RP negative, HILIC positive and HILIC negative 
LC-MS conditions, respectively (features present in 85 % of the samples).53 Although the removal 
of background ions was not reported for this study, the number of acceptable features detected 
using RP chromatography, which correspond mostly to lipid-related features, was only 
approximately two times higher than the number of filtered features obtained in the present work 
via SPME and the described lipidomics LC-MS method. In another work involving the analysis of 
lung tissue via solvent extraction followed by instrumental analysis by LC-MS, a total number of 
1350 and 352 features remained in positive and negative mode, respectively, after aligning samples 
and QC samples prepared to assess the method’s reproducibility.20 While this methodology 
provided more than twice the number of features in positive mode in comparison with the average 
number of features obtained in the present work through employment of the PFP chromatographic 
method at the same ionization conditions, the currently presented SPME method yielded a slightly 
higher number of metabolite features in negative mode in comparison with the abovementioned 
work. While other studies involving untargeted tissue analysis have reported a much larger number 
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of significant features with acceptable RSD values, 242,243 these studies are all comprised of labor 
intensive methodologies, wherein the amounts of tissue needed per sample vary from 100 to 400 
mg. Despite the fact that the recoveries offered by SPME are considerably lower in comparison 
with such approaches, in many cases, the application of this microextraction technology can 
provide complementary information to traditional methodologies since the system under study is 
accessed in vivo, thus minimizing the risks of metabolome alterations that are typically incurred in 
traditional workflows.  
5.3.3. Extraction time profiles 
The construction of extraction time profiles in SPME can provide valuable information regarding 
the affinity of a given compound for the employed SPME coating at a defined set of conditions. 
In SPME, equilibration time is defined as the time necessary for 95% of the equilibrium amount 
of a given analyte to be extracted onto the fiber. Parameters such as convection, matrix 
composition, temperature, analyte physicochemical properties, coating chemistry, and coating 
thickness all influence the equilibration time. With this in mind, extraction time profiles for 
metabolite features detected in each of the SPME coating types tested (C18, HLB, and MM) were 
investigated in homogenized cow brain tissue. Extracts obtained from HLB and MM fibers were 
run using the PFP method, whereas desorption solutions from C18 fibers were run using the 
chromatographic method for the analysis of lipids. On this note, methanol was used as desorption 
solution for HLB and MM fibers, whereas 1:1 (v/v) isopropanol:methanol and 10 % acetone (v/v) 
were employed as desorption and washing solutions for the C18 fibers, respectively. As already 
described in the experimental section, 5, 10, 20, 30, and 40 min were chosen as extraction points. 




5.3.3.1.Extraction time profiles corresponding to metabolite features detected using the PFP 
chromatographic method 
Aiming to estimate the types of metabolites that fail to reach an extraction plateau after 40 min of 
extraction, pairwise comparisons were carried out between 5 and 40 min extracts, and between 30 
and 40 min extracts, employing the pairwise comparison tool provided by XCMS online. Statistical 
analyses were carried out using the unpaired parametric Welch t-test, while data visualization was 
enabled through the cloud plot option offered by the aforementioned platform, as shown in Figures 
5.15 and 5.16. Circles in green represent features exhibiting higher intensities at 40 min, whereas 
circles in red correspond to those features having higher intensities at 5 and 30 min. Here, the circle 
radius is proportional to the fold changes observed, while p-value significance is proportional to 
the shade of the colour. Data was filtered by only retaining features with p-values lower than 0.05, 
fold changes higher than 1.5, and intensities above 3000. As the cloud plot tool employed for this 
determination does not enable the removal of background artefacts, all detected features were 
taken into account for these comparisons. Although extracts were run in both positive and negative 
modes, for practical purposes, only plots obtained in positive mode were included. As can be seen 
in Figures 5.15 and 5.16, for both HLB and MM coatings, a considerably lower number of features 
showing statistical differences was found in a pairwise comparison of 30 vs. 40 min extracts as 
opposed to 5 vs. 40 min, indicating that various metabolites were able to reach equilibrium after 
30 min of extraction, despite the lack of agitation and the slower diffusion that is expected to occur 
in brain tissue. To better understand the extraction kinetics behaviour observed at the described 







Figure 5.16. Cloud plots corresponding to a pairwise comparison of HLB extracts obtained in 
positive mode. Features showing significant differences (p-value<0.05 and fold changes > 1.5) in 
a comparison between two pairwise groupings, 5 versus 40 min extractions (above) and 30 versus 
40 min extractions (below), are represented in green (higher intensities in 40 min extracts) and red 







Figure 5.17. Cloud plots corresponding to a pairwise comparison of MM extracts obtained in 
positive mode. Features showing significant differences (p-value<0.05 and fold changes > 1.5) in 
a comparison between 2 pairwise groupings, 5 versus 40 min extractions (above) and 30 versus 40 
min extractions (below), are represented in green (higher intensities in 40 min extracts) and red 




As can be seen in Figure 5.18, highly polar compounds such as choline, citrulline, tyrosine, 
arginine, isoleucine, and carnitine were able to achieve equilibrium in less than 10 min of 
extraction. Other compounds such as tryptophan and niacinamide, which are slightly less polar 
and bear aromatic functionalities in their structure, exhibited longer equilibration times, owing to 
their higher affinities for both HLB and MM extraction phases. Conversely, the extraction of 
riboflavin was observed to still be within its linear regime past the 40 minute extraction period. 
Considering that the extraction process is mediated by the diffusion of the analyte towards the 
coating under the tested conditions, as expected, no significant differences were observed between 
the two coating types. Despite the high polarity of this metabolite, the aromatic moieties that 
riboflavin possesses in its structure enhance its affinity for both HLB and MM functionalities, 
leading to longer equilibration times that are even more pronounced at static extraction conditions. 
Although, as previously emphasized, all features that remained after data filtering were detectable 
using both HLB and MM coatings, our results suggest that the vinyl pyrrolidone functionality of 
HLB provides slightly improved recoveries for some polar metabolites. Nevertheless, as the 
employed HLB fibers were made in house, high standard deviations due to inter-fiber variability 
were also noticed for this particular experiment. Irrespective of the fiber being employed, however, 
considering the observed differences among various metabolites in terms of equilibration times 
and extraction kinetics, precise control of the time that the SPME probe is exposed to the sample 
matrix is imperative when performing untargeted studies. Longer extraction times will ensure 
better method precision, but will come with a compromise in temporal resolution, as the final 
amount of analyte extracted is proportional to its average concentration over the extraction period. 







Figure 5.18. Extraction time profiles constructed with HLB and MM coatings corresponding to representative metabolites occurring in 























































































































































A B C 
D E F 
G H I 
Choline, logP -3.6 Citrulline, logP -3.3 Tyrosine, logP -2.4 
Arginine, logP -3.5 Isoleucine, logP -1.7 
Tryptophan, logP -1.1 Niacinamide, logP -0.75 Riboflavin, logP -1.1 
Carnitine, logP -2.9 
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particularly for in vivo studies, relate to the technical aspects of the experiment being undertaken. 
In studies in which multiple animals are employed as subject, the time lapse required to 
place/remove the SPME probes in/from each animal is also important. If the extraction time 
selected is too short (few minutes), SPME fibers set to extract first may need to be removed before 
all probes have been placed in all subjects. This presents an inconvenience, especially in cases 
where the availability of personnel qualified to handle animals is limited. As an alternative, 
animals can be studied in smaller groups; however, this could lead to a reduction in analysis 
throughput, particularly when conducting studies that involve pre and post analysis of long 
treatments. For these reasons, extraction times ranging between 20 and 40 min would offer a good 
compromise for such applications.  
 
5.3.3.2.Extraction time profile corresponding to lipid related features 
An initial screening was also carried out with respect to lipids and fatty acids able to achieve 
equilibrium within 30 min of extraction. Using the same strategy and parameters described in 
section 3.3.1, comparisons between 5 and 40 min and between 30 and 40 min extractions were 
carried out. As can be seen in Figure 5.19, 193 and 289 metabolite features detected in positive 
and negative mode, respectively, exhibited statistically significant differences in a comparison 
between features obtained for 5 and 40 min extracts. Conversely, only close to half of those 
features showed statistical variations in a comparison between 30 and 40 min extracts (Figure 
5.20). Considering that the total number of detected unfiltered features used for this comparison 
amounted to 3651 and 5885 in positive and negative mode, respectively, these findings 
demonstrate that at the experimental conditions selected for this study, relatively fast equilibration 
times can be reached for large non-polar metabolites such as lipids. Based on the high 







Figure 5.19. Cloud plots corresponding to the pairwise comparison of 5 versus 40 min extractions 
conducted with C18 fibers and run using the LC-MS method for lipids analysis. Features showing 
significant differences (p-value<0.05 and fold changes > 1.5) in positive (above) and negative 
(below) modes are represented in green (higher intensities in 40 min extracts) and in red circles 







Figure 5.20. Cloud plots corresponding to a pairwise comparison of 30 versus 40 min extractions 
conducted with C18 fibers, and run using the LC-MS method for lipids analysis. Features showing 
significant differences (p-value<0.05 and fold changes > 1.5) in positive (above) and negative 
(below) modes are represented in green (higher intensities in 40 min extracts) and red circles 






Figure 5.21. Extraction time profiles corresponding to representative fatty acids and lipids occurring in brain tissue (n=4). Extractions 
were conducted using C18 fibers, and the post-extraction rinsing step was carried out in 10 % acetone (v/v). Lysophosphatidyletha-
nolamine (LysoPE), galactosyl or glucosyl ceramide (Gal/GlcCer), sphingomyelin (SM), phosphatidylethanolamine (PE), 
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Gal/GlcCer (C50H95NO8) 
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affinities for SPME coatings, as well as long equilibration times when present in aqueous matrices. 
However, considering that the matrix is brain tissue, which is substantially hydrophobic, 
metabolites such as lipids will display low coating distribution constants along with short 
equilibration times due to the high affinity of these compounds for the sample matrix. In order to 
obtain a clearer picture in respect to the extraction kinetics of lipids and fatty acids, extraction time 
profiles corresponding to representative metabolites were plotted. As can be seen in Figure 5.21, 
equilibration times for lipids of different classes ranged around 10 min, whereas fatty acids 
required an average of 30 min to reach an extraction plateau. Although further investigation of the 
mass transfer processes occurring in complex matrices such as brain tissue are needed, our results 
indicate that employment of extraction times ranging between 20 to 30 min will allow for optimum 
SPME recoveries and precision. As a means to verify the effect of extraction time on method 
precision for lipid-related features, an evaluation of the inter-fibre RSD values corresponding to 
the different time points selected for this study was conducted. As shown in Table 5.8, longer 
extraction times enabled improved RSD values, a finding that is in agreement with the above 
discussion. 
Table 5.8. Assessment of RSD values estimated for lipid-related features detected in positive and 
negative mode at different extraction times using C18 fibers (n=4).   
Lipid related features, positive mode 
Extraction time, min 
5  10 20  30 40  
Number of features with RSD  less than 30% 309 291 468 421 464 
% of features with RSDs below 30 % 57 54 86 78 85 
Total number of features 543 
Lipid related features, negative mode 5 10 20 30 40 
Number of features with RSD  less than 30% 907 739 1075 1009 1106 
% of features with RSDs below 30 % 69 57 82 77 85 







In this study, a comprehensive evaluation of SPME as a sample preparation tool for untargeted 
studies in brain tissue was presented for the first time. In terms of coating chemistries, HLB yielded 
the best results among the three tested coatings based on its broad metabolite coverage and on the 
intensities attained for significant detected features. Nonetheless, high HLB inter-fiber RSD values 
were also found in some of the experiments, as the devices were prepared using an in-house 
protocol. In regards to the performance of the commercially available coatings, the performance 
of MM was comparable to HLB with respect to the extraction of polar compounds, whereas C18 
was able to offer satisfactory results in the extraction of non-polar metabolites such as lipids and 
fatty acids. In addition to a coating chemistry evaluation, this work demonstrated that the use of 
different desorption solvents greatly influences the final composition of brain extracts obtained 
with SPME. The use of methanol, for instance, facilitated the desorption of non-polar metabolites 
such as lipids and fatty acids, which are highly abundant in brain, while the use of 1:1 (v/v) 
ACN:water allowed for improved recoveries of some polar compounds such as those that contain 
a purine base in their structure (e.g. xanthine, inosine, guanosine, or deoxyguanosine). Therefore, 
employment of more than one solvent per coating type, and of at least two fibers in the same 
sampling point are recommended. The results of this study also revealed that despite the non-
exhaustive nature of SPME, rewarding results in terms of method precision can be achieved 
through optimization of this method. For all evaluated coating types, 60 to 80 % of the detected 
brain-related features showed RSD values below 30 % at optimized desorption conditions. In 
respect to highly hydrophobic metabolites such as lipids, the introduction of a washing step with 
10 % acetone (v/v) enabled their reproducible analysis from brain tissue. As for equilibration times 
attained in brain homogenate, highly polar metabolites were observed to be able to reach an 
extraction plateau in 5 min or less. Surprisingly, for highly hydrophobic metabolites such as lipids, 
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relatively short times (close to 10 min) were needed for equilibrium to be reached due to the high 
affinity that these compounds display for the matrix under study. Considering the simplicity of 
SPME, the practicability of performing sampling and sample preparation in a single step, the 
biocompatibility of the SPME probes, which enables their use in vivo, and the broad coverage 
offered by SPME coatings, further implementation of SPME in multiple applications involving 
tissue analysis is foreseen. Although the results of this study provide a reliable basis for the future 
application of SPME in untargeted brain studies, current work is being conducted in our lab to 
fully characterize the metabolites that can be extracted via SPME from brain tissue through 
employment of high resolution MS/MS and other chromatographic methods such as hydrophilic 












Chapter 6: Application of solid phase microextraction (SPME) for in vivo monitoring of 
metabolic changes after deep brain stimulation (DBS) 
 
6.1. Preamble and introduction 
6.1.1. Preamble 
The research project related to this section started in August 2015, and is still ongoing. The results 
presented in this chapter have not yet been published in any journal. In vivo sampling was carried 
out in the facilities of the Center for Addiction and Mental Health (CAMH) in Toronto. Clement 
Hamani, Barbara Bojko, and Janusz Pawliszyn participated in the design of the experiment. 
Clement Hamani surgically implanted the sampling cannulas and DBS electrodes into the brains 
of the animals. All animals used in this study were solely handled by Mustansir Diwan. Barbara 
Bojko, Ezel Boyaci, German A. Gómez-Ríos, Nathaly Reyes-Garcés, and Tijana Vasilejvic 
participated in in vivo sampling procedures. German A. Gómez-Ríos designed the fibre holder 
used for in vivo sampling, while its construction was undertaken by the Machine Shop of the 
University of Waterloo. Ezel Boyaci and Nathaly Reyes-Garcés desorbed all probes and ran the 
corresponding extracts in the LC-MS system. Nathaly Reyes-Garcés conducted all the data 
processing and wrote the corresponding discussion herein presented. 
6.1.2. Introduction 
Deep brain stimulation (DBS) is a medical therapy successfully used to treat several disorders, 
including Parkinson’s disease, essential tremor, epilepsy, chronic pain, and depression, among 
others.244 In DBS, electrical pulses are delivered in specific brain regions by surgically implanting 
electrodes in the target area. The effectiveness of this treatment in alleviating symptoms of 
neurological and psychiatric conditions presenting in patients resistant to available medical 
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treatments is reflected in the growing number of new patients receiving DBS devices per year 
(8,000 – 10,000 new patients per year worldwide).245 Despite the fact that DBS has been used for 
decades, a clear understanding regarding the neurophysiological mechanisms behind this 
technique has yet to be presented.246–248 One of the main questions that remains to be answered is 
whether DBS inhibits or excites neuronal elements.244,246 Considering that the effects of DBS are 
comparable to those of stereotactic lesions (a technique involving the infliction of precise, 
irreversible lesions to the brain), both treatments were originally believed to function by inhibiting 
the activity of local neurons.247 However, while scientific evidence supports that DBS inhibits 
neuronal activity in some cases,249,250 DBS has also been demonstrated to elicit an excitatory effect 
in neuronal elements at certain conditions.251,252 Indeed, the effect of DBS has been shown to be 
largely dependent on the stimulation parameters under use, on the region of the brain stimulated, 
as well as on the disease under treatment.244,246,247 In view of this, a general conclusion regarding 
the mechanisms of action of DBS cannot be easily obtained solely based on experimental findings 
garnered at different conditions.  
Various studies, involving application of electrophysiological, imaging, biochemical, and 
molecular methods, have been previously undertaken by researchers with aims of gathering further 
insights into the mechanisms of action of DBS.244 However, the currently presented study focuses 
solely on the elucidation of DBS mechanisms from a biochemical and molecular perspective. The 
majority of studies related to metabolic changes in the brain due to DBS have targeted 
neurotransmitter systems. Dopamine, for instance, is an important signaling compound involved 
in the modulation of body movements and of neuronal firing within the globus pallidus internus 
(GPi) and in the subthalmic nucleus (STN).253 Several studies carried out in animals have 
demonstrated that STN DBS induces an increase in extracellular dopamine in the striatum of 
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normal rats, partially 6-hydroxydopamine (6-OHDA) lesioned rats (rat model of Parkinsonism), 
and in Parkinsonian rhesus monkeys.254–257 However, other reports establish that no statistical 
changes were observed in the striatal dopamine of rats after stimulation. Similarly, studies 
employing positron emission tomography (PET) in human Parkinson’s disease (PD) patients did 
not show evidence of increases in dopamine levels after DBS.258,259 Although most results obtained 
by employment of PET are limited by this technique’s poor sensitivity towards measurements of 
small concentration changes, the controversial results obtained in the abovementioned study 
support the importance of further validating findings obtained in animal models through human 
studies. Other neurotransmitters that have been previous subjects of study with aims of unravelling 
DBS mechanisms include gamma-aminobutyric acid (GABA), glutamate, and serotonin. For 
instance, levels of GABA, a key neurotransmitter in different control mechanisms due to its 
inhibitory role in neuronal excitability, have been shown to increase in the basal ganglia (BG) 
region after application of STN and GPi DBS.260,261 Likewise, increases in GABA concentrations 
were detected in cerebrospinal fluid of PD patients after 6 months of DBS treatment.262 For 
glutamate, increases in the levels of this neurotransmitter after DBS have been observed in several 
animal experiments. Windel et al., for instance, reported a rise in extracellular glutamate in the 
STN, GPi, and substantia nigra pars reticulate (SNpr) of normal rodents after STN DBS.263 
Furthermore, enhancements in glutamate levels, detected using in vivo microdialysis, were 
observed to occur in the nucleus accumbens and in the dorsal raphe after electrical stimulation of 
the ventromedial prefrontal cortex (vmPFC) of normal rats.264,265 Interestingly, no significant 
changes in glutamate levels were observed in human PD patients following STN DBS treatment; 
however, for the same group of patients, an increase in cyclic guanosine monophosphate (cGMP), 
a secondary messenger of glutamate, was noted to occur, indicating DBS had an effect in the 
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modulation of the glutamatergic pathway.266 Changes in serotonin levels may also vary according 
to the stimulation conditions selected for DBS. For instance, a decrease in extracellular serotonin 
has been found to occur after application of STN DBS in animal studies. Considering that STN 
DBS is used for the treatment of PD, this finding may correlate to depression and suicidal 
tendencies in PD patients undergoing DBS.267,268 On the other hand, stimulation of the vmPFC and 
lateral habenula (LHb) regions has been shown to exert a modulatory effect in the serotonergic 
system, resulting in increases in hippocampal and striatal serotonin levels, respectively.269,270 In 
fact, an increase in serotonin levels has been found in the blood and hippocampus of chronic 
unpredictable mild stress model (CUMS) animals following chronic LHb DBS treatment.271 Based 
on these and other findings, the antidepressant effect of DBS has been suggested to be linked to 
serotonin projections to areas such as the hippocampus and the prefrontal cortex, both areas known 
to be affected by depression disorders. 272 Save for reported measurements of metabolic changes 
in adenosine and noradrenaline, few other metabolites have been targeted in studies involving 
DBS.265,273 This certainly opens up a range of possibilities for the investigation of DBS 
mechanisms using untargeted metabolomics platforms.  
In terms of methodologies available to measure the aforementioned metabolites, microdialysis 
(MD) and electrochemical techniques are perhaps the mostly used approaches, owing to their 
suitability for in vivo analysis. As was already emphasized in Section 1.1.2., MD is a sampling 
approach widely accepted in the neuroscientific community, as it allows for analysis of free small 
molecules (e.g. neurotransmitters) present in extracellular brain fluid. Selective determination of 
a number of target metabolites is made possible through analysis of the collected “extract” or 
dialysate in appropriate instrumentation. Some limitations of MD include the high content of 
inorganic salts present in the dialysate, which can hinder the use of mass spectrometry; the low 
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concentration of metabolites collected in the dialysates; and the difficulties associated with the 
analysis of less polar and larger compounds, which are known to sometimes adhere to the MD 
membrane. Electrochemical methods, in turn, rely on the measurement of currents or potentials, 
which are generated as a result of charge-transfer processes that occur at the surface of an 
electrode. Considering the high ionic strength of biological media, and the fact that several brain 
metabolites such as neurotransmitters are electrochemically detectable, electrochemical methods 
are well suited for analytical measurements of different metabolites present in the central nervous 
system. The main advantages of electrochemical methods lie in their ability to provide high 
temporal and spatial resolution, as such approaches allow for the monitoring of rapid changes in 
metabolite concentrations, while the size of their electrodes can be up to twenty times smaller than 
typical microdialysis probes. However, electrochemical-based techniques are limited by their low 
selectivity, as well as their inherent inaptitude towards determination of non-electroactive 
species.274 For that reason, analytical methods that involve application of MD coupled to liquid 
chromatography used in combination with various detector types have gained broad acceptability 
within the scientific community.   
Application of solid phase microextraction (SPME) offers a valuable opportunity toward further 
elucidation of metabolic changes resulting from DBS treatments. As previously discussed, SPME 
is a useful sample preparation tool with demonstrated suitability for investigations of different 
biological systems, including in vivo measurement of metabolic changes in rat brains.56 The small 
size of the sampling probes and the availability of biocompatible SPME coatings make of this 
technology an attractive approach for in vivo determinations. Taking advantage of such features, 
in this section, we present results corresponding to the application of SPME for monitoring of in 
vivo metabolic changes occurring in the hippocampus of rat brains after application of DBS in 
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their prefrontal cortex. As already emphasized, the hippocampus and the prefrontal cortex are 
critical brain regions known to be affected by depression.275 The results of this work aim to shed 
light on the mechanisms behind DBS, particularly in cases where the vmPFC region is stimulated 
to produce anti-depression-like effects. 
6.2. Experimental procedure 
6.2.1. Materials 
4 mm C18 and MM fibers (45 µm thickness) were provided by Supelco (Bellefonte, PA, USA). 
All fibers were pre-conditioned in 1:1 methanol:water for at least 30 min prior to extraction. After 
conditioning, SPME fibers were rinsed with nanopure water so as to remove any organic solvent 
excess remaining on the coating surface. For in vivo extractions, each SPME probe was assembled 
in the sampling holder, as shown in Figure 6.1. These holders facilitated the introduction and 











4 mm coating 
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6.2.2. SPME sampling procedure and analysis 
 
 
Figure 6.2. General schematic of the sampling procedure. 
Four-month-old male Fischer rats were used as subjects to investigate metabolic changes resulting 
from DBS. Prior to the experiment, electrodes used to deliver electrical pulses in the pre-frontal 
cortex region of the brain and cannulas used to guide the sampling devices directly to the 
hippocampus were surgically implanted in each animal. All animal experiments were conducted 
in the Centre for Addiction and Mental Health (Toronto, ON) under ethical approval. Two groups 
of animals were considered for the study: a treatment group, sampled before treatment (baseline 
(BL)) and after DBS (n=17); and a control group (n= 13), which did not undergo DBS therapy, 
but nonetheless received the surgical implantation of the electrodes. The sampling procedure was 
carried out as shown in Figure 6.2. First, SPME probes mounted on the previously described 
sampling holders were exposed to rat brain for 30 min (C18 fibres were deployed first, with 





3 h DBS (200 µA, 130 




30 minutes for each extraction phase, all animals in the treatment group were then submitted to 3 
hours of DBS (200 µA, 130 Hz, 90 µs pulses). Once the DBS treatment was completed, new SPME 
probes were exposed to each animal’s brain for the same period of time (30 minutes per fiber). As 
SPME allows for non-lethal extraction, the sampling procedure was repeated in the same animals 
two weeks after the first sampling. During the two-week period in between the two samplings, 
animals were subjected to DBS therapy every day for 8 hours (chronic DBS). However, for the 
purpose of this thesis, only the metabolic changes occurring as a result of acute DBS exposure (3 
hours) are presented and discussed. Subsequent to the completion of the extraction process, all 
probes were cleaned with Kimwipes, quickly rinsed with LC-MS grade water, and stored at -80 
°C for further analysis. Employed mixed mode fibres were desorbed in 300 µL of 1:1 
water:acetonitrile, whereas C18 probes were first desorbed in 100 µL of methanol, with the 
obtained solution then further diluted with 100 µL of water to ensure good chromatographic 
retention.  
6.2.3. LC- mass spectrometry (MS) analysis 
All brain extracts were run using a pentafluorophenyl (PFP) column at the same instrumental 
conditions described in Section 5.2.5. For metabolite identity confirmation, MS/MS analysis was 
conducted using an Q-Exactive Quadrupole-Orbitrap Mass Spectrometer (ThermoFisher 
Scientific, Waltham, MA) coupled to a Dionex UltiMate 3000 UPLC System (Dionex Corporation, 
Bannockburn, IL), and equipped with a heated electrospray (H-ESI) source. The MS system was 
operated under parallel reaction monitoring (PRM) conditions using an inclusion list. Other MS 
conditions were set as follows: MS resolution = 35000, automatic gain control (AGC) target = 2e5, 
and normalized collision energies (NCE) = 20 and 40. MS/MS spectra were compared against 
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standard fragmentation patterns obtained at the same conditions (when available) and against the 
METLIN MS/MS database. 
6.2.4. Data analysis 
The same data processing parameters described in Section 5.2.6 were applied to analyse the data 
obtained from experiments discussed in this current section. Statistical analysis was carried out by 
employing the non-parametric Mann-Witney test (univariate analysis), with false discovery rate 
(FDR) correction applied (q-values) to the obtained data. Features with p-value ≤ 0.01, q-value ≤ 
0.05, and a fold change ≥ 1.5 were considered significant. Identification of statistically significant 
features was undertaken by comparing their accurate masses with METLIN and HMDB databases, 
and by running available standards and comparing their MS/MS spectra. 
6.3. Results and discussion 
Aiming to gather a better understanding of the chemistry behind the effect of DBS on the 
hippocampus in response to vmPFC stimulation, an in vivo MS-metabolomics study in rodents 
(Fischer rats) was conducted, with SPME employed as a sampling tool. Scientific evidence has 
been presented by several researchers regarding the clinical benefits associated with application of 
electrical stimulation in specific brain areas of patients diagnosed with major depressive 
disorder.276–279 Brain regions targeted to treat depression disorders via electrical stimulation 
include the subcallosal cingulate, the nucleus accumbens, the ventral capsule/ventral striatum, the 
medial forebrain bundle, the inferior thalamic penducle, and the lateral habenula.280–284 Given the 
limitations associated with human studies, animal models represent a viable alternative to 
investigate the mechanisms underlying therapies such as DBS. In this work, DBS electrodes were 
surgically implanted in the ventromedial prefrontal cortex (vmPFC) of rodents, as this area has 
been found to be homologous with the Broadman area 25 of the cingulate region in humans.275 
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Monitoring of metabolic changes induced by vmPFC DBS in the hippocampus of animals was 
enabled through surgical implantation of microdialysis cannulas that allowed for precise sampling 
positioning. It is worth highlighting that the hippocampus is a complex brain structure strongly 
correlated to mood disorders and depressive episodes.272 Previous rodents studies have 
demonstrated that vmPFC DBS can produce a positive behavioral effect, as observed in forced 
swim tests, as well as through an increase in serotonin levels in the hippocampus.269,275 In view of 
this, further investigations of metabolic changes occurring in the hippocampal region in response 
to electrical stimulation of the vmPFC were seen as a valuable line of inquiry that may lead to a 
better understanding of the biochemical effect of DBS on patients diagnosed with major depressive 
disorders. The sampling probes employed in this study were composed of nitinol wires with a 4 
mm coating on their tips. The length of the coating enabled the monitoring of changes in a defined 
brain region, providing a certain degree of spatial resolution. As described in Section 6.2.2, two 
coating chemistries were used for these experiments (immobilized C18 particles with a benzene 
sulfonic functionality (mixed mode), and C18 particles), with two types of solvents selected for 
desorption of probes. As presented in Chapter 5, employment of different SPME extraction 
sorbents and different desorption solutions can facilitate broad metabolite coverage, a highly 
desired outcome in this particular case.  
As one of the main advantages of using SPME is that it allows for non-lethal sampling, all animals 
employed in investigations were submitted to sampling at different time points: rats submitted to 
treatment were monitored before and after each vmPFC DBS treatment (2 sampling sessions in 
total), for a total of 4 distinct samplings per specimen. Similarly, control groups were sampled 
once in each sampling session for comparison of profiles and elucidation into metabolic changes 
resulting from DBS. Brain metabolic profiles collected from all animals, before vmPFC DBS and 
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after 3 hours of treatment, were compared for statistically significant differences between data sets. 
The list of metabolic features retrieved by XCMS online was filtered so that only features 
exhibiting less than 20% relative standard deviation in the pooled QC were retained. Considering 
that approximately 70% of those filtered features (for each coating type and for each ionization 
mode) did not meet the assumption of normality once the Shapiro-Wilk test (data not shown) was 
employed on the data, a non-parametric test (Mann-Witney) was used for univariate analysis. For 
brain extracts obtained with mixed mode coatings, 105 and 93 features in positive and negative 
modes, respectively, were found, using a threshold value of p-value < 0.01 and fold changes >1.5. 
In the case of C18, 255 features in positive mode and 295 features in negative mode were found 
to meet the same threshold. Although the number of dysregulated features seems to be small, it is 
worth noting that SPME is a non-exhaustive extraction technique, and the advantages of its easy 
applicability for in vivo studies comes along with a compromise in terms of sensitivity. Following 
feature detection, some of the dysregulated features associated with metabolic changes occurring 
after DBS were then characterized. Table 6.1 presents a list of these characterized features and 
their corresponding identities. 
The first finding worth of discussion is the upregulation of citrulline. As shown in Table 6.1 and 
in Figure 6.3, a substantial increase in the hippocampal citrulline level (↑5 fold change, p-
value<0.0001, q-value<0.0001) was observed after DBS. Citrulline is a known co-product of the 
enzymatic generation of nitric oxide (NO), a reaction that is catalyzed by nitric oxide synthase 
(NOS), where arginine is the only substrate of all NOS isoforms. NO is a key signaling molecule 
involved in multiple cellular functions, including neurotransmission, blood pressure regulation, 
and immune response.285 In the central nervous system (CNS), this gaseous compound has been 
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Table 6.1. Dysregulated metabolites tentatively characterized by MS/MS and employment of authentic standards (when available).  
      Compound 
Time 
(min) 
m/z Δ ppm 
BL vs DBS Control vs DBS Other 
adducts 
Isotopes Standard 





























































0 ↑1.9 9.0E-05 3.0E-02 ↑2.1 5.7E-06 3.0E-03 [M-H]-  Yes 
Uric acid 1.6 
169.0357 
[M+H]+ 









































1 ↑2.9 8.4E-05 2.0E-03 ↑2.6 5.2E-04 1.5E-02 [M-H-H20]-  No 



































































PE (22:6/16:0) 25.3 
764.5223 
[M+H]+ 










PE (22:6/18:1) 25.5 
790.5381 
[M+H]+ 






















PE (P-16:0/22:6) 25.7 
748.5275 
[M+H]+ 



















PE (22:6/18:0) 26.2 
792.5536 
[M+H]+ 








PC (38:6) 26.5 
806.5694 
[M+H]+ 





PC (32:1) 26.7 
732.5535 
[M+H]+ 




PC (40:7) 26.8 
832.5848 
[M+H]+ 




PC (38:5) 27.2 
808.5850 
[M+H]+ 









0 ↑9.2 2.0E-08 7.3E-06 ↑9.3 5.4E-08 3.3E-05   No 
   
Lysophosphatidylethanolamine (LysoPE), cerebroside (glucosylceramide (GluCer) or galactosylceramide (GalCer)), sphingomyelin 







Figure 6.3. Box plots, MS/MS spectra obtained at 20 NCE, and overlaid extracted ion chromatograms corresponding to citrulline (A, 
















































associated with cognitive and physiological functions such as memory, sleep, feeding behaviour, 
pain reception,  thermoregulation, and microcirculation, among others.286 The synthesis of NO in 
specific brain regions is definitely dependent on several factors, including the availability of 
arginine and NOS. In addition, the activation of N-methyl-D-aspartate (NMDA) receptors by 
glutamate has been shown to function as a signal for the synthesis of NO.287 Taking into account 
that increases in glutamate levels in response to vmPFC DBS have already been reported ,264,265 
and that in this study, a rise in glutamate was also observed (↑1.7 fold change, p-value<0.001, q-
value<0.05) (Figure 6.3), NO upregulation can be then be presumed to be one of the effects exerted 
by vmPFC DBS when the technique is applied at the specified conditions. Interestingly, in recent 
work published by Chakravarty et al., statistical increases of the hippocampal and thalamic 
volumes, as well as in the diameter of blood vessels in the hippocampus were observed after 
vmPFC DBS.288 This finding also supports our hypothesis, considering that NO has an important 
role in the neuronal control of brain blood flow, where it induces a vasodilating effect by either 
activating the production of cGMP, or by inhibiting the synthesis of 20-hydroxyeicosatetraenoic 
acid (20-HETE), a known vasoconstrictor.289 However, further studies are required to confirm this 
correlation. Another compound that has been found to be upregulated by activation of glutamate 
receptors is taurine.290 In this work, taurine levels were found to be remarkably higher in post-DBS 
extracts in comparison to BL measurements (↑9 fold change, p-value < 0.0001, q-value<0.0001) 
(Figure 6.4). This ubiquitous sulphur-containing amino acid has been found to exert a 
neuroprotective role in cases of excessive release of excitatory amino acids such as glutamate, 
known as the major excitatory neurotransmitter.291,292 Indeed, overstimulation of excitatory amino 





Figure 6.4. Box plots, MS/MS spectra obtained at 20 NCE, and overlaid extracted ion chromatograms corresponding to taurine (A, B 
















































some neurological diseases.290 Considering that a rise in glutamate was observed after DBS, one 
could expect that such an increase could have contributed to an enhancement in hippocampal 
taurine levels. In addition, taurine release is also modulated by the NO cascade.293 In vitro studies 
using slices from mouse hippocampus have demonstrated that an increase in taurine levels takes 
place after addition of NO donors to the medium.294 Similarly, in vivo upregulation of extracellular 
taurine in rat striatum has been observed after administration of NO release-inducing substances.295 
Likewise, results supporting the NO modulatory role in taurine release were reported after taurine 
inhibition was observed in relation to the administration of the  NO synthase inhibitor NG‐nitro‐
L‐arginine methyl ester.293 Based on the currently presented findings, the upregulation of NO is 
postulated to also induce taurine release in the rat hippocampus as an excitotoxicity avoidance 
mechanism. To this end, it is worth noting that depending on its concentration, NO can be either 
neuroprotective or neurotoxic.285 High concentrations of NO can lead to nitrosative stress, a 
condition caused by the inability of a given system to eliminate reactive nitrogen species.285 At 
excitotoxic conditions, and at a low arginine concentration, enzymatic production of superoxide 
radicals can occur via NOS.296,297 Superoxide radicals are oxidative species that can react with NO 
to produce peroxynitrite ONOO-, a highly toxic oxidative anion that can induce DNA damage and 
lipid oxidation.298 Although our results indicate that at the specified experimental conditions, 
vmPFC DBS can induce NO upregulation, the reached concentration levels of NO resulting from 
DBS could not be established at this time. However, it is worth mentioning that uric acid, a potent 
antioxidant and free radical scavenger, is among the compounds found to undergo significant 
increases after DBS treatment (↑2.6 fold change, p-value<0.0001, q-value<0.05) in this study 
(Figure 6.4). Uric acid is generated from an enzymatic reaction undertaken by xanthine in the 
presence of xanthine oxidoreductase (XOR).299 In vitro experiments with rat hippocampal neurons 
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have shown that this product of purine catabolism is able to suppress the accumulation of reactive 
oxygen species, preserve the mitochondrial function at conditions of cerebral ischemia, and 
attenuate free cellular calcium levels induced by glutamate exposure. In addition, administration 
of uric acid to adult rats prior to middle cerebral artery occlusion was shown to cause a remarkable 
reduction in ischemic damage to the cerebral cortex and striatum.300 Based on this information, 
vmPFC DBS could be postulated to induce an oxidative environment in the brain that in turn elicits 
metabolic changes such as the release of uric acid, which at the specified conditions, plays a 
neuroprotective role against oxidative species. It should be noted that an increase in carnitine levels 
after DBS was also observed (↑1.8 fold change, p-value<0.001, q-value<0.05). Considering that 
carnitine has shown antioxidant properties as a scavenger of reactive oxygen species,301 this 
finding may also support the hypothesis of DBS inducing an oxidative response in the brain.  
Several amino acids are also present among the group of small metabolites that displayed statistical 
changes after electrical stimulation (Table 6.1). Among these amino acids is proline (↑1.9 fold 
change, p-value<0.0001, q-value<0.01), an amino acid that is synthesized from glutamate and 
ornithine, a compound resulting from the enzymatic cleavage of arginine to urea. Proline has been 
suggested to be capable of potentiating glutamate transmission, as at certain levels, this amino acid 
is known to activate NMDA and α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid 
(AMPA) receptors.302 Additionally, proline can display excitotoxic properties at high 
concentrations; for instance, it is known to inhibit the uptake of glutamate by astrocytes, a 
neuroprotective mechanism activated by glutamatergic excitotoxicity.303 Other amino acids 
upregulated after DBS include threonine (↑1.8 fold change, p-value < 0.001, q-value <0.05), an 
essential amino acid; serine (↑1.8 fold change, p-value < 0.001, q-value <0.05), involved in several 
metabolic pathways, including the synthesis of phospholipids and sphingolipids;304 and histidine 
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(↑2.1 fold change, p-value < 0.0001, q-value <0.01), an amino acid essential in protein synthesis 
that is metabolized through three different pathways, including the synthesis of histamine. 
Methionine and methionine sulfoxide also exhibited an increase in their levels after DBS 
(methionine: ↑1.7 fold change, p-value < 0.0001, q-value <0.05; methionine sulfoxide: ↑1.8 fold 
change, p-value < 0.001, q-value <0.05). Interestingly, the presence of methionine residues in 
proteins has been reported to represent an important scavenging system against oxidative 
conditions. Under the presence of different oxidants, methionine is readily oxidized into 
methionine sulfoxide, which in turn is converted back into methionine by methionine sulfoxide 
reductase.305 Although SPME is only able to extract from the free fractions of compounds present 
in a given system, an increase in methionine sulfoxide may also support our findings in regards to 
DBS favoring oxidative conditions in the brain environment. 
Another finding of this work worthy of discussion corresponds to the upregulation of feature m/z 
333.2075, which was detected in negative mode (↑2.9 fold change, p-value < 0.0001, q-value 
<0.01) (Table 6.1). Based on the MS/MS fragmentation pattern, this ion was tentatively identified 
to represent either a cyclopentone prostaglandin (prostaglandin (PG)A2 or PGJ2) or a cyclopentone 
isoprostane (IsoPs), more specifically 8-isoPGA2 (Figure 6.5). In regards to PGA2 and PGJ2, very 
little evidence can be found in the literature regarding their endogenous production. Conversely, 
past research has evidenced the substantial presence of cyclopentone IsoPs in in vivo.306,307 As the 
formation of cyclopentone IsoPs takes place due to the peroxidation of arachidonic acid in the 
presence of free radicals, the upregulation of such compound is in agreement with the already 
discussed results. However, further confirmation of the identity of this compound through certified 
standard identification is required for further clarifications regarding its possible role in metabolic 
changes associated with DBS. 
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In addition to enabling measurements of changes in concentrations of several small and/or polar 
















Figure 6.5. Box plots (A), overlaid extracted ion chromatograms (B), and MS/MS spectrum 
obtained at 20 NCE (C) for the feature m/z 333.2075. Comparison of experimental MS/MS 
spectrum with PGA2 (D), and 8-iso PGA2 (E) MS/MS spectra. *** p-value<0.0001, ** p-
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above 700. Figures 6.6 and 6.7 present cloud plots depicting features captured with C18 probes 
that exhibited statistically significant changes between baseline and post-DBS, and control versus 
treated groups (p-value<0.01 and fold changes>1.5). As can be seen, the several circles found in 
the 20 to 35 min region indicate significant variations occurred for non-polar compounds.  MS/MS 
analysis of several of these features revealed them to correspond to different lipid classes (Table 
6.1 and Figure 6.8). Among the lipids characterized are lysophosphatidylethanolamine (LysoPE), 
cerebroside (glucosylceramide (GluCer) or galactosylceramide (GalCer)), sphingomyelin (SM), 
phosphatidylethanolamine (PE), and phosphocholine (PC) species. Considering that MD is not 
well-suited to monitor large non-polar metabolites, our results confirm that one of the most 
remarkable advantages of the proposed SPME platform relies on its capacity for extraction of 
lipids in vivo. However, due to the small size of the probes and the non-exhaustive extraction 
capabilities of SPME, some of the statistically changing metabolites could not be easily analyzed 
via MS/MS due to low signal intensities (data not shown).  
Regarding the correlation of the findings herein presented and the antidepressant-like effects 
associated with application of DBS in animals and also in humans, additional studies under more 
specific experimental conditions are required for further insights into DBS mechanisms in the 
treatment of depression. For instance, the upregulation of NO after DBS that is suggested by our 
work is contradictory to results reported by other studies, where different NOS inhibitors have 
been demonstrated to exert antidepressant-like effects in various animal models.308 Interestingly, 
evidence showing correlations between increased NO levels and antidepressant-like effects has 
been reported as well in other works.309,310 Regarding the role of glutamate, the modulation of the 







Figure 6.6. Metabolomic cloud plots representing upregulated (green) and downregulated (red) 
features (p-value<0.01, fold change>1.5) detected in positive mode using C18 fibres. Comparisons 









Figure 6.7. Metabolomic cloud plots representing upregulated (green) and downregulated (red) 
features (p-value<0.01, fold change>1.5) detected in negative mode using C18 fibres. 
Comparisons of baseline versus post-DBS extracts, and controls versus treated animals are shown 





Figure 6.8. Boxplots and overlaid extracted ion chromatograms of representative lipids showing 
statistically significant differences when comparing before (BL) versus after DBS and control 

























































































inducing a decrease in the local release of glutamate has been shown to induce positive 
antidepressant-like effects.311 On the other hand, works conducted to assess DBS mechanisms to 
treat depression have reported increased glutamate levels in the nucleus accumbens and dorsal 
raphe after electrical stimulation of the VmPFC.264,265 Based on the high complexity of the brain, 
multiple biochemical changes are expected to occur in response to DBS; however, future studies 
oriented towards the elucidation of the DBS antidepressant mechanism should be focused on 
targeting specific metabolic pathways, such as the urea cycle. In relation to taurine, 
supplementation of this amino acid to rats has been shown to elicit an antidepressant-like effect; 
for instance, its administration was shown to reduce immobility in forced swim tests, as well as 
play a role in the modification of various signaling cascades in the hippocampus.312,313 
Furthermore, past work has reported a remarkable reduction in hippocampal taurine levels of male 
rats displaying anxiety-like behaviours caused by maternal deprivation at 11 days of age.314 To the 
best of our knowledge, no reports concerning DBS studies to treat depression provide information 
regarding changes in taurine levels before and after stimulation. However, a rise in extracellular 
levels of taurine was observed in Parkinsonian rats after stimulation of the STN.315 Uric acid, 
another metabolite that exhibited significant changes after DBS in this study, has also been linked 
to mechanisms of mood regulation.316 Interestingly, lower levels of uric acid have been found in 
serum samples of patients with major depression in comparison to healthy controls317,318 As the 
currently reported work established that levels of uric acid were increased after electrical 
stimulation, further investigation of involved pathways may shed light onto the mechanisms 
activated by DBS in relation to its positive effect on depression symptoms. Finally, changes in the 
brain lipidome in relation to mood disorders have also been documented.319,320 Indeed, recent 
research has demonstrated that the mechanism of action of antidepressant drugs such as 
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amitriptyline and fluoxetine is mediated by the acid sphingomyelinase-ceramide system.321 In fact, 
high levels of ceramide in the hippocampus have been found to be correlated with low rates of 
neuronal proliferation, and with depression-like behaviours. On the other hand, a reduction of acid 
sphingomyelinase activity, associated with the intake of antidepressant drugs, has been shown to 
lead to a decrease in ceramide levels, allowing for behavioral improvements in depressed rodents. 
In addition to sphingolipids, polyunsaturated fatty acids, glycerolipids, and glycerophospholipids 
have also been found to play crucial roles in anxiety and depression behaviours.320,322 In regards 
to the results obtained in this work, no well-defined trends could be established in relation to the 
specific classes corresponding to the dysregulated lipids uncovered in this study. However, among 
the characterized compounds that showed a remarkable increase after electrical stimulation, two 
different sphingomyelins were characterized; in light of the facts just discussed, further exploration 
of the role of this class of lipids in DBS mechanisms of action should be considered. Although 
additional experiments are required to validate the lipid variations observed with the use of in vivo 
SPME, efforts to explain DBS mechanisms should be also focused on monitoring lipidome 
alterations.      
6.4. Conclusions 
The featured work presented an in vivo untargeted metabolomics study oriented at an elucidation 
of the metabolic changes occurring in rat hippocampus after DBS of the vmPFC. Use of in vivo 
SPME allowed for the monitoring of significant variations, not only in small polar metabolites 
such as amino acids, but also in lipids belonging to different classes. The changes observed in 
citrulline and glutamate levels are possible indicators of alterations to the citrulline-NO cycle 
caused by electrical stimulation. Moreover, metabolites previously found to be involved in 
mechanisms trigged to counteract the presence of oxidative species in the brain such as taurine, 
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uric acid, and carnitine were shown to undergo significant increases after DBS. These findings, 
together with the demonstrated upregulation of some compounds previously associated with 
oxidative stress conditions, may provide new insights into metabolic modifications induced in the 
hippocampal region by vmPFC DBS. Lastly, statistical variations in several lipids belonging to 
sphingolipid and glycerophospholipid classes demonstrate that DBS also induces alterations in the 
brain lipidome. Despite the need for further studies to confirm the contribution of these 
biochemical changes to the overall DBS effect in the treatment of depression, our work provides 
new directions towards a better understanding of the mechanisms involved in electrical stimulation 














Chapter 7: Summary and future directions 
 
7.1. Summary 
The analysis of complex biological matrices via liquid chromatography-mass spectrometry (LC-
MS) is more often than not subjected to sample preparation workflows that are either time 
consuming, or prone to undesired ionization effects, often resulting in low throughput and/or poor 
analytical performance. In this regard, alternative sample preparation approaches such as solid-
phase microextraction (SPME) offer new opportunities for expansion in the selection of tools 
currently available for bioanalytical determinations. Indeed, the large number of studies available 
in the literature to date evidence the usefulness of SPME for the quantitation of different target 
compounds in various matrices of bioanalytical interest. A summary of the main advantages of 
this technique in regards to its application for the analysis of diverse biological systems is 
presented in Figure 7.1. However, from a practical perspective, SPME is still far from being a 
broadly adopted tool in the clinical laboratory; in this sense, further acceptance and successful 
adaptation of unconventional methodologies such as microextraction-based techniques in clinical 
applications can be said to be directly related to the degree to which their principles and capabilities 
are understood. This thesis contributes to the progress and further implementation of SPME in the 
analysis of biological samples by presenting new insights into the performance of this 
microextraction technology towards the analysis of complex matrices, and by introducing novel 
SPME applications and developments. In chapters 2 and 3, the suitability of SPME coupled with 
LC-MS/MS is demonstrated for the concomitant quantitation of a broad range of substances in 
plasma, urine, and blood samples with the use of various doping compounds as model analytes.  
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Following relatively simple analytical workflows, satisfactory clean-up with minimum sample 
pre-treatment and rewarding figures of merit were obtained by employing biocompatible SPME  
 
 Figure 7.1. Summary of the advantages of SPME as a sample preparation technique in the 
investigation of biological samples and systems. 
 
devices made of hydrophilic-lipophilic balanced (HLB) particles embedded in polyacrylonitrile 
(PAN). In Chapter 2, SPME was presented in a high throughput and fully automated configuration 
that enabled the easy determination of multiple doping substances in human plasma samples. In 
SPME features
Suitable for in vivo analysis 
(low invasiveness and non-lethal sampling)
Able to integrate sampling and sample preparation in a single 
step (metabolism quenching)
Biocompatible and highly selective for small molecules
Flexible towards various applications (enables tuning of 
coating and device)
Requires minimum sample pre-treatment
Enables temporal and spatial resolution
Allows for balanced analyte coverage
Easily coupled with LC-MS and/or MS
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addition, the developed approach was also shown to facilitate the multi-residue analysis of 
matrices with high protein content. Unlike SPE, the open-bed configuration of SPME is not 
vulnerable to clogging, and limitations related to breakthrough volumes are not a matter of concern 
due to the non-exhaustive extraction nature of SPME. Chapter 3, in turn, introduced an alternative 
material, polybutylene terephthalate (PBT), as a flexible, chemically stable, and cost-effective 
support for preparation of single-use and multi-purpose SPME devices compatible with complex 
matrices. Definitely, the adoption of new materials in the manufacturing of SPME devices opens 
up new opportunities for the introduction of this technique in novel applications. Considering that 
SPME is a non-exhaustive extraction technique where the uptake of analytes occurs via the free 
portion of analytes present in the matrix, the presence of variable matrix components able to 
display certain affinity for compounds of interest introduces a potential source of error that should 
be carefully evaluated. For this reason, Chapter 4 discussed the effect of variable red blood cell 
content, known as the hematocrit (Hct) of a blood sample, on SPME recovery of various analytes. 
The main findings of this investigation showed that while the effect of the Hct varies according to 
the characteristics of a given analyte, that effect is also dependent on the experimental conditions 
selected for extraction. Interestingly, the relative affinity of a given compound for the matrix 
components versus its affinity for the coating material proved to be one of the main factors 
governing the effect of different erythrocyte levels on SPME recoveries. Despite the demonstrated 
effect of Hct on the uptake of certain analytes, and the dependency of this phenomena on the 
selected parameters for sampling, correction of matrix variability was made feasible with the use 
of appropriate internal standards, thereby enabling correct quantification of analytes.  
In addition to the applicability of SPME for targeted studies, the potential of this sample 
preparation technique for untargeted analysis has been demonstrated in several applications. 
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Indeed, the suitability of SPME for in vivo determinations is undoubtedly one of its most attractive 
features, particularly for metabolomics studies. Although typical analytical workflows followed in 
untargeted studies have shown outstanding robustness and satisfactory results in the identification 
of metabolites that are significantly altered due to a particular condition or disease, the complexity 
of biological sample matrices (e.g. tissue), and indeed, of the metabolome itself, both pose a 
remarkable challenge to the isolation of a truly representative snapshot of the metabolic status of 
a given system under investigation. In this regard, implementation of in vivo SPME can offer a 
complementary perspective to that offered by traditional approaches. As further acceptance of 
SPME towards metabolomics applications relies on a thorough assessment of its performance in 
different matrices, Chapter 5 presented remarkable results corresponding to the evaluation of three 
SPME extraction phases for untargeted analysis of brain tissue, taking into consideration a variety 
of parameters, such as extraction phase chemistry, desorption solvent, and extraction time. Among 
the coatings tested throughout this assessment, HLB was revealed to offer the best compromise in 
terms of metabolite coverage. Solvent optimization, in turn, revealed that selection of desorption 
solvent plays a major role in the composition of the final extract. Further, use of 10 % acetone in 
the washing step was shown to facilitate reproducible analysis of hydrophobic metabolites such as 
lipids in brain tissue. Aiming to demonstrate the potential of SPME for untargeted in vivo studies, 
the optimized procedure was then applied towards the monitoring of metabolic changes occurring 
in rat brain following deep brain stimulation (DBS) of the ventromedial prefrontal cortex 
(vmPFC). In these experiments, employment of 4 mm SPME probes mounted in a custom-made 
holder enabled direct measurements of metabolic variations occurring in the hippocampus of freely 
moving rats. As shown in Chapter 6, application of SPME coupled with LC-high resolution MS 
allowed for the capture of several classes of metabolites (e.g. amino acids and lipids) exhibiting 
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statistically significant changes after DBS treatment. To the best of our knowledge, this work 
represents the first untargeted study aimed at the elucidation of DBS mechanisms. Although 
further studies are needed to establish a correlation between the biochemical changes observed in 
this study and the anti-depressant mechanisms of DBS, this work provided new insights into the 
effect of vmPFC DBS on the brain hippocampus.  
 
7.2. Future directions  
Considering the satisfactory performance of different biocompatible SPME devices for analysis of 
complex biological systems, further application of these techniques in novel studies of clinical and 
bioanalytical interest is certainly anticipated. Undoubtedly, a key determinant factor in the 
implementation of SPME is the availability of cost-effective coating chemistries suitable for 
different analytical purposes. For instance, the rewarding results exhibited by HLB-PAN coated 
devices in the determination of a broad range of compounds demand the commercial availability 
of such SPME extraction phases. The availability of materials capable of offering selectivity for 
targeted analysis, improved affinity for polar compounds, and high reproducibility, all while 
ensuring biocompatibility, will also aid in the further implementation of SPME in the analysis of 
biological systems. In addition to the availability of a variety of coating types, the high throughput 
feature offered by SPME plays a crucial role in the future development of this microextraction 
technology. In this regard, the results of this work contribute to the further validation of thin film 
in high throughput format as a well-suited approach for the simultaneous analysis of a broad range 
of analytes in complex matrices. However, future studies should be oriented towards achieving 
shorter analysis times and higher enrichment factors with minimum sample volumes. In addition, 
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the feasibility of incorporating matrix modification techniques (e.g. addition of organic solvent, 
use of high extraction temperatures, etc.) in analytical workflows as a means of enhancing free 
analyte concentrations, increasing extraction recoveries, and normalizing relative matrix effects 
should be further evaluated for the analysis of biological matrices via SPME and LC-MS.  
The introduction of alternative materials for the manufacture of novel devices also plays an 
important role in the adoption of SPME for innovative applications. For instance, the use of 
polymers as coating support materials may expand the suitability of SPME for various new 
biological applications through the creation of biocompatible SPME samplers optimized for easy 
sample collection and analysis. The coupling of such alternative devices with analytical 
approaches such as desorption electrospray ionization (DESI), either for imaging or sample 
profiling, presents itself as an attractive line of research for the near future.   
In terms of untargeted analysis, SPME opens new paths for investigations of biochemical 
processes. By enabling in vivo (or close to in vivo) sampling of complex biological systems, SPME 
streamlines the metabolism quenching step, thus facilitating the capture of unstable metabolites. 
Unquestionably, a large number of studies could benefit from the complementary information that 
this microextraction technology can provide in relation to data obtained via traditional sample 
preparation methodologies. In addition, as in vivo SPME enables non-lethal and/or non-destructive 
sampling, thus allowing for multiple samplings to be carried out from the same animal or sample, 
time course-based metabolomics studies are also facilitated through employment of this 
technology. However, further work is necessary in order to demonstrate and validate the 
performance of SPME in untargeted metabolomics investigations. To this end, future outlooks 
should involve a thorough comparison of SPME versus traditional sample preparation approaches 
through applications of both workflows to already studied animal models (e.g. control vs. 
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diabetes). Such studies will help elucidate the type of information that SPME is able to provide 
compared to typical extraction approaches, and will support further application of this 
microextraction tool in the metabolomics field. The suitability of SPME for the extraction of a 
broad range of metabolites also opens new pathways for SPME-based fast-profiling applications. 
Indeed, new developments in SPME technology, including the coupling of SPME directly to MS, 
point towards the use of such analytical platforms for fast sample discrimination. From a 
bioanalytical and clinical perspective, the application of SPME-MS approaches towards fast 
diagnosis and monitoring of different drugs and biomarkers offers promising new directions, 
possibly allowing for the development of alternative protocols that enable faster, greener, and more 
cost-effective analyses. Moreover, based on the capabilities of SPME for lipid extraction, 
combinations of this microextraction technique with shotgun lipidomics strategies present an 
opportunity for the development of new platforms aimed at facilitating tissue analysis. Other future 
directions targeted at the integration of SPME in the study of biological systems involve the use 
of smaller probes for improved spatial resolution, the coupling of SPME with more sensitive and 
advanced instrumentation, and the development of novel SPME samplers aimed at facilitating 
SPME operation by personnel from different fields. Owing to its versatility and simplicity, SPME 
is a promising technology, with a myriad of possible future applications directed at providing new 
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